
<html lang="en"     class="pb-page"  data-request-id="baeffb0b-7071-4da6-b30d-ee0d15e17f0b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-8;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00032"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity" /></meta><meta name="dc.Creator" content="Shijie  Dai" /></meta><meta name="dc.Creator" content="Haofei  Hong" /></meta><meta name="dc.Creator" content="Kun  Zhou" /></meta><meta name="dc.Creator" content="Kai  Zhao" /></meta><meta name="dc.Creator" content="Yuntian  Xie" /></meta><meta name="dc.Creator" content="Chen  Li" /></meta><meta name="dc.Creator" content="Jie  Shi" /></meta><meta name="dc.Creator" content="Zhifang  Zhou" /></meta><meta name="dc.Creator" content="Lei  Nie" /></meta><meta name="dc.Creator" content="Zhimeng  Wu" /></meta><meta name="dc.Description" content="Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally oc..." /></meta><meta name="Description" content="Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally oc..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 7, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00032" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00032" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00032" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00032" /></link>
        
    
    

<title>Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00032" /></meta><meta property="og:title" content="Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0012.jpeg" /></meta><meta property="og:description" content="Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally occurring antibody binders for peptide half-life extension. The glucagon-like peptide 1 receptor agonist exendin 4 was site-specifically functionalized with the dinitrophenyl (DNP) hapten at the C-terminus via sortase A-mediated ligation. The resulting Ex4–DNP conjugates retained GLP-1 receptor activation potency in vitro and had a similar in vivo acute glucose-lowering effect comparable to that of native Ex4. Pharmacokinetic studies and hypoglycemic duration tests demonstrated that the Ex4–DNP conjugates displayed significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies. In chronic treatment studies, once-daily administration of optimal conjugate 7 demonstrated more beneficial effects without prominent toxicity compared with Ex4. This strategy provides a new approach and represents an alternative to the well-established peptide-Fc fusion strategy to improve the peptide half-life and the therapeutic efficacy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00032"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00032">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00032&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00032&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00032&amp;href=/doi/10.1021/acs.jmedchem.1c00032" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4947-4959</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00019" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00045" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Shijie Dai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shijie Dai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shijie++Dai">Shijie Dai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haofei Hong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haofei Hong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haofei++Hong">Haofei Hong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kun Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kun Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kun++Zhou">Kun Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kai Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kai Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kai++Zhao">Kai Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuntian Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuntian Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuntian++Xie">Yuntian Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chen Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Li">Chen Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Shi">Jie Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhifang Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhifang Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhifang++Zhou">Zhifang Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Nie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Nie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hisun Biopharmaceutical Co., Limited, 8 Hisun Road, Xialian Village, Xukou Town, Fuyang District, 311404 Hangzhou, Zhejiang, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#5a363f330534333f1a6b686c74393537"><span class="__cf_email__" data-cfemail="375b525e68595e52770605011954585a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Nie">Lei Nie</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zhimeng Wu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhimeng Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 214122 Wuxi, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#88f2fffdc8e2e1e9e6efe6e9e6a6edecfda6ebe6"><span class="__cf_email__" data-cfemail="6c161b192c06050d020b020d0242090819420f02">[email protected]</span></a>. Phone: 86-51085197582. Fax: 86-51085197582.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhimeng++Wu">Zhimeng Wu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7583-7268" title="Orcid link">http://orcid.org/0000-0001-7583-7268</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00032&amp;href=/doi/10.1021%2Facs.jmedchem.1c00032" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4947–4959</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 7, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 January 2021</li><li><span class="item_label"><b>Published</b> online</span>7 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00032" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00032</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4947%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DShijie%2BDai%252C%2BHaofei%2BHong%252C%2BKun%2BZhou%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D8%26contentID%3Dacs.jmedchem.1c00032%26title%3DExendin%2B4-Hapten%2BConjugate%2BCapable%2Bof%2BBinding%2Bwith%2BEndogenous%2BAntibodies%2Bfor%2BPeptide%2BHalf-life%2BExtension%2Band%2BExerting%2BLong-Acting%2BHypoglycemic%2BActivity%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4959%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00032"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">548</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00032" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Shijie&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Haofei&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Kun&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Kai&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Yuntian&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Zhifang&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Nie&quot;},{&quot;first_name&quot;:&quot;Zhimeng&quot;,&quot;last_name&quot;:&quot;Wu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4947-4959&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00032&quot;},&quot;abstract&quot;:&quot;Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally occurring antibody binders for peptide half-life extension. The glucagon-like peptide 1 receptor agonist exendin 4 was site-specifically functionalized with the dinitrophenyl (DNP) hapten at the C-terminus via sortase A-mediated ligation. The resulting Ex4–DNP conjugates retained GLP-1 receptor activation potency in vitro and had a similar in vivo acute glucose-lowering effect comparable to that of native Ex4. Pharmacokinetic studies and hypoglycemic duration tests demonstrated that the Ex4–DNP conjugates displayed significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies. In chronic treatment studies, once-daily administration of optimal conjugate 7 demonstrated more beneficial effects without prominent toxicity compared with Ex4. This strategy&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00032&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00032" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00032&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00032" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00032&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00032" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00032&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00032&amp;href=/doi/10.1021/acs.jmedchem.1c00032" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00032" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00032" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00032%26sid%3Dliteratum%253Aachs%26pmid%3D33825469%26genre%3Darticle%26aulast%3DDai%26date%3D2021%26atitle%3DExendin%2B4-Hapten%2BConjugate%2BCapable%2Bof%2BBinding%2Bwith%2BEndogenous%2BAntibodies%2Bfor%2BPeptide%2BHalf-life%2BExtension%2Band%2BExerting%2BLong-Acting%2BHypoglycemic%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D8%26spage%3D4947%26epage%3D4959%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/jmcmar.2021.64.issue-8/20210422/jmcmar.2021.64.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Hapten-specific endogenous antibodies are naturally occurring antibodies present in human blood. Herein, we investigated a new strategy in which small-molecule haptens were utilized as naturally occurring antibody binders for peptide half-life extension. The glucagon-like peptide 1 receptor agonist exendin 4 was site-specifically functionalized with the dinitrophenyl (DNP) hapten at the C-terminus via sortase A-mediated ligation. The resulting Ex4–DNP conjugates retained GLP-1 receptor activation potency in vitro and had a similar in vivo acute glucose-lowering effect comparable to that of native Ex4. Pharmacokinetic studies and hypoglycemic duration tests demonstrated that the Ex4–DNP conjugates displayed significantly elongated half-lives and improved long-acting antidiabetic activity in the presence of endogenous anti-DNP antibodies. In chronic treatment studies, once-daily administration of optimal conjugate 7 demonstrated more beneficial effects without prominent toxicity compared with Ex4. This strategy provides a new approach and represents an alternative to the well-established peptide-Fc fusion strategy to improve the peptide half-life and the therapeutic efficacy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Type 2 diabetes mellitus (T2DM) accounts for 90–95% of all diabetes cases and is defined as a progressive loss of adequate β-cell insulin secretion frequently in the context of insulin resistance.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Its prevalence has increased throughout both developed and developing countries over the past three decades, making this disease a key health priority globally.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Glucagon-like peptide 1 (GLP-1) and its analogues (e.g., exendin-4), as an incretin-targeting therapy, have been approved as an effective approach for T2DM treatment in recent years.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Mechanistic studies demonstrated that GLP-1 and its analogues stimulate the G protein-coupled glucagon-like peptide-1 receptor (GLP-1R) to enhance insulin secretion in a glucose-dependent manner through the cyclic adenosine monophosphate (cAMP) signal pathway.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Multiple beneficial effects, including slowing of gastric emptying, reduction of food intake and body weight, and improvement of pancreatic endocrine function, were also observed in this treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, one major challenge of using GLP-1-based peptide biologics as antidiabetes drugs in clinic is their relatively short half-life in vivo due to the inherent characteristics of the peptide, such as susceptibility to enzymatic degradation and rapid renal clearance; thus, they require high dosages and increased administration frequencies to achieve a therapeutic effect in clinic. To address this key issue, several elegant strategies have been successfully developed to increase the circulation time of GLP-1-based peptide drugs, such as peptide sequence optimization,<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> peptide post-translational modification with small functional molecules (e.g., lipidation<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> and dicoumarinization<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>), polymer conjugation (e.g., PEGylation<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and carbohydrate conjugation<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a>), protein fusion (album or Fc fusion), and sustained delivery systems. Generally, increasing the hydrodynamic radius by reducing renal elimination and steric shielding to reduce metabolic degradation are the two classical mechanisms of peptide half-life extension. To date, although the abovementioned strategies have achieved great success by generating several clinically approved GLP-1-based peptide drugs for T2DM treatment, there is still a significant demand to explore a novel strategy that includes a new mechanism to improve the peptide half-life and the therapeutic window and efficacy.</div><div class="NLM_p">Of these strategies, genetically fusing peptides with antibody Fc fragments is an established approach to increase the circulation half-life of therapeutic peptides in the pharmaceutical industry.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Fusing the therapeutic peptide with the Fc fragment can not only provide steric hindrance from proteolysis but also reduce renal filtration by increasing the molecular weight. Importantly, the Fc domain in the fusion protein has been shown to mediate the neonatal Fc receptor (FcRn) salvage recycling pathway to further improve the serum half-life of peptide-Fc biologics.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Several Fc fusion peptide biologics have been clinically approved and are available on the market, including dulaglutide (Trulicity), etanercept (Enbrel), and aflibercept (Elyea).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, the Fc fusion strategy also faces limitations and challenges. For example, peptide-Fc fusion therapeutic proteins are biomolecules that are usually produced by complex bacterial, yeast, or mammalian expression systems, and relatively expensive upstream and downstream processes are needed to obtain a pure and homogenous product for medical applications.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Another major concern is the potential immunogenicity elicited by frequent administration of peptide-Fc fusion drugs because these molecules are large and complex biologic counterparts compared with small molecules.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> The generation of neutralizing anti-drug antibodies (nADAs) may diminish drug efficacy and induce severe adverse reactions as well.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> For instance, 2.2% of patients were detected to have ADAs when treated with dulaglutide.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Endogenous antibodies are naturally occurring antibodies present in human serum. A number of reports have documented that several antibodies against small-molecule haptens, such as galactose-α-1,3-galactose (α-Gal),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> rhamnose,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and nitroarene,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> exist in human blood abundantly, ranging from 1 to 8%.<a onclick="showRef(event, 'ref24 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref26">(24,26)</a> Redirection of these endogenous antibodies with different isotype classes presents a variety of hapten-dependent biological functions.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27−30)</a> For example, our group<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and others<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> have demonstrated that small-molecule hapten-modified nanobodies or biotin can form in situ immune complexes with pre-existing endogenous antibodies, thus leading to significantly enhanced pharmacokinetic profiles. Moreover, small-molecule haptens, such as digoxin or cotinine, could be utilized as antibody binders to extend their circulatory half-lives or as a conjugate by forming immune complexes with the corresponding antibodies generated by a preimmunization approach in vitro or in vivo.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> In this study, we proposed that small-molecule haptens may be utilized as naturally occurring antibody binders to extend the circulatory half-lives of peptide pharmaceuticals when conjugated with parent peptide drugs. Presumably, the rationally designed peptide–hapten conjugates could bind with pre-existing endogenous antibodies to generate a peptide–hapten–antibody complex that will prolong the half-life of the peptide following similar mechanisms as those of the peptide-Fc fusion strategy. However, a distinct feature of this approach, which is superior to the peptide-Fc fusion strategy, is that nonimmunogenic endogenous antibodies are harnessed; thus, it greatly avoids potential immunogenicity issues. As a proof of concept, GLP-1 analogue exendin 4 (Ex4) was selected as a model peptide to test the feasibility of this new strategy, while dinitrophenyl (DNP) hapten was selected as an endogenous antibody binder since naturally occurring anti-DNP antibodies are abundant in human blood across all genders, ethnicities, and ages.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> C-terminal DNP-modified Ex4 analogues with different lengths of polyethylene glycol (PEG) as spacers were prepared by a well-established sortase A-mediated ligation method (SML).<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> The in vitro GLP-1R activation activity, in vivo acute glucose-lowering capability, long-term hypoglycemic activity, and in vivo pharmacokinetic properties of these conjugates were evaluated. Finally, the chronic treatment effect of a selected Ex4–DNP conjugate in db/db mice for a seven-week trial was described.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and Synthesis of Ex4–DNP Conjugates 6–8 and 9–11 via SrtA-Mediated Ligation</h3><div class="NLM_p">Ex4 is a clinically approved twice-daily peptide drug to treat T2DM. Previous studies have confirmed that the C-terminal modification of Ex4 has a limited impact on its potency. Thus, the C-terminus of native Ex4 was prolonged with a sorting signal motif (LPETGGS) that will conjugate with glycine-modified DNP hapten through a ligation reaction catalyzed by the transpeptidase sortase A (SrtA).<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Three peptides, Ex4, Ex4-LPETGGS (1), and FITC-Ahx-Ex4-LPETGGS (2), were synthesized by standard solid-phase peptide synthesis (SPPS) procedures, further purified by semipreparative HPLC and characterized using MALDI-TOF or ESI MS and analytical HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figures S1–S6</a>). Glycine-modified DNP derivatives 3, 4, and 5 containing different lengths of PEG were synthesized following our previous procedures.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Then, peptide 1 was incubated with 3, 4, or 5 in Tris buffer (pH = 7.4) in the presence of SrtA overnight to generate Ex4–DNP conjugates 6, 7, or 8 (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The reaction progress was monitored by RP-HPLC, as presented in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a–c, which shows that the conversion yields were 80% for 6, 78% for 7, and 80% for 8. The ESI-MS analysis further confirmed that the conjugates were successfully synthesized. The reactions were scaled up to produce multiple milligrams of 6 (3.2 mg, 62% yield), 7 (3.1 mg, 60% yield), and 8 (3.0 mg, 57% yield) as a white powder after purification by semipreparative HPLC and lyophilization. The purities of conjugates 6–8 determined by analytic HPLC were over 95% (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figures S7–S9</a>), which is suitable for biological studies. N-terminal FITC-labeled Ex4–DNP conjugates 9–11 were prepared following the same procedure and were characterized by ESI-MS (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>d–f). These conjugates will be used for in vivo pharmacokinetic studies. It is worth noting that the optimal pH for the synthesis of conjugates 9–11 in the presence of SrtA should be adjusted to 7.8 because peptide 2 has poor solubility at pH 7.4.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HPLC profile of SrtA-mediated ligation and ESI-MS analysis of 6 (a), 7 (b), 8 (c), 9 (d), 10 (e), and 11 (f). HPLC conditions: 10–90% gradient of CH<sub>3</sub>CN/H<sub>2</sub>O over 20 min at a flow rate of 1 mL/min and monitored at 220 nm (# represents SrtA; (▲) represents the unreacted peptide or hydrolysis product; and (*) represents the unreacted peptide 2 or hydrolysis product).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemoenzymatic Synthesis of Ex4–DNP Conjugates 6–8 and FITC-Labeled Ex4–DNP Conjugates 9–11</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> GLP-1 Receptor Activation Potency</h3><div class="NLM_p">GLP-1 and its analogues function by binding and activating GLP-1R, whose downstream signaling is mediated by a second messenger cAMP cascade and eventually results in the secretion of insulin to regulate blood glucose. Therefore, the level of cAMP is evaluated as an indicator of GLP-1R activation.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> To examine whether Ex4 analogue 1 and its DNP-modified conjugates 6–8 retained the activity of GLP-1 receptor binding, we measured the intracellular cAMP levels by incubation of human embryonic kidney 293 (HEK293) cells that were stably transfected with human GLP-1R with various concentrations of the abovementioned peptides. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, both native Ex4 and 1 could significantly enhance intracellular cAMP levels in a concentration-dependent manner and displayed comparable EC<sub>50</sub> values (0.99 nM vs 1.03 nM), which proved that extending the C-terminus of native Ex4 with a peptide motif (LPETGGS) did not significantly alter its receptor activation activity. Ex4–DNP conjugates 6, 7, and 8 exhibited slightly decreased potency in terms of stimulating GLP-1R compared with native Ex4 and 1, but the EC<sub>50</sub> values remained at the nanomolar level (6: 1.39 nM; 7: 1.98 nM; and 8: 4.03 nM). Conjugate 8 displayed the worst receptor activation potency, indicating that a longer linker was not preferred in this modification (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Activity was examined in vitro by measuring the cAMP response after receptor stimulation with native Ex4 and 1, and Ex4–DNP conjugates 6–8 in HEK293 cells that overexpressed human GLP-1R. (b) EC<sub>50</sub> (nM) values of each compound against GLP-1 R derived from the cAMP response curve fitting. The results were described as the mean ± SEM, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Acute Glucose-Lowering Effect of Ex4–DNP Conjugates on Diabetic db/db Mice</h3><div class="NLM_p">To examine the glucose-regulating bioactivities of Ex4–DNP conjugates in vivo, IPGTT experiments were performed using Lepr<sup>db</sup> mutation C57BLKS/J db/db mice as a diabetes model. The experiments were performed by intraperitoneal injection with phosphate-buffered saline (PBS) and native Ex4 and Ex4–DNP conjugates 6–8 at a single dose of 25 nmol/kg of body weight. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a, the blood glucose levels of mice pretreated with PBS increased rapidly, reached peak values at 30 min (24.4 mmol/L) after glucose challenge (i.p., 1 g/kg), and maintained a state of hyperglycemia for 0–120 min, which was due to the impaired glucoregulatory function of the pancreas. However, groups treated with native Ex4 and Ex4–DNP conjugates 6, 7, and 8 showed rapid decreases in blood glucose levels to 12.8, 14.3, 13.9, and 14.0 mmol/L at 15 min after the same level glucose challenge (i.p., 1 g/kg), respectively, which gradually returned to baseline levels within 60 min. In addition, the AUC values of the blood glucose levels within 2 h after glucose challenge were reduced by 53.9% (native Ex4), 52.4% (6), 51.9% (7), and 50.3% (8) compared with those of the PBS group (*<i>P</i> < 0.05), as presented in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Table S1</a>. Thus, Ex4–DNP conjugates 6–8 exhibited similar glucose-regulating capabilities in vivo and were comparable to native Ex4, indicating that DNP modification of Ex4 did not impair its ability to promote insulin secretion bioactivities.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Glucose tolerance tests of PBS, native Ex4, and Ex4–DNP conjugates 6–8 (25 nmol/kg) in diabetic db/db mice. (a) Time response curves for the blood glucose level of each group. (b) Acute glucose-lowering effects are presented as calculated glucose AUC<sub>glucose 0–120min</sub> values. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) ELISA results of total antibody titers of pooled antisera collected on different days from C57BL/6 mice immunized with DNP–OVA conjugates (<i>n</i> = 20). (b) Assessment of the pharmacokinetic properties of FITC-labeled native Ex4 (peptide 2) and Ex4–DNP conjugates 9–11 in preimmunized C57BL/6 mice subcutaneously administered with 75 nmol/kg FITC-labeled native Ex4. Blood samples were collected at various time points for fluorescence quantification. For peptide 2, the clearance rate after 6 h was not plotted because the plasma concentrations promptly fell below the quantification limit. A noncompartmental fit was applied to the data to deduce the pharmacokinetic parameters shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Results are depicted as the mean ± SEM, <i>n</i> = 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> In Vivo Pharmacokinetic Study in C57BL/6 Mice Preimmunized with DNP–OVA</h3><div class="NLM_p">To validate our hypothesis that DNP-modified Ex4 conjugates can increase the in vivo half-lives through the interaction of DNP hapten with the corresponding endogenous anti-DNP antibodies, normal C57BL/6 mice were vaccinated with DNP–OVA conjugates to generate high titers of anti-DNP antibodies, as demonstrated by enzyme-linked immunosorbent assay (ELISA, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). Then, pharmacokinetic studies were performed using FITC-labeled Ex4–DNP conjugates 9–11 at a dosage of 75 nmol/kg. The plasma concentration–time courses (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b) were analyzed using a noncompartmental fit to derive the pharmacokinetic parameters listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. After a single subcutaneous injection, native Ex4 exhibited a very short residence time in circulation, which was expected, with a plasma <i>T</i><sub>1/2</sub> value of 0.72 ± 0.07 h. In contrast, the plasma <i>T</i><sub>1/2</sub> values of 9, 10, and 11 were 2.07 ± 0.05, 3.55 ± 0.33, and 2.62 ± 0.17 h, respectively, which represented 2.9-, 4.9-, and 3.6-fold increases relative to those of native Ex4. Interestingly, the peak plasma drug concentrations (<i>C</i><sub>max</sub>) of conjugates 9–11 in preimmunized mice were significantly improved and approximately 5-fold higher than those of native Ex4. These differences in the pharmacokinetics resulted in an approximately 8- to 15-fold increase in the AUC values for conjugates 9–11 compared with those of native Ex4. These data suggested that modification of Ex4 with hapten DNP could significantly prolong the half-life of the Ex4 peptide when abundant anti-DNP antibodies existed in the body. In addition, conjugate 10, which contained a medium-length PEG linker, possessed the best pharmacokinetic properties compared with other conjugates and native Ex4.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pharmacokinetic Parameters of Native Ex4 and FITC-Labeled Ex4–DNP Conjugates 9–11 in Preimmunized C57BL/6 Mice, Deduced from Data in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char="±">AUC (μg·h/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">native Ex4</td><td class="colsep0 rowsep0" align="char" char="±">0.72 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.55 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char="±">2.07 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.71 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">0.74 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">1.77 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">3.55 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">1.03 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">0.81 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">3.09 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="char" char="±">2.62 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">0.99 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">0.78 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">2.37 ± 0.10</td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Long-Term Hypoglycemic Activity of Ex4–DNP Conjugates in Diabetic db/db Mice</h3><div class="NLM_p">Long-term hypoglycemic experiments were performed in diabetic db/db mouse models without or with anti-DNP antibodies in the blood. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a, in the diabetic db/db mouse model without anti-DNP antibodies in the blood, the mouse glucose level in the native Ex4 treatment group took 2 h to reach the lowest level and returned to the baseline level within 12 h. Ex4–DNP conjugates exhibited very similar glucose-lowering profiles as well. For the diabetic db/db mouse model with high titers of anti-DNP antibodies in the blood, the native Ex4 treatment group displayed a glucose-lowering profile similar to that of the diabetic db/db mouse model. However, in this model, the mice’s blood glucose levels in the conjugate 6–8 treatment groups decreased rapidly within 1 h and gradually reached the lowest levels in 6 h, and the blood glucose level still did not return to the baseline level even after 24 h of injection (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b). Compared with the PBS group, native Ex4 and Ex4–DNP conjugates 6–8 in the diabetic db/db mouse model without anti-DNP antibodies exhibited comparable AUCs<sub>glucose 0–24h</sub> values, which were 31.0, 29.7, 31.1, and 31.6%, respectively (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>d and <a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Table S1</a>). In the diabetic db/db mouse model with high titers of anti-DNP antibodies, however, the AUC<sub>glucose 0–24h</sub> values of native Ex4 and Ex4–DNP conjugates 6–8 were reduced by 27.4, 42.8, 53.6, and 45.1% with significant differences (*<i>P</i> < 0.05), respectively. There were significant improvements in the AUC<sub>glucose 0–24h</sub> values between the Ex4–DNP conjugate administration groups in the two diabetic db/db mouse models (6: 29.7% vs 42.8%; 7: 31.1% vs 53.6%; and 8: 31.6% vs 45.1%, <sup>&</sup><i>P</i> < 0.05). These results demonstrated that the long-acting hypoglycemic activity was enhanced when Ex4 was modified with hapten DNP in the presence of anti-DNP antibodies. Among the Ex4–DNP conjugates, conjugate 7 containing a 3PEG linker was found to display the best long-term hypoglycemic effect, which was consistent with the results of previous pharmacokinetic experiments.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Glucose-lowering profile in the db/db mouse model without anti-DNP antibodies in blood after subcutaneous injection of PBS, native Ex4, and Ex4–DNP conjugates 6–8 (25 nmol/kg, <i>n</i> = 5). (b) Glucose-lowering profile in the db/db mouse model with anti-DNP antibodies in blood after subcutaneous injection of PBS, native Ex4, and Ex4–DNP conjugates 6–8 (25 nmol/kg, <i>n</i> = 5). (c) ELISA results of total antibody titers of pooled antisera collected on different days from db/db mice immunized with DNP–OVA conjugates (<i>n</i> = 25). (d) Hypoglycemic effect of PBS, native Ex4, and Ex4–DNP conjugates 6–8 was calculated by the glucose AUC value between 0 and 24 h (<i>n</i> = 5). The results are depicted as the means ± SEM, *<i>P</i> < 0.05 vs native Ex4 group, and <sup>&</sup><i>P</i> < 0.05 vs Ex4–DNP conjugate 6–8 groups before immunization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Chronic Treatment Effects of Ex4–DNP Conjugate 7</h3><div class="NLM_p">As Ex4–DNP conjugate 7 exhibited the best pharmacokinetic profile and superior long-term hypoglycemic duration activity among all DNP-modified Ex4 conjugates, it was selected to conduct a seven-week chronic treatment on preimmunized db/db mice. Based on the obtained pharmacokinetic profiles, conjugate 7 was administered once daily, while native Ex4 was given twice daily in these experiments.</div><div id="sec2_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Effect on Body Weight, Food Intake, Water Consumption, and Fasting Blood Glucose Levels</h4><div class="NLM_p">We monitored the body weight change, food intake, water intake, and fasting blood glucose (FBG) levels during the whole chronic treatment period. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a, both the native Ex4 and 7 treatments slowed the weight gain of the mice to a certain degree, especially in the initial intervention stage. At the experimental endpoint, mice in the native Ex4 and conjugate 7 groups showed a weight gain of approximately 1.9 and 2.4%, respectively, which was significantly different (*<i>P</i> < 0.05) from that of the PBS group (11.8% weight gain). In terms of the influence on food intake, Ex4–DNP conjugate 7 maintained a good inhibitory effect on mice throughout the chronic experiment, while native Ex4 only had a good inhibitory effect in the early stage (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b). Administration of native Ex4 and conjugate 7 significantly reduced water consumption and FBG levels during the whole experiment. Conjugate 7 exhibited obvious improvement effects over native Ex4 on the water consumption and FBG levels.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of PBS, twice-daily native Ex4, and once-daily conjugate 7 by subcutaneous injection on (a) body weight, (b) food intake, (c) water intake, and (d) FBG (fasted for 8 h) levels during chronic treatment in preimmunized db/db mice. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group, and <sup>#</sup><i>P</i> < 0.05 vs the native Ex4 group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Effect on Glucose Tolerance, HbA1c, Lipid Metabolism, and Toxicity Indicators</h4><div class="NLM_p">IPGTT was performed at the endpoint of therapy in diabetic mice to investigate the glucose tolerance ability of each group after chronic treatment. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>a,b, the AUC<sub>glucose 0–120min</sub> values of the native Ex4 and conjugate 7 groups were significantly decreased, showing improved glucose tolerance compared with those of the PBS group. By comparison of HbA1c levels before and after seven weeks of chronic treatment (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>c), the HbA1c levels of the native Ex4- and conjugate 7-treated groups were decreased by 0.7 and 1.6%, respectively, but those of the PBS group were increased by 1.3%, indicating that both native Ex4- and conjugate 7-treated diabetic mice exhibited improved HbA1c levels. Notably, chronic administration of once-daily conjugate 7 improved glucose tolerance and reduced the HbA1c levels to a greater extent than the native Ex4 twice-daily injection treatment. Given the notable loss of body weight in the native Ex4 and conjugate 7 treatment groups, the indicators of lipid metabolism were also measured after chronic treatment. As illustrated in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>d–g, native Ex4 and conjugate 7 significantly reduced the plasma LDL-C and TG levels of diabetic mice compared with the PBS group (*<i>P</i> < 0.05), and evaluations of HDL-C and TC levels did not reveal any substantial differences between groups. These results demonstrated that native Ex4 and conjugate 7 can improve lipid metabolism in db/db mice to a certain extent and the benefit of conjugate 7 treatments on lipid metabolism seemed to be better than that of native Ex4. In addition, toxicity indicators, such as hepatotoxicity (AST and ALT) and renal toxicity (Crea and urea), were measured (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a–d). The levels of the abovementioned toxicity indicators in the conjugate 7 treatment group were close to those in the PBS and native Ex4 groups, except that the Crea levels in the conjugate 7 groups were slightly higher than those of the PBS group. Taken together, these data proved that Ex4–DNP conjugate 7 did not show prominent toxicity effects during the seven-week treatment.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chronic treatment effects of PBS, native Ex4, and conjugate 7 on glucose tolerance, HbA1c, and lipid metabolism indicators in preimmunized db/db mice. (a) Blood glucose excursion during IPGTT performed at the end of the chronic treatment. (b) AUC of IPGTT for 0–120 min after the administration of glucose (dosage of 0.5 g/kg). (c) HbA1c levels before and after chronic treatment. (d) Plasma TG, (e) LDL-C, (f) HDL-C, and (g) TC levels measured after the sacrifice of animals. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group, and <sup>#</sup><i>P</i> < 0.05 vs the native Ex4 group. (▲) Note: Since the range of the glucometer is 1–33.3 mmol/L, when the reading of the glucometer is displayed as “HI”, maximal values of 33.3 mmol/L were substituted to enable statistical analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Toxicity effects of native Ex4 and conjugate 7 on the liver and kidney in preimmunized db/db mice after seven weeks of treatment. (a) AST, (b) ALT, (c) Crea, and (d) urea levels were measured by the corresponding assay kits on a BS-420 automatic biochemical analyzer after the sacrifice of animals. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Histological Analyses and Immunohistochemistry</h4><div class="NLM_p">Finally, we performed H&E staining of the liver, kidney, and pancreas and immunohistochemistry analyses of the pancreatic islets of db/db mice after chronic treatment. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>a,b, native Ex4- and conjugate 7-treated groups alleviated hypertrophy and empty cytoplasm in the liver and led to less structural alterations of the glomerular basement membrane in the kidney than the PBS group. More importantly, the pancreatic islets and acinus of pancreatic tissue samples in the conjugate 7 group were equally distributed and showed clear shapes and boundaries, which were much better than those of the PBS treatment group (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>c). In the pancreas immunohistochemistry analysis, distinct positive signals to insulin were detected in the cytoplasm of endocrine islets. As indicated in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>d, the area of insulin-positive β-cells in the conjugate 7 and native Ex4 treatment groups, which were stained brown, was obviously larger than that of the PBS group, indicating that both conjugate 7 and native Ex4 had notable protective effects on the pancreatic islets. Quantitative analysis of the insulin-positive cell area and the islet area revealed that conjugate 7 displayed the best insulin secretion effect, followed by native Ex4 and PBS (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figure S17</a>).</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Protective effect of native Ex4 and conjugate 7 on the kidney, liver, and pancreas of db/db mice. Histological examination of the liver (a), kidney (b), and pancreas (c) sections with H&E staining. (d) Immunohistochemistry examination of pancreas sections with insulin antibodies. A denser color reflects more insulin secretion (scale bars = 50 μm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14103" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14103" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The platform technology of recombinant fusion with the fragment crystallizable (Fc) domain of antibodies has been a widely used approach for the sustained delivery of peptide and protein therapeutics, as evident from several Fc fusion proteins approved by the FDA and more in clinical trials.<a onclick="showRef(event, 'ref20 ref39'); return false;" href="javascript:void(0);" class="ref ref20 ref39">(20,39)</a> However, accumulated data have revealed that the Fc fusion strategy is still facing several intrinsic problems, such as complicated manufacturing processes, immunogenicity, and potential safety issues.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> In this work, we took advantage of the small-molecule hapten, which serves as a naturally occurring endogenous antibody binder, to modify the native Ex4 peptide and increase its circulation half-life by the in vivo formation of the Ex4–hapten–antibody complex. The underlying mechanism of our strategy is quite similar to that of the Fc-fusion approach. Thus, this novel strategy can serve as a viable alternative to Fc fusion.</div><div class="NLM_p">To site-specifically modify the C-terminus of Ex4, a well-established sortase A-mediated ligation was applied to synthesize Ex4–DNP conjugates. The conjugation of Ex4 analogue 1 with DNP derivatives was achieved in the presence of the biocatalyst sortase A with good conversion yields (approximately 80%). Three Ex4–DNP conjugates and their FITC-labeled Ex4–DNP conjugates with different lengths of PEG linker (<i>n</i> = 1, 3, 6) were obtained on a milligram scale. The GLP-1R activation abilities by the in vitro cAMP accumulation assay revealed that DNP modification at the C-terminus of Ex4 did not impair their biological activities dramatically, probably because the modification site is away from the N-terminus of Ex4, which is a crucial motif for receptor activation.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> However, the activation potency was dependent on the length of the PEG linker in the conjugates, where a shorter PEG linker exhibited more potency. On the other hand, in vivo IPGTT experiments showed that the three conjugates displayed very similar acute glucose-lowering capabilities compared with those of native Ex4 since there was no significant difference in the calculated AUC<sub>glucose 0–120min</sub> values among the Ex4–DNP conjugates and native Ex4.</div><div class="NLM_p">In the next PK studies (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) and hypoglycemic duration tests (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), three Ex4–DNP conjugates displayed improved pharmacokinetic properties in preimmunized C57BL/6 mice and improved long-acting hypoglycemic activity in preimmunized db/db mice compared with native Ex4. The degrees of improvement in the pharmacokinetic and pharmacodynamic properties of conjugates were related to the length of the PEG linker between DNP and native Ex4, in which conjugate 7 containing a 3PEG linker was superior to the other conjugates. Since Ex4–DNP conjugates can easily form an in situ immune complex with an abundance of endogenous anti-DNP antibodies in the blood, we speculated that DNP modification of therapeutic peptides is an alternative and convenient approach to improve the half-life through three known primary mechanisms: an increased hydrodynamic radius to prevent rapid renal clearance, reduced proteolysis by DPP-4, and an anti-DNP antibody Fc portion-directed FcRn-mediated recycling pathway. Therefore, our strategy can achieve the comparative benefits of the peptide-Fc fusion strategy through modification of the therapeutic peptide with hapten by a facile and convenient chemoenzymatic reaction. Meanwhile, the current approach could potentially avoid the immunogenicity issue caused by different allotypes of the Fc portion generated in the Fc-fusion strategy because biocompatible endogenous antibodies were involved in this strategy.</div><div class="NLM_p last">Finally, we conducted chronic treatment of preimmunized db/db mice to assess the potential therapeutic effect of Ex4–DNP conjugate 7. The long-term results show that once-daily administration of conjugate 7 delivered obvious beneficial effects on water and diet consumption and FBG levels compared with twice-daily administration of native Ex4 during the treatment period. More importantly, the glycosylated hemoglobin levels, glucose tolerance ability, and blood lipid levels of diabetic mice in the conjugate 7-treated group were significantly improved after continuous treatment for nearly 2 months compared with those of the native Ex4 group. In addition, no obvious toxicity effects were observed after chronic treatment with conjugate 7 on db/db mice, as determined by toxicity indicators. Finally, the histological results also suggested that conjugate 7 could reduce tissue injury and promote tissue repair of the kidney and liver, which were similar to the effects of native Ex4. The mouse sera from seven conjugate chronic treatment groups were pooled and analyzed by ELISA experiments using native Ex4 and Ex4–DNP conjugates 6–8 as capture antigens. The ELISA results are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figure S16</a>. The results showed that Ex4–DNP conjugates 6–8 could bind with the anti-DNP serum at high absorbance, indicating that a substantial amount of anti-DNP antibodies remained in the chronic treatment group. Notably, no absorption was observed in the Ex4 peptide coating group, which revealed that the mice treated with Ex4–DNP conjugate 7 did not produce detectable anti-Ex4 antibodies, even after nearly 2 months of treatment. This result strongly suggested that Ex4–DNP is essentially less or nonimmunogenic. The results of HE staining of the pancreas (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) and quantitative immunohistochemistry analyses for insulin in the pancreas sections (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figure S17</a>) demonstrated that the once-daily administration of 7 has a significantly better improvement effect on islet function than twice-daily administration of native Ex4.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, new GLP-1 analogues 6–8 with DNP modification at the C-terminus were efficiently synthesized by a chemoenzymatic method. In vitro GLP-1R activation studies and in vivo acute glucose-lowering experiments demonstrated that the resultant Ex4–DNP conjugates maintained similar potency and glucose-regulating capabilities as native Ex4. In PK and long-term hypoglycemic activity studies, the half-lives and long-acting antidiabetic activity of Ex4–DNP conjugates were remarkably improved in the presence of anti-DNP antibodies compared with those of native Ex4. In chronic treatment studies, once-daily administration of optimal Ex4–DNP conjugate 7 demonstrated superior therapeutic effects compared to twice-daily administration of native Ex4. Further investigations based on the structure of Ex4–DNP conjugate 7, such as introducing multivalent DNP or other haptens to enhance the interaction with endogenous antibodies, may lead to the development of once-weekly GLP-1 analogues. This strategy provides a new alternative to the peptide-Fc fusion strategy to improve the peptide half-life and therapeutic efficacy. Given the fact that peptide therapeutics are significantly growing in pharmaceutical industry,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> our approach is conveniently amendable to other peptides.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Materials</h3><div class="NLM_p last">Fmoc-protected amino acids, Rink amide MBHA resin, 2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), and 1-hydroxybenzotriazole (HOBt) were purchased from GL Biochem (Shanghai, China). FITC, trifluoroacetic acid (TFA), and triisopropylsilane (TIPS) were purchased from J&K Chemical Technology Co., Ltd. (Beijing, China). OVA (Cat. no. S25067), BSA (Cat. no. S12012), and HSA (Cat. no. S12018) were purchased from Shanghai Yuanye Bio-Technology Co., Ltd. (Shanghai, China). Dulbecco’s modified Eagle Medium (DMEM, Cat. no. SH30243.01), fetal bovine serum (FBS, Cat. no. SH30084.03), penicillin–streptomycin solution (Cat. no. SV30010), and 0.25% Trypsin–EDTA (Phenol Red, Cat. no. SH30042.01) were purchased from GE Healthcare (Chicago, US). HRP-labeled goat anti-mouse IgG antibody (Cat. no. A0216), HRP-labeled goat anti-rabbit IgG antibody (Cat. no. A0208), and TMB solution (for ELISA, Cat. no. P0209) were purchased from Beyotime (Shanghai, China). The HbA1c assay kit (Cat. no. 044618002), TC assay kit (Cat. no. 141620003), LDL-C assay kit (Cat. no. 142019006), HDL-C assay kit (Cat. no. 142119010), and TG assay kit (Cat. no. 141719008), urea assay kit (Cat. no. 141318005), Crea assay kit (Cat. no. 141119010), AST assay kit (Cat. no. 140218005), and ALT assay kit (Cat. no. 140120005) were purchased from Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Shenzhen, China). All other reagents were obtained from commercial sources if not otherwise indicated.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Peptide Synthesis of Native Ex4 and Its Analogues 1 and 2</h3><div class="NLM_p last">All peptides were prepared by SPPS on Rink amide resin (loading: 0.227 mmol/g, 0.05 mmol scale) using a CEM Liberty Blue automatic microwave peptide synthesizer (CEM Corporation, USA), as described in previous research.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In the process of synthesizing native Ex4 and its analogue peptides 1–2 (native Ex4: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS, 1: HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-LPETGGS, 2: FITC-Ahx-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-LPETGGS), 5 equiv of Fmoc-amino acids (dissolved in DMF), 10 equivalents of DIPEA (dissolved in NMP), and 5 equiv of the activator (dissolved in DMF) were added together to conduct condensation reactions under microwaves of recommended parameter power in each coupling cycle. Deprotection of the N-terminal Fmoc group was performed using piperidine/DMF (20%, v/v). Since the coupling efficiency decreased with the prolongation of the peptide fragment, the coupling of the amino acids Ile<sup>21</sup>, Ala1<sup>7</sup>, and Glu<sup>16</sup> was performed twice according to the prediction by amino acid condensation software in the peptide synthesizer. According to previous studies,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> the deprotection of Asp<sup>9</sup> was conducted in 20% piperidine (containing 0.1 mol·L<sup>–1</sup> HOBT), and the coupling of Ser<sup>8</sup> and His<sup>1</sup> was conducted in TBTU (containing equivalent HOBT) by lowering the reaction temperature to 50 °C. For coupling with FITC, the condensation reaction was performed twice manually under 10 equiv of DIPEA without other activators. After completion of synthesis, the resin was treated with a cleavage mixture of TFA/H2O/TIPS (95:2.5:2.5, v/v/v) for 2 h at room temperature. The crude peptides were centrifuged and triturated with cold ether to obtain a suspension, followed by semipreparative HPLC purification (Agilent 1260 Infinity II) using an XBridgeTM Prep C18 column (250 mm × 10 mm, 5 μm, 130 Å). The molecular weights of native Ex4 and its analogues 1–2 were confirmed by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS, ultrafleXtreme, Bruker Daltonics Inc., USA) or electrospray ionization mass spectrometry (MALDI SYNAPT mass spectrometer, Waters, USA). The purity of native Ex4 and its analogues 1–2 was determined by analytical HPLC (Agilent 1260 infinity) using a Diamonsil C18 column (250 mm × 4.6 mm, 3.5 μm, 100 Å) and confirmed to be ≥95% purity for all peptides based on the UV absorption at 220 nm. The results are shown in the Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figures S1–S6</a>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of DNP Derivatives 3–5</h3><div class="NLM_p last">Small DNP derivatives 3–5 were synthesized following our previous procedures.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Reaction of Native Ex4 Analogues 1 or 2 with DNP Derivatives via SrtA-Mediated Ligation</h3><div class="NLM_p last">Analogues 1 or 2 (1.0 μmol, 1.0 equiv), DNP derivatives 3, 4, or 5 (5 μmol, 5 equiv), and SrtA (6 μM) were dissolved in 2 mL of Tris buffer (50 mM Tris, 150 mM NaCl, 10 mM CaCl<sub>2</sub>, pH = 7.4 or 7.8).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The reaction mixture was stirred at 30 °C overnight. After completion of the reaction as monitored by analytical HPLC, the reaction solution was quenched by the addition of 0.1% TFA aqueous solution. Purification was performed by semipreparative HPLC followed by concentration at reduced pressure and lyophilization to obtain pure Ex4–DNP conjugates 6–8 and FITC-labeled Ex4–DNP conjugates 9–11. Analytical HPLC results revealed that the purities of all conjugates were ≥95%, as determined by UV absorption at 220 nm (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">Figures S7–S12</a>). The ESI was calculated for C<sub>218</sub>H<sub>329</sub>N<sub>59</sub>O<sub>75</sub>S (6) [M + 3H]<sup>3+</sup><i>m</i>/<i>z</i> = 1669.46, [M + 4H]<sup>4+</sup><i>m</i>/<i>z</i> = 1252.34, and [M + 5H]<sup>5+</sup><i>m</i>/<i>z</i> = 1002.08, and the result was 1669.62; 1252.20; and 1002.56, respectively; for C<sub>222</sub>H<sub>337</sub>N<sub>59</sub>O<sub>77</sub>S (7) [M + 3H]<sup>3+</sup><i>m</i>/<i>z</i> = 1698.81, [M + 4H]<sup>4+</sup><i>m</i>/<i>z</i> = 1274.36, and [M + 5H]<sup>5+</sup><i>m</i>/<i>z</i> = 1019.68, and the result was 1698.80; 1274.36; and 1020.47, respectively; for C<sub>228</sub>H<sub>349</sub>N<sub>59</sub>O<sub>80</sub>S (8) [M + 3H]<sup>3+</sup><i>m</i>/<i>z</i> = 1742.83, [M + 4H]<sup>4+</sup><i>m</i>/<i>z</i> = 1307.38, and [M + 5H]<sup>5+</sup><i>m</i>/<i>z</i> = 1046.10, and the result was 1742.51; 1307.14; and 1046.30, respectively; for C<sub>245</sub>H<sub>351</sub>N<sub>61</sub>O<sub>81</sub>S<sub>2</sub> (9) [M + 4H]<sup>4+</sup><i>m</i>/<i>z</i> = 1377.87 and [M + 5H]<sup>5+</sup><i>m</i>/<i>z</i> = 1102.50, and the result was 1377.87 and 1102.49, respectively; for C<sub>249</sub>H<sub>359</sub>N<sub>61</sub>O<sub>83</sub>S<sub>2</sub> (10) [M + 4H]<sup>4+</sup><i>m</i>/<i>z</i> = 1399.88 and [M + 5H]<sup>5+</sup><i>m</i>/<i>z</i> = 1120.11, and the result was 1400.14 and 1120.10, respectively; and for C<sub>255</sub>H<sub>371</sub>N<sub>61</sub>O<sub>86</sub>S<sub>2</sub> (11) [M + 3H]<sup>3+</sup><i>m</i>/<i>z</i> = 1910.20, [M + 4H]<sup>4+</sup><i>m</i>/<i>z</i> = 1432.90, and [M + 5H]<sup>5+</sup><i>m</i>/<i>z</i> = 1146.52, and the result was 1910.36; 1433.04; and 1146.41, respectively.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> In Vitro cAMP Accumulation Assay</h3><div class="NLM_p last">Human embryonic kidney 293 cells stably expressing the human GLP-1 receptor (GLP-1R) were used to evaluate the potency of native Ex4 and Ex4–DNP conjugates to active GLP-1R by determining cAMP production.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In brief, cells in the exponential growth stage were resuspended in DMEM with 2% FBS and seeded into 96-well microplates at a density of 2 × 10<sup>4</sup>/well. After adhering overnight, cells were treated with 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, J&K Chemical Technology, Beijing, China) for 40 min to avoid cAMP degradation, followed by incubation with native Ex4 or Ex4–DNP conjugates diluted in blank DMEM medium to concentrations within the 10<sup>–3</sup> to 10<sup>3</sup> nM range for 20 min. Then, the cells were lysed with lysis buffer and centrifuged at 600<i>g</i> for 10 min at 2–8 °C to remove cellular debris. The intracellular cAMP levels were assayed using competitive cAMP ELISA according to the manufacturer’s instructions (R&D Systems Inc, Minneapolis, MN, USA). Each sample was tested in triplicate, and the in vitro potency of each sample was quantified by determining the half-maximal effective concentration (EC<sub>50</sub>) using GraphPad Prism version 6.0 (San Diego, USA).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vivo Pharmacokinetic (PK) Study</h3><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Immunization of Normal C57BL/6J Mice to Generate Anti-DNP Antibodies in Serum</h4><div class="NLM_p last">A total of 20 female C57BL/6J mice (4 weeks old, 15 ± 2 g) were purchased from Shanghai Slac Laboratory Animal Co., Ltd. (Shanghai, China). On arrival, the mice were first housed and kept in the Animal Experimental Center of Jiangnan University for one week. The DNP–OVA conjugate (2 mg/mL) dissolved in PBS was mixed with alum adjuvant (Cat. no. 77161, Thermo) in an equal volume, followed by adequate shaking on a vortex mixer to prepare the vaccine formulations. Each mouse was inoculated on day 0 by intramuscular (i.m.) injection of 0.1 mL of the abovementioned vaccine formulations and enhanced 3 times on days 7, 14, and 21 by subcutaneous (s.c.) injection. Blood samples were collected on day 0 prior to the initial immunization and on days 7, 14, 21, and 28 one week after each immunization. The blood was centrifuged to obtain antisera, and the anti-DNP serum titers were determined by ELISA according to previous protocols.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> During the entire animal experiment, mice were housed under controlled light on a 12 h light/12 h dark cycle with free access to food and water unless otherwise noted. All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Jiangnan University (JN. No20191115c0300117 [317]).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Pharmacokinetic Determination of Ex4–DNP Conjugates</h4><div class="NLM_p last">The abovementioned immunized C57BL/6J mice were randomly divided into four groups (<i>n</i> = 5). Mice were weighed before injection. Each group of mice received a single subcutaneous injection of FITC-labeled native Ex4 and Ex4–DNP conjugates at a dosage of 75 nmol/kg. Each blood sample (20 μL) was obtained from the leg veins and using a pipette added into 80 μL of PBS solution (containing EDTA) at 40 s, 25 min, 50 min, 1.2 h, 1.6 h, 2 h, 4.8 h, 6.5 h, 8.5 h, 10 h, and 24 h after injection. Diluent blood samples were centrifuged at 4 °C and 3000 rpm for 15 min to extract the plasma for fluorescence reading at excitation 485 nm and emission 528 nm on a multifunctional microplate reader (synergy H4, Biotek). The plasma concentrations of each sample as a function of time were plotted using Prism 6 (GraphPad Software Inc.), and their pharmacokinetic parameters were estimated using WinNonlin Professional Version 6.0 (Pharsight Corp., Mountain View, CA, USA).</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> In Vivo Hypoglycemic Experiment</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Immunization of db/db Mice to Generate Anti-DNP Antibodies in Serum</h4><div class="NLM_p last">Lepr<sup>db</sup> mutation db/db mice (C57BL/6 background, male, 6–7 weeks) were purchased from the Model Animal Research Center of Nanjing University. On arrival, the mice were first housed and kept in the Animal Experimental Center of Jiangnan University for one week. Then, the mice were immunized with an emulsion of DNP–OVA conjugates and alum adjuvant (Cat. no. 77161, Thermo, 1 mL) to generate anti-DNP antibodies in serum according to the abovementioned procedure. All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Jiangnan University (JN. no. 20200430db0150825[004]).</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Intraperitoneal Glucose Tolerance Test (IPGTT)</h4><div class="NLM_p last">The acute glucose-lowering activity of native Ex4 and Ex4–DNP conjugates was measured by IPGTT on db/db mice (<i>n</i> = 5). Before the experiment, mice were fasted for 18 h. Thirty minutes after intraperitoneal administration of each sample, the mice received the glucose challenge by intraperitoneal injection of 1 g/kg glucose. The second 1–2 μL of blood drop was collected by nicking the tail vein, and the glucose level was measured at −30, 0, 15, 30, 60, 90, and 120 min using a one-touch glucometer (Sannuo, Changsha, China). The area under the curve (AUC) of the blood glucose profiles was calculated for the period from 0 to 120 min with respect to the 0% baseline.</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Hypoglycemic Duration Test</h4><div class="NLM_p last">The long-acting antidiabetic effect of native Ex4 and Ex4–DNP conjugates was assessed in db/db mice (<i>n</i> = 5) using a previously described method.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Under nonfasting conditions with free access to water and food, mice were administered PBS, native Ex4, and Ex4–DNP conjugates (25 nmol/kg, s.c.). The second 1–2 μL of blood drop was collected via a cut of the tail tip to determine the blood glucose levels at 0, 1, 2, 6, 8, 10, 12, and 24 h using a one-touch glucometer (Sannuo, Changsha, China). The AUC of the glucose profiles was calculated for the period from 0 to 24 h with respect to the 0% baseline.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Chronic In Vivo Studies and Histological Analyses</h3><div class="NLM_p last">To test the sustained therapeutic effect of conjugate 7 with the best performance on the PK study and hypoglycemic duration test, a chronic treatment experiment was performed on the abovementioned preimmunized db/db mice that possessed high anti-DNP antibody titers in the body. All db/db mice were assigned into three groups (<i>n</i> = 5) based on the fasting glucose levels. Mice in the positive control group and blank control group were subcutaneously administered native Ex4 and the same volume of PBS twice daily (9 am and 5 pm). Mice in the experimental group were subcutaneously administered conjugate 7 once daily. The glycated hemoglobin (HbA1c) levels of mice in each group were determined at the beginning and end of the chronic experiment using the corresponding assay kits on a BS-420 automatic biochemical analyzer (Mindray, Shenzhen, China). The FBG levels (fasted for 8 h) of each group were measured weekly by nicking the tail vein using a one-touch glucometer (Sannuo, Changsha, China). The amounts of food intake, water consumption, and body weight were recorded daily during the entire treatment. At the end of the chronic experiment, IPGTT was performed to determine the glucose tolerance. Specifically, following 18 h of fasting, mice were injected intraperitoneally with glucose (0.5 g/kg) at 0 min, and the blood glucose levels were determined at 0, 15, 30, 60, 90, and 120 min. Finally, all mice fasted overnight were sacrificed to collect blood samples by extracting eyeballs with EDTA to prevent blood from clotting. After centrifugation, the plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Crea), urea, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were determined using the corresponding assay kits on a BS-420 automatic biochemical analyzer (Mindray, Shenzhen, China). At the same time, kidney, liver, and pancreas tissues in each group of mice were collected and fixed in 4% paraformaldehyde for H&E staining. Immunohistochemistry analyses for insulin in pancreas sections were performed with an Expose mouse-specific AP detection IHC kit (dilution ratio = 1:1000, Abcam, Cambridge, UK).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Statistical Analysis</h3><div class="NLM_p last">All data are presented as the means ± SEM. In the in vitro GLP-1R activation experiment, data were analyzed using a sigmoid function (Hill model) to calculate the EC<sub>50</sub> values of each sample (<i>n</i> = 3). The trapezoidal rule was used to determine the AUC values of the glucose profiles. Differences among groups were analyzed using one-way or two-way analysis of variance (ANOVA), followed by Dunnett’s post hoc multiple comparison test. Differences with <i>P</i> values <0.05 were considered statistically significant. Statistical analysis and plotting were performed with GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00032" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40822" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40822" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00032?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00032</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data and characterizations of native Ex4, Ex4-LPETGGS (peptide 1), FITC-labeled Ex4-LPETGGS (peptide 2), and conjugate 6–11; standard curve of the cAMP concentration using competitive cAMP ELISA, peptide 2 and conjugate 9–11 generated by fluorescence reading, and DNP moiety concentration as a function of optical density; ELISA results of the binding activity between Ex4–DNP conjugates and anti-DNP antibodies; quantitative analysis of immunostaining for insulin; flow cytometry evaluation of the HEK293-GLP1-R-AcGFP cell construction; procedure and protocol for the expression and purification of SrtA in <i>Escherichia coli</i> BL21 (DE3); preparation of DNP-carrier protein conjugates; ELISA protocol for DNP-antibody titer determination; ELISA protocol for determination of the binding activity between Ex4–DNP conjugates and anti-DNP antibodies or preimmunized mouse serum; and HEK293-GLP1-R-AcGFP construction (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf">jm1c00032_si_001.pdf (1.03 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00032" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Nie</span> - <span class="hlFld-Affiliation affiliation">Hisun
Biopharmaceutical Co., Limited, 8 Hisun Road, Xialian Village, Xukou Town, Fuyang
District, 311404 Hangzhou, Zhejiang, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bbd7ded2e4d5d2defb8a898d95d8d4d6"><span class="__cf_email__" data-cfemail="cda1a8a492a3a4a88dfcfffbe3aea2a0">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhimeng Wu</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7583-7268" title="Orcid link">http://orcid.org/0000-0001-7583-7268</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2a505d5f6a40434b444d444b44044f4e5f044944"><span class="__cf_email__" data-cfemail="2d575a586d47444c434a434c4303484958034e43">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shijie Dai</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haofei Hong</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kun Zhou</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai Zhao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuntian Xie</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Li</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Shi</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhifang Zhou</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Carbohydrate Chemistry & Biotechnology, Ministry
of Education, School of Biotechnology, Jiangnan
University, 214122 Wuxi, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (nos. 21907038 and 32000904), Natural Science Foundation of Jiangsu Province (no. BK20200601), China Postdoctoral Science Foundation (no. BX20200153), and Jiangsu Key Research and Development Plan (BE2019632). This work was partly supported by the Health and Family Planning Commission of Wuxi, China (no. Z202005), the Basic Research Program of Jiangnan University (no. JUSRP12016), the 111 Project (no. 111-2-06), the Open Foundation of Key Laboratory of Carbohydrate Chemistry & Biotechnology Ministry of Education (no. 202006), and the National First-class Discipline Program of Food Science and Technology (JUFSTR20180101).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">T2DM</td><td class="NLM_def"><p class="first last">type 2 diabetes mellitus</p></td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide 1</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">FcRn</td><td class="NLM_def"><p class="first last">neonatal Fc-receptor</p></td></tr><tr><td class="NLM_term">nADAs</td><td class="NLM_def"><p class="first last">neutralizing antidrug antibodies</p></td></tr><tr><td class="NLM_term">SML</td><td class="NLM_def"><p class="first last">sortase A-mediated ligation</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SPPS</td><td class="NLM_def"><p class="first last">solid-phase peptide synthesis</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">HEK293</td><td class="NLM_def"><p class="first last">human embryonic kidney 293</p></td></tr><tr><td class="NLM_term">Ahx</td><td class="NLM_def"><p class="first last">aminocaproic acid</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin-eosin</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TC</td><td class="NLM_def"><p class="first last">total cholesterol</p></td></tr><tr><td class="NLM_term">TG</td><td class="NLM_def"><p class="first last">serum triglycerides</p></td></tr><tr><td class="NLM_term">LDL-C</td><td class="NLM_def"><p class="first last">low-density lipoprotein cholesterol</p></td></tr><tr><td class="NLM_term">HDL-C</td><td class="NLM_def"><p class="first last">high-density lipoprotein cholesterol</p></td></tr><tr><td class="NLM_term">HbA1c</td><td class="NLM_def"><p class="first last">hemoglobin A1c</p></td></tr><tr><td class="NLM_term">FBG</td><td class="NLM_def"><p class="first last">fasting blood glucose</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01621" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01621" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">American
Diabetes Association</span> <span> </span><span class="NLM_article-title">2. Classification
and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">S14</span>– <span class="NLM_lpage">S31</span>, <span class="refDoi"> DOI: 10.2337/dc20-S002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.2337%2Fdc20-S002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=31862745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2020&pages=S14-S31&author=American%0ADiabetes+Association&title=2.+Classification%0Aand+Diagnosis+of+Diabetes%3A+Standards+of+Medical+Care+in+Diabetes-2020&doi=10.2337%2Fdc20-S002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2337%2Fdc20-S002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc20-S002%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3D2.%2520Classification%250Aand%2520Diagnosis%2520of%2520Diabetes%253A%2520Standards%2520of%2520Medical%2520Care%2520in%2520Diabetes-2020%26jtitle%3DDiabetes%2520Care%26date%3D2020%26volume%3D43%26spage%3DS14%26epage%3DS31%26doi%3D10.2337%2Fdc20-S002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magliano, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, E. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavkov, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koye, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. E.</span></span> <span> </span><span class="NLM_article-title">Trends in incidence of total or type 2 diabetes: systematic review</span>. <i>BMJ</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">l5003</span>, <span class="refDoi"> DOI: 10.1136/bmj.l5003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1136%2Fbmj.l5003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=31511236" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=l5003&author=D.+J.+Maglianoauthor=R.+M.+Islamauthor=E.+L.+M.+Barrauthor=E.+W.+Greggauthor=M.+E.+Pavkovauthor=J.+L.+Hardingauthor=M.+Tabeshauthor=D.+N.+Koyeauthor=J.+E.+Shaw&title=Trends+in+incidence+of+total+or+type+2+diabetes%3A+systematic+review&doi=10.1136%2Fbmj.l5003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1136%2Fbmj.l5003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.l5003%26sid%3Dliteratum%253Aachs%26aulast%3DMagliano%26aufirst%3DD.%2BJ.%26aulast%3DIslam%26aufirst%3DR.%2BM.%26aulast%3DBarr%26aufirst%3DE.%2BL.%2BM.%26aulast%3DGregg%26aufirst%3DE.%2BW.%26aulast%3DPavkov%26aufirst%3DM.%2BE.%26aulast%3DHarding%26aufirst%3DJ.%2BL.%26aulast%3DTabesh%26aufirst%3DM.%26aulast%3DKoye%26aufirst%3DD.%2BN.%26aulast%3DShaw%26aufirst%3DJ.%2BE.%26atitle%3DTrends%2520in%2520incidence%2520of%2520total%2520or%2520type%25202%2520diabetes%253A%2520systematic%2520review%26jtitle%3DBMJ%26date%3D2019%26volume%3D366%26spage%3Dl5003%26doi%3D10.1136%2Fbmj.l5003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scully, C. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00835</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=905-927&author=R.+Suzukiauthor=G.+A.+Brownauthor=J.+A.+Christopherauthor=C.+C.+G.+Scullyauthor=M.+Congreve&title=Recent+Developments+in+Therapeutic+Peptides+for+the+Glucagon-like+Peptide+1+and+2+Receptors&doi=10.1021%2Facs.jmedchem.9b00835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span></div><div class="casAuthors">Suzuki, Rie; Brown, Giles A.; Christopher, John A.; Scully, Conor C. G.; Congreve, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake.  These mols. are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents.  The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide mols. that hold promise as novel peptide therapeutics.  One emerging area is the discovery of multifunctional mols. that act at two or more pharmacol. systems to enhance therapeutic efficacy.  In addn., drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery.  These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdugqq7LLcprVg90H21EOLACvtfcHk0liOBGm4ywCYEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I&md5=98554f261b9fd88ed7a12e806869be6e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00835%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DScully%26aufirst%3DC.%2BC.%2BG.%26aulast%3DCongreve%26aufirst%3DM.%26atitle%3DRecent%2520Developments%2520in%2520Therapeutic%2520Peptides%2520for%2520the%2520Glucagon-like%2520Peptide%25201%2520and%25202%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D905%26epage%3D927%26doi%3D10.1021%2Facs.jmedchem.9b00835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koliaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doupis, J.</span></span> <span> </span><span class="NLM_article-title">Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus</span>. <i>Diabetes Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1007/s13300-011-0002-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2Fs13300-011-0002-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22127804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVehsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=101-121&author=C.+Koliakiauthor=J.+Doupis&title=Incretin-based+therapy%3A+a+powerful+and+promising+weapon+in+the+treatment+of+type+2+diabetes+mellitus&doi=10.1007%2Fs13300-011-0002-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Koliaki, Chrysi; Doupis, John</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-121</span>CODEN:
                <span class="NLM_cas:coden">DTIHAP</span>;
        ISSN:<span class="NLM_cas:issn">1869-6961</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease that increases significantly cardiovascular morbidity and mortality.  It is assocd. with obesity, insulin resistance, beta-cell dysfunction, and hyperglucagonemia, the combination of which typically leads to hyperglycemia.  Incretin-based treatment modalities, and in particular glucagon-like peptide 1 (GLP-1) receptor agonists, are able to successfully counteract several of the underlying pathophysiol. abnormalities of T2DM.  The pancreatic effects of GLP-1 receptor agonists include glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release in a strictly glucose-dependent manner, increased beta-cell proliferation, and decreased beta-cell apoptosis.  GLP-1 receptors are widely expressed throughout human body; thus, GLP-1-based therapies exert pleiotropic and multisystemic effects that extend far beyond pancreatic islets.  A large body of exptl. and clin. data have suggested a considerable protective role of GLP-1 analogs in the cardiovascular system (decreased blood pressure, improved endothelial and myocardial function, functional recovery of failing and ischemic heart, arterial vasodilatation), kidneys (increased diuresis and natriuresis), gastrointestinal tract (delayed gastric emptying, reduced gastric acid secretion), and central nervous system (appetite suppression, neuroprotective properties).  The pharmacol. use of GLP-1 receptor agonists has been shown to reduce bodyweight and systolic blood pressure, and significantly improve glycemic control and lipid profile.  Interestingly, wt. redn. induced by GLP-1 analogs reflects mainly loss of abdominal visceral fat.  The crit. issue of whether the emerging pos. cardiometabolic effects of GLP-1 analogs can be translated into better clin. outcomes for diabetic patients in terms of long-term hard endpoints, such as cardiovascular morbidity and mortality, remains to be elucidated with prospective, large-scale clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk98wVHFdMC7Vg90H21EOLACvtfcHk0ljm2kYxMCCA5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVehsbzF&md5=8fcf51bba726a7d30d07d1e3d592abd3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs13300-011-0002-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13300-011-0002-3%26sid%3Dliteratum%253Aachs%26aulast%3DKoliaki%26aufirst%3DC.%26aulast%3DDoupis%26aufirst%3DJ.%26atitle%3DIncretin-based%2520therapy%253A%2520a%2520powerful%2520and%2520promising%2520weapon%2520in%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDiabetes%2520Ther.%26date%3D2011%26volume%3D2%26spage%3D101%26epage%3D121%26doi%3D10.1007%2Fs13300-011-0002-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.cmet.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=29617641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=740-756&author=D.+J.+Drucker&title=Mechanisms+of+Action+and+Therapeutic+Application+of+Glucagon-like+Peptide-1&doi=10.1016%2Fj.cmet.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-756</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.  GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting wt. gain.  Here I review the circuits engaged by endogenous vs. pharmacol. GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-pos. cell types and pathways transducing metabolic and non-glycemic GLP-1 signals.  The role(s) of GLP-1 in the benefits and side effects assocd. with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiol. are highlighted.  Refinement of the risk-vs.-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimol. multi-agonists, all targeting the GLP-1R.  This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w0J5LcxUeLVg90H21EOLACvtfcHk0ljm2kYxMCCA5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D&md5=1bdfca5836ed6bd1d2cf49de109f5e65</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520of%2520Action%2520and%2520Therapeutic%2520Application%2520of%2520Glucagon-like%2520Peptide-1%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D740%26epage%3D756%26doi%3D10.1016%2Fj.cmet.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span> <span> </span><span class="NLM_article-title">GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2012.140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnrendo.2012.140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22945360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=728-742&author=J.+J.+Meier&title=GLP-1+receptor+agonists+for+individualized+treatment+of+type+2+diabetes+mellitus&doi=10.1038%2Fnrendo.2012.140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Meier, Juris J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">728-742</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and lowers glucose concns. by augmenting insulin secretion and suppressing glucagon release.  Addnl. effects of GLP-1 include retardation of gastric emptying, suppression of appetite and, potentially, inhibition of β-cell apoptosis.  Native GLP-1 is degraded within ∼2-3 min in the circulation; various GLP-1 receptor agonists have, therefore, been developed to provide prolonged in vivo actions.  These GLP-1 receptor agonists can be categorized as either short-acting compds., which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compds. (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose.  The pharmacokinetic differences between these drugs lead to important differences in their pharmacodynamic profiles.  The short-acting GLP-1 receptor agonists primarily lower postprandial blood glucose levels through inhibition of gastric emptying, whereas the long-acting compds. have a stronger effect on fasting glucose levels, which is mediated predominantly through their insulinotropic and glucagonostatic actions.  The adverse effect profiles of these compds. also differ.  The individual properties of the various GLP-1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GZovdW_ldbVg90H21EOLACvtfcHk0lhAvoZecuCTtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP&md5=5dc374bda9f06bb96494f8ed7a61018f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2012.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2012.140%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26atitle%3DGLP-1%2520receptor%2520agonists%2520for%2520individualized%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2012%26volume%3D8%26spage%3D728%26epage%3D742%26doi%3D10.1038%2Fnrendo.2012.140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miossec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, F.</span></span> <span> </span><span class="NLM_article-title">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1223</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.942638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1517%2F17460441.2014.942638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=25119443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1223&author=M.+Christensenauthor=P.+Miossecauthor=B.+Larsenauthor=U.+Wernerauthor=F.+Knop&title=The+design+and+discovery+of+lixisenatide+for+the+treatment+of+type+2+diabetes+mellitus&doi=10.1517%2F17460441.2014.942638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Christensen, Mikkel; Miossec, Patrick; Larsen, Bjarne Due; Werner, Ulrich; Knop, Filip K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1223-1251</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Lixisenatide is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM).  It is used in combination with oral antidiabetics and/or basal insulin in patients inadequately controlled on these medications and who are undergoing diet and lifestyle modification.  GLP-1RAs glucose-dependently increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, thereby improving glycemic control.  GLP-1RAs are assocd. with body wt. benefits and low rates of hypoglycemia which are welcome in patients with T2DM.  Areas covered: The authors describe the identification of GLP-1RAs as suitable targets for modification with structure-inducing probe technol. to improve stability and resistance to proteolytic degrdn.  Clin. studies have assessed lixisenatide across > 5000 patients as a monotherapy or add-on to a variety of commonly used antidiabetic medications.  These studies highlighted the effects of lixisenatide on gastric emptying, explaining its particular improvements in postprandial plasma glucose (PPG) excursions and underscoring its efficacy in combination with insulin glargine.  Lixisenatide was well tolerated, with nausea and vomiting being the most frequently reported adverse events.  Expert opinion: The once-daily administration of lixisenatide as well as its substantial sustained effect on gastric emptying and, hence, PPG excursions are all important features compared with the other GLP-1RAs.  The combination of two injectables, such as basal insulin to lower fasting plasma glucose and a GLP-1RA that curtails PPG excursions, is clin. valuable and could differentiate lixisenatide from other GLP-1RAs, esp. from those continuously acting GLP-1RAs with little effect on gastric emptying and PPG excursions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW0IfTdZVP3bVg90H21EOLACvtfcHk0lhAvoZecuCTtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN&md5=aaf08b96c53617d3044e56447ca8e7f1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.942638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.942638%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DMiossec%26aufirst%3DP.%26aulast%3DLarsen%26aufirst%3DB.%26aulast%3DWerner%26aufirst%3DU.%26aulast%3DKnop%26aufirst%3DF.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520lixisenatide%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D1223%26doi%3D10.1517%2F17460441.2014.942638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">578</span>, <span class="refDoi"> DOI: 10.3390/ijms18030578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.3390%2Fijms18030578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=578&author=W.+Saiauthor=H.+Tianauthor=K.+Yangauthor=D.+Tangauthor=J.+Baoauthor=Y.+Geauthor=X.+Songauthor=Y.+Zhangauthor=C.+Luoauthor=X.+Gaoauthor=W.+Yao&title=Systematic+Design+of+Trypsin+Cleavage+Site+Mutated+Exendin4-Cysteine+1%2C+an+Orally+Bioavailable+Glucagon-Like+Peptide-1+Receptor+Agonist&doi=10.3390%2Fijms18030578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic design of trypsin cleavage site mutated exendin4-cysteine 1, an orally bioavailable glucagon-like peptide-1 receptor agonist</span></div><div class="casAuthors">Sai, Wenbo; Tian, Hong; Yang, Kangmin; Tang, Daoqi; Bao, Jinxiao; Ge, Yang; Song, Xiaoda; Zhang, Yu; Luo, Cheng; Gao, Xiangdong; Yao, Wenbing</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">578/1-578/15</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Exendin-4 is a strong therapeutic candidate for the treatment of metabolic syndrome.  Related receptor agonist drugs have been on the market since 2005.  However, tech. limitations and the pain caused by s.c. injection have severely limited patient compliance.  The goal of the study is to investigate a biol. active exendin-4 analog could be administered orally.  Using i.p. glucose tolerance tests, we discovered that exendin4-cysteine administered by oral gavage had a distinct hypoglycemic effect in C57BL/6J mice.  Using Rosetta Design and Amber, we designed and screened a series of exendin4-cysteine analogs to identify those that retained biol. activity while resisting trypsin digestion.  Trypsin Cleavage Site Mutated Exendin4-cysteine 1 (TSME-1), an analog whose bioactivity was similar to exendin-4 and was almost completely resistant to trypsin, was screened out.  In addn., TSME-1 significantly normalized the blood glucose levels and the availability of TSME-1 was significantly higher than that of exendin-4 and exendin4-cysteine.  Collectively orally administered TSME-1, a trypsin-resistant exendin-4 analog obtained by the system, is a strong candidate for future treatments of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_hulc1rrukrVg90H21EOLACvtfcHk0lhAvoZecuCTtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSjuro%253D&md5=eed720e67d6298f6e5434b145988cf7d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fijms18030578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18030578%26sid%3Dliteratum%253Aachs%26aulast%3DSai%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DD.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DW.%26atitle%3DSystematic%2520Design%2520of%2520Trypsin%2520Cleavage%2520Site%2520Mutated%2520Exendin4-Cysteine%25201%252C%2520an%2520Orally%2520Bioavailable%2520Glucagon-Like%2520Peptide-1%2520Receptor%2520Agonist%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D578%26doi%3D10.3390%2Fijms18030578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.ejmech.2018.07.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=30096651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=177-187&author=J.+Hanauthor=Y.+Huangauthor=X.+Chenauthor=F.+Zhouauthor=Y.+Feiauthor=J.+Fu&title=Rational+design+of+dimeric+lipidated+Xenopus+glucagon-like+peptide+1+analogues+as+long-acting+antihyperglycaemic+agents&doi=10.1016%2Fj.ejmech.2018.07.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycemic agents</span></div><div class="casAuthors">Han, Jing; Huang, Yue; Chen, Xinyu; Zhou, Feng; Fei, Yingying; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Dimerization is viewed as an effective means to enhance the binding affinity and therapeutic potency of peptides.  Both dimerization and lipidation effectively prolong the half-life of peptides in vivo by increasing hydrodynamic size and facilitating phys. interactions with serum albumin.  Here, we report a novel method to discover long-acting glucagon-like peptide 1 (GLP-1) analogs by rational design based on Xenopus GLP-1 through a combined dimerization and lipidization strategy.  On the basis of our previous structure anal. of Xenopus GLP-1, palmitic acid and a C-terminal Cys were firstly introduced into two Xenopus GLP-1 analogs (1 and 2), and the afforded 3 and 4 were further reacted with bis-maleimide amine to afford two dimeric lipidated Xenopus GLP-1 analogs (5 and 6).  The in vitro and in vivo biol. activities of 5 and 6 were significantly improved as compared with their monomers.  Moreover, the selected compd. 6 showed greater hypoglycemic and insulinotropic activities than liraglutide even when the dose of 6 was reduced to half in db/db mice.  Pharmacokinetic test revealed that 6 had a ∼ 3-fold longer half-life than liraglutide in Kunming mice and SD rats, and the longer half-life of 6 led to excellent long-acting hypoglycemic effects as confirmed by two different pharmacol. methods conducted on db/db mice.  Finally, a 7 wk chronic study conducted on db/db mice demonstrated the better therapeutic efficacies of 6 on glucose tolerance normalization, HbA1c redn. and pancreas islets protection than liraglutide.  The present research showed that combined dimerization and lipidization is effective when applied to Xenopus GLP-1 analog to develop novel GLP-1 analog for the treatment of type 2 diabetes.  In addn., the promising preclin. data of 6 suggested the therapeutic potential of 6 as a novel anti-diabetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu69hLGs6cPLVg90H21EOLACvtfcHk0lgQlFppkxirSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO&md5=ae25a20f5222a840602f9bece420e690</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.072%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DRational%2520design%2520of%2520dimeric%2520lipidated%2520Xenopus%2520glucagon-like%2520peptide%25201%2520analogues%2520as%2520long-acting%2520antihyperglycaemic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D177%26epage%3D187%26doi%3D10.1016%2Fj.ejmech.2018.07.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofoed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gram, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedtz-Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7370</span>– <span class="NLM_lpage">7380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaardauthor=H.+M.+Straussauthor=D.+X.+Gramauthor=S.+M.+Knudsenauthor=F.+S.+Nielsenauthor=P.+Thygesenauthor=S.+Reedtz-Rungeauthor=T.+Kruse&title=Discovery+of+the+Once-Weekly+Glucagon-Like+Peptide-1+%28GLP-1%29+Analogue+Semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0lgQlFppkxirSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26aulast%3DStrauss%26aufirst%3DH.%2BM.%26aulast%3DGram%26aufirst%3DD.%2BX.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%26aulast%3DNielsen%26aufirst%3DF.%2BS.%26aulast%3DThygesen%26aufirst%3DP.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DKruse%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520Once-Weekly%2520Glucagon-Like%2520Peptide-1%2520%2528GLP-1%2529%2520Analogue%2520Semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9955</span>– <span class="NLM_lpage">9968</span>, <span class="refDoi"> DOI: 10.1021/jm4017448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9955-9968&author=J.+Hanauthor=L.+Sunauthor=Y.+Chuauthor=Z.+Liauthor=D.+Huangauthor=X.+Zhuauthor=H.+Qianauthor=W.+Huang&title=Design%2C+synthesis%2C+and+biological+activity+of+novel+dicoumarol+glucagon-like+peptide+1+conjugates&doi=10.1021%2Fjm4017448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates</span></div><div class="casAuthors">Han, Jing; Sun, Lidan; Chu, Yingying; Li, Zheng; Huang, Dandan; Zhu, Xiaoyun; Qian, Hai; Huang, Wenlong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9955-9968</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Twelve novel dicoumarol glucagon-like peptide 1 (GLP-1) conjugates were designed, synthesized, and tested for biol. activity.  All derivs. retained receptor activation efficacy, and exhibited improved albumin affinity and in vitro stability in rat plasma.  The in vivo elimination half-lives of 13c and 13l (22.07 and 18.78 h, resp.) were much longer than those of the GLP-1 receptor agonists exendin-4 (2.82 h) and liraglutide (12.53 h).  The prolonged in vivo antidiabetic effects of 13c and 13l on db/db mice were confirmed by the hypoglycemic efficacy test and the multiple i.p. glucose tolerance test.  Importantly, a once daily administration of 13c to db/db mice for 7 wk provided long-term beneficial effects by lowering glycated Hb (HbA1c) levels to 5.05%, which was lower than with liraglutide treatment (5.41%).  These results suggest that 13c is a promising long-lasting GLP-1 mimetic that may be suitable for clin. use following further research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTz1d3aaqq0LVg90H21EOLACvtfcHk0lgQlFppkxirSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnJ&md5=cc6a253589304c9b29db4871474dbedf</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm4017448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017448%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activity%2520of%2520novel%2520dicoumarol%2520glucagon-like%2520peptide%25201%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9955%26epage%3D9968%26doi%3D10.1021%2Fjm4017448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simakova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luginbuhl, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershfield, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyjaszewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity</span>. <i>Nat. Biomed. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">0002</span>, <span class="refDoi"> DOI: 10.1038/s41551-016-0002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41551-016-0002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ahur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=0002&author=Y.+Qiauthor=A.+Simakovaauthor=N.+J.+Gansonauthor=X.+Liauthor=K.+M.+Luginbuhlauthor=I.+Ozerauthor=W.+Liuauthor=M.+S.+Hershfieldauthor=K.+Matyjaszewskiauthor=A.+Chilkoti&title=A+brush-polymer+conjugate+of+exendin-4+reduces+blood+glucose+for+up+to+five+days+and+eliminates+poly%28ethylene+glycol%29+antigenicity&doi=10.1038%2Fs41551-016-0002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity</span></div><div class="casAuthors">Qi, Yizhi; Simakova, Antonina; Ganson, Nancy J.; Li, Xinghai; Luginbuhl, Kelli M.; Ozer, Imran; Liu, Wenge; Hershfield, Michael S.; Matyjaszewski, Krzysztof; Chilkoti, Ashutosh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biomedical Engineering</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">0002</span>CODEN:
                <span class="NLM_cas:coden">NBEAB3</span>;
        ISSN:<span class="NLM_cas:issn">2157-846X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The delivery of therapeutic peptides and proteins is often challenged by short half-lives and the consequent need for frequent injections that limit efficacy, reduce patient compliance and increase treatment cost.  Here, we demonstrate that a single s.c. injection of site-specific (C-terminal) conjugates of exendin-4 (exendin)-a therapeutic peptide that is clin. used to treat type 2 diabetes mellitus-and poly[oligo(ethylene glycol) Me ether methacrylate] (POEGMA) with precisely controlled mol. wts. lowered blood glucose for up to 120 h in fed mice.  Most notably, we show that an exendin-C-POEGMA conjugate with an av. of nine side-chain ethylene glycol (EG) repeats exhibits significantly lower reactivity towards patient-derived anti-poly(ethylene glycol) (anti-PEG) antibodies than two US FDA-approved PEGylated drugs, and that reducing the side-chain length to three EG repeats completely eliminates PEG antigenicity without compromising in vivo efficacy.  Our findings establish the site-specific conjugation of POEGMA as a next-generation PEGylation technol. for improving the pharmacol. performance of traditional PEGylated drugs, whose safety and efficacy are hindered by pre-existing anti-PEG antibodies in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EnxB3iRfBLVg90H21EOLACvtfcHk0ljdvoAcAGrJ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ahur3J&md5=6b947841a437e5c765b0d7d6f053e94e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41551-016-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41551-016-0002%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSimakova%26aufirst%3DA.%26aulast%3DGanson%26aufirst%3DN.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLuginbuhl%26aufirst%3DK.%2BM.%26aulast%3DOzer%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHershfield%26aufirst%3DM.%2BS.%26aulast%3DMatyjaszewski%26aufirst%3DK.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DA%2520brush-polymer%2520conjugate%2520of%2520exendin-4%2520reduces%2520blood%2520glucose%2520for%2520up%2520to%2520five%2520days%2520and%2520eliminates%2520poly%2528ethylene%2520glycol%2529%2520antigenicity%26jtitle%3DNat.%2520Biomed.%2520Eng.%26date%3D2017%26volume%3D1%26spage%3D0002%26doi%3D10.1038%2Fs41551-016-0002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S. K.</span></span> <span> </span><span class="NLM_article-title">Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">4121</span>– <span class="NLM_lpage">4128</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2010.01.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.biomaterials.2010.01.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=20149450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFKis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=4121-4128&author=J.-H.+Kongauthor=E.+J.+Ohauthor=S.+Y.+Chaeauthor=K.+C.+Leeauthor=S.+K.+Hahn&title=Long+acting+hyaluronate%2D%2Dexendin+4+conjugate+for+the+treatment+of+type+2+diabetes&doi=10.1016%2Fj.biomaterials.2010.01.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Long acting hyaluronate - exendin 4 conjugate for the treatment of type 2 diabetes</span></div><div class="casAuthors">Kong, Ji-Hyun; Oh, Eun Ju; Chae, Su Young; Lee, Kang Choon; Hahn, Sei Kwang</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4121-4128</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite clin. exploitation of exendin 4 for the treatment of type 2 diabetes, the significantly short half-life requiring twice a day injection has limited the wide applications.  In this work, a protocol for the synthesis of long acting hyaluronate (HA) - exendin 4 conjugate was successfully developed using Michael addn. chem. between vinyl sulfone modified HA (HA-VS) and thiolated exendin 4.  The exendin 4 content could be controlled in the range of 5-30 mols. per single HA chain with a bioconjugation efficiency higher than 90%.  The conjugation of exendin 4 with HA resulted in about 20 times improved in vitro serum stability maintaining the hypoglycemic and gluco-regulatory bioactivities of exendin 4.  HA - exendin 4 conjugates showed excellent glucose-lowering capabilities in type 2 db/db mice demonstrating protracted hypoglycemic effect up to 3 days after a single s.c. injection.  Furthermore, insulin immunohistochem. anal. of islets in db/db mice confirmed the improved insulinotropic activity of HA - exendin 4 conjugates.  The HA - exendin 4 conjugates will be investigated further as a twice a week injection dosage form for clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUN06zMLTLlLVg90H21EOLACvtfcHk0ljdvoAcAGrJ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFKis78%253D&md5=9eed2b7dd0a6228bcb0595104960d3db</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2010.01.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2010.01.091%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DJ.-H.%26aulast%3DOh%26aufirst%3DE.%2BJ.%26aulast%3DChae%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DHahn%26aufirst%3DS.%2BK.%26atitle%3DLong%2520acting%2520hyaluronate--exendin%25204%2520conjugate%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DBiomaterials%26date%3D2010%26volume%3D31%26spage%3D4121%26epage%3D4128%26doi%3D10.1016%2Fj.biomaterials.2010.01.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment</span>. <i>Carbohydr. Polym.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>249</i></span>,  <span class="NLM_fpage">116864</span>– <span class="NLM_lpage">116872</span>, <span class="refDoi"> DOI: 10.1016/j.carbpol.2020.116864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.carbpol.2020.116864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=32933691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2020&pages=116864-116872&author=S.+Daiauthor=S.+Liuauthor=C.+Liauthor=Z.+Zhouauthor=Z.+Wu&title=Site-selective+modification+of+exendin+4+with+variable+molecular+weight+dextrans+by+oxime-ligation+chemistry+for+improving+type+2+diabetic+treatment&doi=10.1016%2Fj.carbpol.2020.116864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment</span></div><div class="casAuthors">Dai, Shijie; Liu, Shaozhong; Li, Chen; Zhou, Zhifang; Wu, Zhimeng</div><div class="citationInfo"><span class="NLM_cas:title">Carbohydrate Polymers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">249</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116864</span>CODEN:
                <span class="NLM_cas:coden">CAPOD8</span>;
        ISSN:<span class="NLM_cas:issn">0144-8617</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dextrans, as natural and biocompatible polysaccharides, are a promising candidate as PEG alternatives to improve the therapeutic profiles of biotherapeuticals.  In this work, we chem. mutated the lysine residue in native Ex4 to aminooxyl contg. lysine (K*) and three Ex4 analogs (Ex4-12K*, Ex4-27K*, Ex4-12K*-27K*) were synthesized and site-selectively modified with variable Mw of dextrans by facile oxime-ligation chem.  The biol. activities of six dextran-Ex4 conjugates were studied by in vitro and in vivo expt.  It was demonstrated that dextranylation at the 12-site of Ex4 detd. the in vitro potency as GLP-1R agonist and the in vivo acute glucose-lowering activity.  Furthermore, the in vivo long-acting antidiabetic expt. demonstrated that hypoglycemic effect was strongly dependent on the dextranylation site of Ex4 as well as the size of dextran.  And Dextran-Ex4-12K*(20,000) exhibited the best long acting hypoglycemic activity in STZ/HFD-induced T2D mice and is a promising once daily reagent for T2D treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6pk86P6OKaLVg90H21EOLACvtfcHk0ljdvoAcAGrJ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKnt7%252FL&md5=1cf12aa03e1570169b9d834c00963e82</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.carbpol.2020.116864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.carbpol.2020.116864%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSite-selective%2520modification%2520of%2520exendin%25204%2520with%2520variable%2520molecular%2520weight%2520dextrans%2520by%2520oxime-ligation%2520chemistry%2520for%2520improving%2520type%25202%2520diabetic%2520treatment%26jtitle%3DCarbohydr.%2520Polym.%26date%3D2020%26volume%3D249%26spage%3D116864%26epage%3D116872%26doi%3D10.1016%2Fj.carbpol.2020.116864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Molecular Design of Peptide-Fc Fusion Drugs</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.2174/1389200219666180821095355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.2174%2F1389200219666180821095355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=30129406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFejsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=203-208&author=L.+Ningauthor=B.+Heauthor=P.+Zhouauthor=R.+Derdaauthor=J.+Huang&title=Molecular+Design+of+Peptide-Fc+Fusion+Drugs&doi=10.2174%2F1389200219666180821095355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Design of Peptide-Fc Fusion Drugs</span></div><div class="casAuthors">Ning, Lin; He, Bifang; Zhou, Peng; Derda, Ratmir; Huang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-208</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptide-Fc fusion drugs, also known as peptibodies, are a category of biol. therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest.  However, to develop such kind of drugs is laborious and expensive.  Rational design is urgently needed.  We summarized the key steps in peptide-Fc fusion technol. and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs.  We also raised open questions about the computer-aided mol. design of peptide-Fc.  The design of peptibody consists of four steps.  First, identify peptide leads from native ligands, biopanning, and computational design or prediction.  Second, select the proper Fc region from different classes or subclasses of Ig.  Third, fuse the peptide leads and Fc together properly.  At last, evaluate the immunogenicity of the constructs.  At each step, there are quite a few useful resources and computational tools.  Reviewing the mol. design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo78dJRpa4-97Vg90H21EOLACvtfcHk0ljFz5pnB-MREw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFejsbzF&md5=ee8643ca6b72120311586f14b590d527</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1389200219666180821095355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200219666180821095355%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DDerda%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DMolecular%2520Design%2520of%2520Peptide-Fc%2520Fusion%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2019%26volume%3D20%26spage%3D203%26epage%3D208%26doi%3D10.2174%2F1389200219666180821095355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roopenian, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akilesh, S.</span></span> <span> </span><span class="NLM_article-title">FcRn: the neonatal Fc receptor comes of age</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1038/nri2155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnri2155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=17703228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsV2qtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=715-725&author=D.+C.+Roopenianauthor=S.+Akilesh&title=FcRn%3A+the+neonatal+Fc+receptor+comes+of+age&doi=10.1038%2Fnri2155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">FcRn: the neonatal Fc receptor comes of age</span></div><div class="casAuthors">Roopenian, Derry C.; Akilesh, Shreeram</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">715-725</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from a mother to her fetus.  In addn., throughout life, FcRn protects IgG from degrdn., thereby explaining the long half-life of this class of antibody in the serum.  In recent years, it has become clear that FcRn is expressed in various sites in adults, where its potential function is now beginning to emerge.  In addn., recent studies have examd. the interaction between FcRn and the Fc portion of IgG with the aim of either improving the serum half-life of therapeutic monoclonal antibodies or reducing the half-life of pathogenic antibodies.  This review summarizes these two areas of FcRn biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5skHElvYC7rVg90H21EOLACvtfcHk0ljFz5pnB-MREw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsV2qtbw%253D&md5=2a8ac184952c13877635d8ebc0e53956</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnri2155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2155%26sid%3Dliteratum%253Aachs%26aulast%3DRoopenian%26aufirst%3DD.%2BC.%26aulast%3DAkilesh%26aufirst%3DS.%26atitle%3DFcRn%253A%2520the%2520neonatal%2520Fc%2520receptor%2520comes%2520of%2520age%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D715%26epage%3D725%26doi%3D10.1038%2Fnri2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heath, C.</span>; <span class="NLM_string-name">Pettit, D.</span></span> <span> </span><span class="NLM_article-title">“Fc Fusion Proteins”</span>.  <i>Challenges in Protein Product Development</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">558</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2F978-3-319-90603-4_24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=545-558&author=C.+Heath&author=D.+Pettit&title=Challenges+in+Protein+Product+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-90603-4_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-90603-4_24%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DC.%26atitle%3D%25E2%2580%259CFc%2520Fusion%2520Proteins%25E2%2580%259D%26btitle%3DChallenges%2520in%2520Protein%2520Product%2520Development%26pub%3DSpringer%26date%3D2018%26spage%3D545%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span> <i>Fusion Protein Technologies for Biopharmaceuticals. Applications and Challenges</i>; <span class="NLM_publisher-name">Wiley</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2F9781118354599" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Schmidt&title=Fusion+Protein+Technologies+for+Biopharmaceuticals.+Applications+and+Challenges"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2F9781118354599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118354599%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DS.%26btitle%3DFusion%2520Protein%2520Technologies%2520for%2520Biopharmaceuticals.%2520Applications%2520and%2520Challenges%26pub%3DWiley%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, A.</span></span> <span> </span><span class="NLM_article-title">Comparing antibody and small-molecule therapies for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrc1913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnrc1913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=16929325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=714-727&author=K.+Imaiauthor=A.+Takaoka&title=Comparing+antibody+and+small-molecule+therapies+for+cancer&doi=10.1038%2Fnrc1913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing antibody and small-molecule therapies for cancer</span></div><div class="casAuthors">Imai, Kohzoh; Takaoka, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">714-727</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-mol. compds. have been approved for cancer treatment.  Both antibodies and small-mol. compds. are therefore promising tools for target-protein-based cancer therapy.  We discuss and compare the distinctive properties of these two therapeutic strategies to provide a better view for the development of new drugs and the future direction of cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDfUrcKvj1GLVg90H21EOLACvtfcHk0ljFz5pnB-MREw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D&md5=31cfa17a5e3ddba75b2e32632aaa0deb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc1913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1913%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DK.%26aulast%3DTakaoka%26aufirst%3DA.%26atitle%3DComparing%2520antibody%2520and%2520small-molecule%2520therapies%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D714%26epage%3D727%26doi%3D10.1038%2Fnrc1913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strome, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauna, Z. E.</span></span> <span> </span><span class="NLM_article-title">Fc fusion as a platform technology: potential for modulating immunogenicity</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.tibtech.2014.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.tibtech.2014.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=25488117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=27-34&author=D.+Levinauthor=B.+Goldingauthor=S.+E.+Stromeauthor=Z.+E.+Sauna&title=Fc+fusion+as+a+platform+technology%3A+potential+for+modulating+immunogenicity&doi=10.1016%2Fj.tibtech.2014.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fc fusion as a platform technology: potential for modulating immunogenicity</span></div><div class="casAuthors">Levin, Ditza; Golding, Basil; Strome, Scott E.; Sauna, Zuben E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-34</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The platform technol. of fragment crystallizable (Fc) fusion, in which the Fc region of an antibody is genetically linked to an active protein drug, is among the most successful of a new generation of bioengineering strategies.  Immunogenicity is a crit. safety concern in the development of any protein therapeutic.  While the therapeutic goal of generating Fc-fusion proteins has been to extend half-life, there is a crit. mass of literature from immunol. indicating that appropriate design of the Fc component has the potential to engage the immune system for product-specific outcomes.  In the context of Fc-fusion therapeutics, a review of progress in understanding Fc biol. suggests the prospect of engineering products that have an extended half-life and are able to modulate the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqycjBdv1yE5bVg90H21EOLACvtfcHk0lj-zaaQ3A7Slw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrN&md5=fe4cba49e6eb8c303b0cf7726bc1bf66</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2014.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2014.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DD.%26aulast%3DGolding%26aufirst%3DB.%26aulast%3DStrome%26aufirst%3DS.%2BE.%26aulast%3DSauna%26aufirst%3DZ.%2BE.%26atitle%3DFc%2520fusion%2520as%2520a%2520platform%2520technology%253A%2520potential%2520for%2520modulating%2520immunogenicity%26jtitle%3DTrends%2520Biotechnol.%26date%3D2015%26volume%3D33%26spage%3D27%26epage%3D34%26doi%3D10.1016%2Fj.tibtech.2014.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1007/s13238-017-0408-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2Fs13238-017-0408-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=28421387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFCru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=15-32&author=L.+Liu&title=Pharmacokinetics+of+monoclonal+antibodies+and+Fc-fusion+proteins&doi=10.1007%2Fs13238-017-0408-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins</span></div><div class="casAuthors">Liu, Liming</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-32</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion mol. with the primary determinant being FcRn-mediated recycling.  Through Fab or Fc engineering, IgG-FcRn interaction can be used to generate a variety of therapeutic antibodies with significantly enhanced half-life or ability to remove unwanted antigen from circulation.  Glycosylation of a mAb or Fc-fusion protein can have a significant impact on the PK of these mols.  MAb charge can be important and variants with pI values of 1-2 unit difference are likely to impact PK with lower pI values being favorable for a longer half-life.  Most mAbs display target mediated drug disposition (TMDD), which can have significant consequences on the study designs of preclin. and clin. studies.  The PK of mAb can also be influenced by anti-drug antibody (ADA) response and off-target binding, which require careful consideration during the discovery stage. mAbs are primarily absorbed through the lymphatics via convection and can be conveniently administered by the s.c. (s.c.) route in large doses/vols. with co-formulation of hyaluronidase.  The human PK of a mAb can be reasonably estd. using cynomolgus monkey data and allometric scaling methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxt43BRiGzHLVg90H21EOLACvtfcHk0lj-zaaQ3A7Slw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFCru70%253D&md5=29227aae984bad9b7d2124aaf2f8c6ff</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs13238-017-0408-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-017-0408-4%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DPharmacokinetics%2520of%2520monoclonal%2520antibodies%2520and%2520Fc-fusion%2520proteins%26jtitle%3DProtein%2520Cell%26date%3D2018%26volume%3D9%26spage%3D15%26epage%3D32%26doi%3D10.1007%2Fs13238-017-0408-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umpierrez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofé Povedano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez Manghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shurzinske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pechtner, V.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2168</span>– <span class="NLM_lpage">2176</span>, <span class="refDoi"> DOI: 10.2337/dc13-2759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.2337%2Fdc13-2759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=24842985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFertrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=2168-2176&author=G.+Umpierrezauthor=S.+Tof%C3%A9+Povedanoauthor=F.+P%C3%A9rez+Manghiauthor=L.+Shurzinskeauthor=V.+Pechtner&title=Efficacy+and+Safety+of+Dulaglutide+Monotherapy+Versus+Metformin+in+Type+2+Diabetes+in+a+Randomized+Controlled+Trial+%28AWARD-3%29&doi=10.2337%2Fdc13-2759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)</span></div><div class="casAuthors">Umpierrez, Guillermo; Povedano, Santiago Tofe; Manghi, Federico Perez; Shurzinske, Linda; Pechtner, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2168-2176</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">The objective of the study was to compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes.  The primary objective compared dulaglutide 1.5 mg and metformin on change from baseline glycosylated Hb A1c (HbA1c) at 26 wk.  This 52-wk double-blind study randomized patients to s.c. dulaglutide 1.5 mg, dulaglutide 0.75 mg, or metformin.  Patients (N = 807) had HbA1c ≥6.5% (≥48 mmol/mol) and ≤9.5% (≤80 mmol/mol) with diet and exercise alone or low-dose oral antihyperglycemic medication (OAM) monotherapy; OAMs were discontinued at beginning of lead-in period.  At 26 wk, changes from baseline HbA1c (least squares [LS] mean ± SE) were: dulaglutide 1.5 mg, -0.78 ± 0.06% (-8.5 ± 0.70 mmol/mol); dulaglutide 0.75 mg, -0.71 ± 0.06% (-7.8 ± 0.70 mmol/mol); and metformin, -0.56 ± 0.06% (-6.1 ± 0.70 mmol/mol).  Dulaglutide 1.5 and 0.75 mg were superior to metformin (LS mean difference): -0.22% (-2.4 mmol/mol) and -0.15% (-1.6 mmol/mol) (one-sided P < 0.025, both comparisons), resp.  Greater percentages reached HbA1c targets <7.0% (<53 mmol/mol) and ≤6.5% (≤48 mmol/mol) with dulaglutide 1.5 and 0.75 mg compared with metformin (P < 0.05, all comparisons).  No severe hypoglycemia was reported.  Compared with metformin, decrease in wt. was similar with dulaglutide 1.5 mg and smaller with dulaglutide 0.75 mg.  Over 52 wk, nausea, diarrhea, and vomiting were the most common adverse events; incidences were similar between dulaglutide and metformin.  Dulaglutide improves glycemic control and is well tolerated as monotherapy in patients with early stage type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPn3-np1l5YLVg90H21EOLACvtfcHk0lj-zaaQ3A7Slw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFertrfN&md5=7addb4e532a46045d81054967ade6437</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2337%2Fdc13-2759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc13-2759%26sid%3Dliteratum%253Aachs%26aulast%3DUmpierrez%26aufirst%3DG.%26aulast%3DTof%25C3%25A9%2BPovedano%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez%2BManghi%26aufirst%3DF.%26aulast%3DShurzinske%26aufirst%3DL.%26aulast%3DPechtner%26aufirst%3DV.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Dulaglutide%2520Monotherapy%2520Versus%2520Metformin%2520in%2520Type%25202%2520Diabetes%2520in%2520a%2520Randomized%2520Controlled%2520Trial%2520%2528AWARD-3%2529%26jtitle%3DDiabetes%2520Care%26date%3D2014%26volume%3D37%26spage%3D2168%26epage%3D2176%26doi%3D10.2337%2Fdc13-2759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perdomo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sällberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahlne, A.</span></span> <span> </span><span class="NLM_article-title">Neutralization of HIV-1 by redirection of natural antibodies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">12515</span>– <span class="NLM_lpage">12520</span>, <span class="refDoi"> DOI: 10.1073/pnas.0805777105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1073%2Fpnas.0805777105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=18719129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKqtL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=12515-12520&author=M.+F.+Perdomoauthor=M.+Leviauthor=M.+S%C3%A4llbergauthor=A.+Vahlne&title=Neutralization+of+HIV-1+by+redirection+of+natural+antibodies&doi=10.1073%2Fpnas.0805777105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization of HIV-1 by redirection of natural antibodies</span></div><div class="casAuthors">Perdomo, Maria F.; Levi, Michael; Saellberg, Matti; Vahlne, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">12515-12520</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The great variability and high glycosylation of gp120 poses a great challenge for the design of a functional immune therapy.  The binding region of the CD4 receptor to gp120, however, is well conserved and may constitute a target to limit viral entry and infectivity.  Our strategy consists in using a preexisting pool of natural antibodies directed toward the gal(α1,3)gal disaccharide and to redirect it to HIV.  We here show that using CD4-derived, gp120-binding, synthetic peptides chem. linked to gal(α1,3)gal can redirect these natural antibodies and improve the HIV-1 neutralizing activity of the CD4-derived peptides in vitro.  Importantly, the binding of the CD4-gal(α1,3)gal peptides to HIV-1-infected cells conferred antibody-dependent cellular cytotoxicity after the addn. of human sera.  Thus, the temporary redirection of naturally occurring antibodies and their biol. activities to a new antigen represents a completely new way of targeting a human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dCLnN9mcX7Vg90H21EOLACvtfcHk0liKT5qvulabAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKqtL7F&md5=5f7633d4dd71b82511704cb0c0feb66b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805777105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805777105%26sid%3Dliteratum%253Aachs%26aulast%3DPerdomo%26aufirst%3DM.%2BF.%26aulast%3DLevi%26aufirst%3DM.%26aulast%3DS%25C3%25A4llberg%26aufirst%3DM.%26aulast%3DVahlne%26aufirst%3DA.%26atitle%3DNeutralization%2520of%2520HIV-1%2520by%2520redirection%2520of%2520natural%2520antibodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D12515%26epage%3D12520%26doi%3D10.1073%2Fpnas.0805777105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, R. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hank, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, L. L.</span></span> <span> </span><span class="NLM_article-title">Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1002/cbic.201402019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fcbic.201402019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=24909955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlOhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1393-1398&author=R.+T.+C.+Sheridanauthor=J.+Hudonauthor=J.+A.+Hankauthor=P.+M.+Sondelauthor=L.+L.+Kiessling&title=Rhamnose+glycoconjugates+for+the+recruitment+of+endogenous+anti-carbohydrate+antibodies+to+tumor+cells&doi=10.1002%2Fcbic.201402019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti-Carbohydrate Antibodies to Tumor Cells</span></div><div class="casAuthors">Sheridan, Rachael T. C.; Hudon, Jonathan; Hank, Jacquelyn A.; Sondel, Paul M.; Kiessling, Laura L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Immunotherapy is a promising strategy for targeting tumors.  One emerging approach is to harness the immune effector functions of natural antibodies to destroy tumor cells.  Dinitrophenyl (DNP) and the galactose-α-1,3-galactose (αGal) epitope are two haptens that bind endogenous antibodies.  One potential alternative is the deoxysugar L-rhamnose.  We compared these candidates by using a biosensor assay to evaluate human sera for endogenous antibody concn., antibody isotype distribution, and longevity of antibody-hapten interactions.  Antibodies recognizing α-rhamnose are of equal or greater abundance and affinity as those recognizing αGal.  Moreover, both rhamnose and αGal epitopes are more effective than DNP at recruiting the IgG antibody subtype.  Exposure of tumor cells to rhamnose-bearing glycolipids and human serum promotes complement-mediated cytotoxicity.  These data highlight the utility of α-rhamnose-contg. glycoconjugates to direct the immune system to target cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfhJfAmJ583LVg90H21EOLACvtfcHk0liKT5qvulabAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlOhtr8%253D&md5=a4107919152fad35bac947a40ec11573</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402019%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DR.%2BT.%2BC.%26aulast%3DHudon%26aufirst%3DJ.%26aulast%3DHank%26aufirst%3DJ.%2BA.%26aulast%3DSondel%26aufirst%3DP.%2BM.%26aulast%3DKiessling%26aufirst%3DL.%2BL.%26atitle%3DRhamnose%2520glycoconjugates%2520for%2520the%2520recruitment%2520of%2520endogenous%2520anti-carbohydrate%2520antibodies%2520to%2520tumor%2520cells%26jtitle%3DChembiochem%26date%3D2014%26volume%3D15%26spage%3D1393%26epage%3D1398%26doi%3D10.1002%2Fcbic.201402019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rullo, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, D. A.</span></span> <span> </span><span class="NLM_article-title">Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3642</span>– <span class="NLM_lpage">3646</span>, <span class="refDoi"> DOI: 10.1002/anie.201510866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fanie.201510866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC28XisV2hu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=3642-3646&author=A.+F.+Rulloauthor=K.+J.+Fitzgeraldauthor=V.+Muthusamyauthor=M.+Liuauthor=C.+Yuanauthor=M.+Huangauthor=M.+Kimauthor=A.+E.+Choauthor=D.+A.+Spiegel&title=Re-engineering+the+Immune+Response+to+Metastatic+Cancer%3A+Antibody-Recruiting+Small+Molecules+Targeting+the+Urokinase+Receptor&doi=10.1002%2Fanie.201510866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor</span></div><div class="casAuthors">Rullo, Anthony F.; Fitzgerald, Kelly J.; Muthusamy, Viswanathan; Liu, Min; Yuan, Cai; Huang, Mingdong; Kim, Minsup; Cho, Art E.; Spiegel, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3642-3646</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Developing selective strategies to treat metastatic cancers remains a significant challenge.  Herein, the authors report the first antibody-recruiting small mol. (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediated destruction of cancer cells.  A co-crystal structure of the ARM-U2/uPAR complex was obtained, representing the first crystal structure of uPAR complexed with a non-peptide ligand.  Finally, the authors demonstrated that ARM-U2 substantially suppresses tumor growth in vivo with no evidence of wt. loss, unlike the std.-of-care agent doxorubicin.  This work underscores the promise of antibody-recruiting mols. as immunotherapeutics for treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9N4WFnZZaibVg90H21EOLACvtfcHk0liKT5qvulabAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisV2hu7k%253D&md5=448db82700404ed8f3cff8b0aea75b81</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510866%26sid%3Dliteratum%253Aachs%26aulast%3DRullo%26aufirst%3DA.%2BF.%26aulast%3DFitzgerald%26aufirst%3DK.%2BJ.%26aulast%3DMuthusamy%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DA.%2BE.%26aulast%3DSpiegel%26aufirst%3DD.%2BA.%26atitle%3DRe-engineering%2520the%2520Immune%2520Response%2520to%2520Metastatic%2520Cancer%253A%2520Antibody-Recruiting%2520Small%2520Molecules%2520Targeting%2520the%2520Urokinase%2520Receptor%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D3642%26epage%3D3646%26doi%3D10.1002%2Fanie.201510866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEnaney, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, D. A.</span></span> <span> </span><span class="NLM_article-title">Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1021/cb300119g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300119g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpsl2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1139-1151&author=P.+J.+McEnaneyauthor=C.+G.+Parkerauthor=A.+X.+Zhangauthor=D.+A.+Spiegel&title=Antibody-recruiting+molecules%3A+an+emerging+paradigm+for+engaging+immune+function+in+treating+human+disease&doi=10.1021%2Fcb300119g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease</span></div><div class="casAuthors">McEnaney, Patrick J.; Parker, Christopher G.; Zhang, Andrew X.; Spiegel, David A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-1151</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Synthetic immunol., the development of synthetic systems capable of modulating and/or manipulating immunol. functions, represents an emerging field of research with manifold possibilities.  One focus of this area has been to create low mol. wt. synthetic species, called antibody-recruiting mols. (ARMs), which are capable of enhancing antibody binding to disease-relevant cells or viruses, thus leading to their immune-mediated clearance.  This article provides a thorough discussion of contributions in this area, beginning with the history of small-mol.-based technologies for modulating antibody recognition, followed by a systematic review of the various applications of ARM-based strategies.  Thus, we describe ARMs capable of targeting cancer, bacteria, and viral pathogens, along with some of the scientific discoveries that have resulted from their development.  Research in this area underscores the many exciting possibilities at the interface of org. chem. and immunobiol. and is positioned to advance both basic and clin. science in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDb9zR6YedEbVg90H21EOLACvtfcHk0lhcLIm1E7wYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpsl2isr0%253D&md5=17dcc667dae735c02b1f35a4cd6139c9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb300119g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300119g%26sid%3Dliteratum%253Aachs%26aulast%3DMcEnaney%26aufirst%3DP.%2BJ.%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DZhang%26aufirst%3DA.%2BX.%26aulast%3DSpiegel%26aufirst%3DD.%2BA.%26atitle%3DAntibody-recruiting%2520molecules%253A%2520an%2520emerging%2520paradigm%2520for%2520engaging%2520immune%2520function%2520in%2520treating%2520human%2520disease%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1139%26epage%3D1151%26doi%3D10.1021%2Fcb300119g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feigman, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, M. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.7b00261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.7b00261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFalt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=664-672&author=M.+J.+S.+Feigmanauthor=M.+M.+Pires&title=Synthetic+Immunobiotics%3A+A+Future+Success+Story+in+Small+Molecule-Based+Immunotherapy%3F&doi=10.1021%2Facsinfecdis.7b00261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?</span></div><div class="casAuthors">Feigman, Mary J. Sabulski; Pires, Marcos M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">664-672</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug resistance to our current stock of antibiotics is projected to increase to levels that threaten our ability to reduce and eliminate bacterial infections, which is now considered one of the primary health care crises of the 21st century.  Traditional antibiotic agents (e.g., penicillin) paved the way for massive advances in human health, but we need novel strategies to maintain the upper hand in the battle against pathogenic bacteria.  Nontraditional strategies, such as targeted immunotherapies, could prove fruitful in complementing our antibiotic arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFM6Jj0ZTk77Vg90H21EOLACvtfcHk0lhcLIm1E7wYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFalt78%253D&md5=ce0f95dab09fcfeb97ecf6c23e4491ab</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.7b00261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.7b00261%26sid%3Dliteratum%253Aachs%26aulast%3DFeigman%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DPires%26aufirst%3DM.%2BM.%26atitle%3DSynthetic%2520Immunobiotics%253A%2520A%2520Future%2520Success%2520Story%2520in%2520Small%2520Molecule-Based%2520Immunotherapy%253F%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2018%26volume%3D4%26spage%3D664%26epage%3D672%26doi%3D10.1021%2Facsinfecdis.7b00261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uvyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Geest, B. G.</span></span> <span> </span><span class="NLM_article-title">Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3036</span>– <span class="NLM_lpage">3043</span>, <span class="refDoi"> DOI: 10.1002/cbic.202000261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fcbic.202000261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=32497371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlGjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=3036-3043&author=A.+Uvynauthor=B.+G.+De+Geest&title=Multivalent+Antibody-Recruiting+Macromolecules%3A+Linking+Increased+Binding+Affinity+with+Enhanced+Innate+Immune+Killing&doi=10.1002%2Fcbic.202000261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing</span></div><div class="casAuthors">Uvyn, Annemiek; De Geest, Bruno G.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3036-3043</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Antibody-recruiting mols. (ARMs) are a novel class of immunotherapeutics.  They are capable of introducing antibodies onto disease-relevant targets such as cancer cells, bacterial cells or viruses.  This can induce antibody-mediated immune responses such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent phagocytosis (ADCP), which can kill the pathogen.  In contrast to the classic ARMs, multivalent ARMs could offer the advantage of increasing the efficiency of antibody recruitment and subsequent innate immune killing.  Such compds. consist of multiple target-binding termini (TBT) and/or antibody-binding termini (ABT).  Those multivalent interactions are able to convert low binding affinities into increased binding avidities.  This minireview summarizes the current status of multivalent ARMs and gives insight into possible benefits, hurdles still to be overcome and future perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeC3-HYj2UrVg90H21EOLACvtfcHk0lhcLIm1E7wYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlGjsrrL&md5=04afa78e2d7d33e05446f6ffa56ae08b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcbic.202000261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.202000261%26sid%3Dliteratum%253Aachs%26aulast%3DUvyn%26aufirst%3DA.%26aulast%3DDe%2BGeest%26aufirst%3DB.%2BG.%26atitle%3DMultivalent%2520Antibody-Recruiting%2520Macromolecules%253A%2520Linking%2520Increased%2520Binding%2520Affinity%2520with%2520Enhanced%2520Innate%2520Immune%2520Killing%26jtitle%3DChembiochem%26date%3D2020%26volume%3D21%26spage%3D3036%26epage%3D3043%26doi%3D10.1002%2Fcbic.202000261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9331</span>– <span class="NLM_lpage">9338</span>, <span class="refDoi"> DOI: 10.1039/c9sc03840j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1039%2FC9SC03840J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=32110296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GisLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=9331-9338&author=H.+Hongauthor=Z.+Zhouauthor=K.+Zhouauthor=S.+Liuauthor=Z.+Guoauthor=Z.+Wu&title=Site-specific+C-terminal+dinitrophenylation+to+reconstitute+the+antibody+Fc+functions+for+nanobodies&doi=10.1039%2Fc9sc03840j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies</span></div><div class="casAuthors">Hong, Haofei; Zhou, Zhifang; Zhou, Kun; Liu, Shaozhong; Guo, Zhongwu; Wu, Zhimeng</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">9331-9338</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Nanobodies are a class of camelid-derived single-domain antibodies that have many potential advantages over conventional antibodies and have been utilized to develop new therapeutic strategies for cancer and other diseases.  However, nanobodies lack the Fc region of a conventional antibody, which possesses many functions, e.g., eliciting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), essential for effective immunotherapy.  The small mol. size of nanobodies also leads to poor pharmacokinetics, such as short in vivo half-life.  To address these deficiencies, an endogenous antibody-based strategy to reconstitute the Fc functions for nanobodies was developed.  As a proof-of-principle, an anti-human EGFR nanobody, 7D12, was selected to conduct C-terminal modification with the dinitrophenyl (DNP) hapten through Sortase A-mediated site-specific ligation.  It was expected that the DNP motif would recruit endogenous human anti-DNP antibodies to indirectly reinstate the Fc functions.  The resultant nanobody-DNP conjugates were shown to exhibit specific and high affinity binding to human EGFR expressed on target cancer cells.  It was further proved that in the presence of anti-DNP antibody, these conjugates could mediate potent ADCC and CDC in vitro and exhibit significantly elongated half-life in vivo.  Ultimately, it was proven in severe combined immunodeficiency (SCID) mice that treatment with the nanobody 7D12-DNP conjugate and anti-DNP mouse serum could inhibit xenograft tumor growth efficiently.  In view of the abundance of anti-DNP and other endogenous antibodies in the human blood system, this could be a generally applicable approach employed to reconstitute the Fc functions for nanobodies and develop nanobody-based cancer immunotherapy and other therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0EAw15epMgbVg90H21EOLACvtfcHk0lhcLIm1E7wYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GisLnL&md5=0be311dbfea15059b4f0574127ca2810</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2FC9SC03840J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC03840J%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSite-specific%2520C-terminal%2520dinitrophenylation%2520to%2520reconstitute%2520the%2520antibody%2520Fc%2520functions%2520for%2520nanobodies%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D9331%26epage%3D9338%26doi%3D10.1039%2Fc9sc03840j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1686</span>– <span class="NLM_lpage">1694</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00350</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00350" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVWlt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1686-1694&author=S.+Liauthor=B.+Yuauthor=J.+Wangauthor=Y.+Zhengauthor=H.+Zhangauthor=M.+J.+Walkerauthor=Z.+Yuanauthor=H.+Zhuauthor=J.+Zhangauthor=P.+G.+Wangauthor=B.+Wang&title=Biomarker-Based+Metabolic+Labeling+for+Redirected+and+Enhanced+Immune+Response&doi=10.1021%2Facschembio.8b00350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response</span></div><div class="casAuthors">Li, Shanshan; Yu, Bingchen; Wang, Jiajia; Zheng, Yueqin; Zhang, Huajie; Walker, Margaret J.; Yuan, Zhengnan; Zhu, He; Zhang, Jun; Wang, Peng George; Wang, Binghe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1686-1694</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Installation of an antibody-recruiting moiety on the surface of disease-relevant cells can lead to the selective destruction of targets by the immune system.  Such an approach can be an alternative strategy to traditional chemotherapeutics in cancer therapy and possibly other diseases.  Herein we describe the development of a new strategy to selectively label targets with an antibody-recruiting moiety through its covalent and stable installation, complementing existing methods of employing reversible binding.  This is achieved through selective delivery of 1,3,4-O-acetyl-N-azidoacetylmannosamine (Ac3ManNAz) to folate receptor-overexpressing cells using an Ac3ManNAz-folate conjugate via a cleavable linker.  As such, Ac3ManNAz is converted to cell surface glycan bearing an azido group, which serves as an anchor to introduce L-rhamnose (Rha), a hapten, via a click reaction with aza-dibenzocyclooctyne (DBCO)-Rha.  We tested this method in several cell lines including KB, HEK-293, and MCF7 and were able to demonstrate the following: (1) Rha can be selectively installed to the folate receptor overexpressing cell surface and (2) the Rha installed on the target surface can recruit anti-rhamnose (anti-Rha) antibodies, leading to the destruction of target cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMhIC7Ddio4rVg90H21EOLACvtfcHk0lhHiF5VjjKqaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVWlt7rM&md5=df3989eba48e1390d954543cc1266130</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00350%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%2BJ.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%2BG.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DBiomarker-Based%2520Metabolic%2520Labeling%2520for%2520Redirected%2520and%2520Enhanced%2520Immune%2520Response%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D1686%26epage%3D1694%26doi%3D10.1021%2Facschembio.8b00350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsubo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakamata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashiruddin, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbas, C. F.,  3rd</span></span> <span> </span><span class="NLM_article-title">In vivo programming of endogenous antibodies via oral administration of adaptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5952</span>– <span class="NLM_lpage">5961</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.bmc.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=28988625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SqtrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5952-5961&author=M.+Naganoauthor=N.+Carrilloauthor=N.+Otsuboauthor=W.+Hakamataauthor=H.+Banauthor=R.+P.+Fullerauthor=N.+K.+Bashiruddinauthor=C.+F.+Barbas&title=In+vivo+programming+of+endogenous+antibodies+via+oral+administration+of+adaptor+ligands&doi=10.1016%2Fj.bmc.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo programming of endogenous antibodies via oral administration of adaptor ligands</span></div><div class="casAuthors">Nagano, Masanobu; Carrillo, Nancy; Otsubo, Nobumasa; Hakamata, Wataru; Ban, Hitoshi; Fuller, Roberta P.; Bashiruddin, Nasir K.; Barbas, Carlos F., III</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5952-5961</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Vaccination is a reliable method of prophylaxis and a crucial measure for public health.  However, the majority of vaccines cannot be administered orally due to their degrdn. in the harsh gut environment or inability to cross the GI tract.  In this study, we report the first proof-of-concept study of orally producible chem. programmed antibodies via specific conjugation of adaptor ligands to endogenous antibodies, in vivo.  Pre-immunization with 2,4-dinitrophenyl (DNP), or the reactive hapten, 1,3-diketone (DK), or a novel reactive hapten, vinyl sulfone (VS) in mice, followed by oral administration of adaptor ligands composed of the hapten and biotin to the pre-immunized mice resulted in successful in vivo formation of the biotin-hapten-antibody complexes within 2 h.  Pharmacokinetic evaluations revealed that apparent serum concns. of programmed antibodies were up to 144 nM and that the serum half-lives reached up to 34.4 h.  These findings show promise for the future development of orally bioavailable drug-hapten-antibody complexes as a strategy to quickly and easily modulate immune targets for aggressive pathogens as well as cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkD-jzH7jQJ7Vg90H21EOLACvtfcHk0lhHiF5VjjKqaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SqtrbF&md5=b216ca9d24b6a6915da82058dfb296e7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DNagano%26aufirst%3DM.%26aulast%3DCarrillo%26aufirst%3DN.%26aulast%3DOtsubo%26aufirst%3DN.%26aulast%3DHakamata%26aufirst%3DW.%26aulast%3DBan%26aufirst%3DH.%26aulast%3DFuller%26aufirst%3DR.%2BP.%26aulast%3DBashiruddin%26aufirst%3DN.%2BK.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DIn%2520vivo%2520programming%2520of%2520endogenous%2520antibodies%2520via%2520oral%2520administration%2520of%2520adaptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D5952%26epage%3D5961%26doi%3D10.1016%2Fj.bmc.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jon, S.</span></span> <span> </span><span class="NLM_article-title">A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2010</span>, <span class="refDoi"> DOI: 10.1002/anie.201811509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fanie.201811509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFShurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2005-2010&author=B.+Yuauthor=D.+Hwangauthor=H.+Jeonauthor=H.+Kimauthor=Y.+Leeauthor=H.+Keumauthor=J.+Kimauthor=D.+Y.+Leeauthor=Y.+Kimauthor=J.+Chungauthor=S.+Jon&title=A+Hybrid+Platform+Based+on+a+Bispecific+Peptide-Antibody+Complex+for+Targeted+Cancer+Therapy&doi=10.1002%2Fanie.201811509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy</span></div><div class="casAuthors">Yu, Byeongjun; Hwang, Dobeen; Jeon, Hyungsu; Kim, Hyungjun; Lee, Yonghyun; Keum, Hyeongseop; Kim, Jinjoo; Lee, Dong Yun; Kim, Yujin; Chung, Junho; Jon, Sangyong</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2010</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Peptide-based therapeutics have suffered from a short plasma half-life.  On the other hand, antibodies suffer from poor penetration into solid tumors owing to their large size.  Herein, we present a new mol. form, namely a hybrid complex between a hapten-labeled bispecific peptide and an anti-hapten antibody ("HyPEP-body"), that may be able to overcome the aforementioned limitation.  The bispecific peptide contg. a cotinine tag was synthesized by linking a peptide specific to fibronectin extra domain B (EDB) and a peptide able to bind and inhibit vascular endothelial growth factor (VEGF), yielding cot-biPEPEDB-VEGF.  Simple mixing of cot-biPEPEDB-VEGF and anti-cotinine antibody (Abcot) yielded the hybrid complex, HyPEPEDB-VEGF.  HyPEPEDB-VEGF retained the characteristics of the included peptides, and showed improved pharmacokinetic behavior.  Moreover, HyPEPEDB-VEGF showed tumor growth inhibition with excellent tumor accumulation and penetration.  These findings suggest that the hybrid platform described here offers a soln. for most peptide therapeutics that suffer from a short circulation half-life in blood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7E2TogCy_E7Vg90H21EOLACvtfcHk0lhHiF5VjjKqaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFShurw%253D&md5=4723c7b7385a8044dbed20bf34534db0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201811509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201811509%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DHwang%26aufirst%3DD.%26aulast%3DJeon%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKeum%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DJon%26aufirst%3DS.%26atitle%3DA%2520Hybrid%2520Platform%2520Based%2520on%2520a%2520Bispecific%2520Peptide-Antibody%2520Complex%2520for%2520Targeted%2520Cancer%2520Therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D2005%26epage%3D2010%26doi%3D10.1002%2Fanie.201811509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, V. P.</span></span> <span> </span><span class="NLM_article-title">Persistence of hapten antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1084/jem.139.2.278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1084%2Fjem.139.2.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=4129823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADyaE2cXksVyns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=1974&pages=278-294&author=D.+H.+Schmidtauthor=B.+M.+Kaufmanauthor=V.+P.+Butler&title=Persistence+of+hapten+antibody+complexes+in+the+circulation+of+immunized+animals+after+a+single+intravenous+injection+of+hapten&doi=10.1084%2Fjem.139.2.278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten</span></div><div class="casAuthors">Schmidt, Donald H.; Kaufman, Bette M.; Butler, Vincent P., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-94</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">When injected into immunized animals, a specific hapten, namely digoxin, formed complexes with its corresponding antibodies, and these complexes persisted in the circulation for longer than 1 year after a single i.v. injection of that hapten.  Thus, the biol. half-life of a hapten may be markedly prolonged when the hapten is bound to specific antibody.  The persistence of antibody-hapten complexes in the circulation suggests that these complexes may not be deposited in tissues and raises the possibility that low mol. wt. determinants may be capable of preventing or reversing the deposition of immune complexes contg. macromol. antigens in the tissues of exptl. animals and man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJoHq3SVmE7Vg90H21EOLACvtfcHk0lhvN3IAXiL7MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXksVyns78%253D&md5=4148c7a56c15ee8ddfb9f24e5dfdb345</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1084%2Fjem.139.2.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.139.2.278%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DD.%2BH.%26aulast%3DKaufman%26aufirst%3DB.%2BM.%26aulast%3DButler%26aufirst%3DV.%2BP.%26atitle%3DPersistence%2520of%2520hapten%2520antibody%2520complexes%2520in%2520the%2520circulation%2520of%2520immunized%2520animals%2520after%2520a%2520single%2520intravenous%2520injection%2520of%2520hapten%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1974%26volume%3D139%26spage%3D278%26epage%3D294%26doi%3D10.1084%2Fjem.139.2.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostovetzky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larralde, C.</span></span> <span> </span><span class="NLM_article-title">Natural DNP-binding immunoglobulins and antibody multispecificity</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1016/0161-5890(84)90143-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2F0161-5890%2884%2990143-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=6504050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADyaL2MXksVSmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1984&pages=883-888&author=E.+Ortegaauthor=M.+Kostovetzkyauthor=C.+Larralde&title=Natural+DNP-binding+immunoglobulins+and+antibody+multispecificity&doi=10.1016%2F0161-5890%2884%2990143-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Natural DNP-binding immunoglobulins and antibody multispecificity</span></div><div class="casAuthors">Ortega, Enrique; Kostovetzky, Myriam; Larralde, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">883-8</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    </div><div class="casAbstract">Anti-dinitrophenyl activity was found in normal human Igs with av. affinities (104-106 L/mol) and frequencies (2-15%) that correlate well with those expected from multispecific binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNE8BZo_MM1LVg90H21EOLACvtfcHk0lhvN3IAXiL7MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXksVSmtQ%253D%253D&md5=3b43fbdf0c9d83ca297948e825381788</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0161-5890%2884%2990143-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0161-5890%252884%252990143-3%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DE.%26aulast%3DKostovetzky%26aufirst%3DM.%26aulast%3DLarralde%26aufirst%3DC.%26atitle%3DNatural%2520DNP-binding%2520immunoglobulins%2520and%2520antibody%2520multispecificity%26jtitle%3DMol.%2520Immunol.%26date%3D1984%26volume%3D21%26spage%3D883%26epage%3D888%26doi%3D10.1016%2F0161-5890%2884%2990143-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farah, F. S.</span></span> <span> </span><span class="NLM_article-title">Natural antibodies specific to the 2, 4 dinitrophenyl group</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">226</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=4733801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADyaE3sXkvFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1973&pages=217-226&author=F.+S.+Farah&title=Natural+antibodies+specific+to+the+2%2C+4+dinitrophenyl+group"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Natural antibodies specific to the 2,4-dinitrophenyl group</span></div><div class="casAuthors">Farah, F. S.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-26</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    </div><div class="casAbstract">An immunoadsorbent, 2,4-dinitrophenyl (DNP)-aminoethyl cellulose, specifically retained a protein fraction from pooled or individual normal human γ-globulins.  The fraction behaved like DNP-antigen-induced antibody in tests of specific activity including fluorescence quenching, spectral shift anal., and equil. dialysis.  The "natural" antibodies to DNP were present in max. concn. of 0.8% of the IgG fraction, and usually less.  A similar fraction was found in normal rabbit serum but not in purified rabbit antibodies of another specificity.  The anti-DNP activity was found in the Fab fragment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryC09QMBDbS7Vg90H21EOLACvtfcHk0liM0SM5kVQcvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXkvFSgu70%253D&md5=30b51e3f284448fa0f6b5cbd66a3b313</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarah%26aufirst%3DF.%2BS.%26atitle%3DNatural%2520antibodies%2520specific%2520to%2520the%25202%252C%25204%2520dinitrophenyl%2520group%26jtitle%3DImmunology%26date%3D1973%26volume%3D25%26spage%3D217%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Sortase-Mediated Transpeptidation for Site-Specific Modification of Peptides, Glycopeptides, and Proteins</span>. <i>J. Carbohydr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1080/07328303.2011.635251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1080%2F07328303.2011.635251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22468018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=48-66&author=Z.+Wuauthor=Z.+Guo&title=Sortase-Mediated+Transpeptidation+for+Site-Specific+Modification+of+Peptides%2C+Glycopeptides%2C+and+Proteins&doi=10.1080%2F07328303.2011.635251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase-Mediated Transpeptidation for Site-Specific Modification of Peptides, Glycopeptides, and Proteins</span></div><div class="casAuthors">Wu, Zhimeng; Guo, Zhongwu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Carbohydrate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-66</span>CODEN:
                <span class="NLM_cas:coden">JCACDM</span>;
        ISSN:<span class="NLM_cas:issn">0732-8303</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Sortases are a family of transpeptidases found in gram-pos. bacteria responsible for covalent anchoring of cell surface proteins to bacterial cell walls.  It has been discovered that sortase A (SrtA) of Staphylococcus aureus origin is rather promiscuous and can accept various mols. as substrates.  As a result, SrtA has been widely used to ligate peptides and proteins with a variety of nucleophiles, and the ligation products are useful for research in chem. biol., proteomics, biomedicine, etc.  This review summarizes the recent applications of SrtA with special emphasis on SrtA-catalyzed ligation of carbohydrates with peptides and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBd9DBA3SnprVg90H21EOLACvtfcHk0liM0SM5kVQcvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWktrY%253D&md5=9d914e9a6f148e53954c75fb56a53630</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1080%2F07328303.2011.635251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07328303.2011.635251%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DSortase-Mediated%2520Transpeptidation%2520for%2520Site-Specific%2520Modification%2520of%2520Peptides%252C%2520Glycopeptides%252C%2520and%2520Proteins%26jtitle%3DJ.%2520Carbohydr.%2520Chem.%26date%3D2012%26volume%3D31%26spage%3D48%26epage%3D66%26doi%3D10.1080%2F07328303.2011.635251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsukiji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamune, T.</span></span> <span> </span><span class="NLM_article-title">Sortase-mediated ligation: a gift from Gram-positive bacteria to protein engineering</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1002/cbic.200800724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fcbic.200800724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=19199328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVajt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=787-798&author=S.+Tsukijiauthor=T.+Nagamune&title=Sortase-mediated+ligation%3A+a+gift+from+Gram-positive+bacteria+to+protein+engineering&doi=10.1002%2Fcbic.200800724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase-mediated ligation: a gift from gram-positive bacteria to protein engineering</span></div><div class="casAuthors">Tsukiji, Shinya; Nagamune, Teruyuki</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review on sortase-mediated ligation and current state of its applications.  Topics discussed include: recombinant sol. sortase; transpeptidation mechanism; substrate specificity; introduction of new functionalities into proteins; covalent immobilization of proteins onto solid supports; protein-protein bioconjugation; protein circularization; and self-cleavable tag for one-step purifn. of recombinant proteins.  It also tackles the prepn. of oligopeptide-nucleic acid hybrids; chemoenzymic synthesis of neoglycoconjugates; and cell-surface protein labeling/engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhN3wUx_gQ97Vg90H21EOLACvtfcHk0liM0SM5kVQcvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVajt7o%253D&md5=121bdaba8de4db865d821683b7d968ff</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200800724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200800724%26sid%3Dliteratum%253Aachs%26aulast%3DTsukiji%26aufirst%3DS.%26aulast%3DNagamune%26aufirst%3DT.%26atitle%3DSortase-mediated%2520ligation%253A%2520a%2520gift%2520from%2520Gram-positive%2520bacteria%2520to%2520protein%2520engineering%26jtitle%3DChembiochem%26date%3D2009%26volume%3D10%26spage%3D787%26epage%3D798%26doi%3D10.1002%2Fcbic.200800724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Göke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehmann, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göke, B.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">19650</span>– <span class="NLM_lpage">19655</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(19)36565-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2FS0021-9258%2819%2936565-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=8396143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A280%3ADyaK3sznsV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=19650-19655&author=R.+G%C3%B6keauthor=H.+C.+Fehmannauthor=T.+Linnauthor=H.+Schmidtauthor=M.+Krauseauthor=J.+Engauthor=B.+G%C3%B6ke&title=Exendin-4+is+a+high+potency+agonist+and+truncated+exendin-%289-39%29-amide+an+antagonist+at+the+glucagon-like+peptide+1-%287-36%29-amide+receptor+of+insulin-secreting+beta-cells&doi=10.1016%2Fs0021-9258%2819%2936565-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells</span></div><div class="casAuthors">Goke R; Fehmann H C; Linn T; Schmidt H; Krause M; Eng J; Goke B</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">19650-5</span>
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Exendin-4 purified from Heloderma suspectum venom shows structural relationship to the important incretin hormone glucagon-like peptide 1-(7-36)-amide (GLP-1).  We demonstrate that exendin-4 and truncated exendin-(9-39)-amide specifically interact with the GLP-1 receptor on insulinoma-derived cells and on lung membranes.  Exendin-4 displaced 125I-GLP-1, and unlabeled GLP-1 displaced 125I-exendin-4 from the binding site at rat insulinoma-derived RINm5F cells.  Exendin-4 had, like GLP-1, a pronounced effect on intracellular cAMP generation, which was reduced by exendin-(9-39)-amide.  When combined, GLP-1 and exendin-4 showed additive action on cAMP.  They each competed with the radio-labeled version of the other peptide in cross-linking experiments.  The apparent molecular mass of the respective ligand-binding protein complex was 63,000 Da.  Exendin-(9-39)-amide abolished the cross-linking of both peptides.  Exendin-4, like GLP-1, stimulated dose dependently the glucose-induced insulin secretion in isolated rat islets, and, in mouse insulinoma beta TC-1 cells, both peptides stimulated the proinsulin gene expression at the level of transcription.  Exendin-(9-39)-amide reduced these effects.  In conclusion, exendin-4 is an agonist and exendin-(9-39)-amide is a specific GLP-1 receptor antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEDSP0hDZIaM-crCu0nI_sfW6udTcc2eY6Q9W2BrOGSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3sznsV2lsw%253D%253D&md5=653efa77c17fd5c860ed9a03f2040f94</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2936565-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252936565-2%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6ke%26aufirst%3DR.%26aulast%3DFehmann%26aufirst%3DH.%2BC.%26aulast%3DLinn%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DG%25C3%25B6ke%26aufirst%3DB.%26atitle%3DExendin-4%2520is%2520a%2520high%2520potency%2520agonist%2520and%2520truncated%2520exendin-%25289-39%2529-amide%2520an%2520antagonist%2520at%2520the%2520glucagon-like%2520peptide%25201-%25287-36%2529-amide%2520receptor%2520of%2520insulin-secreting%2520beta-cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D19650%26epage%3D19655%26doi%3D10.1016%2Fs0021-9258%2819%2936565-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heath, C.</span>; <span class="NLM_string-name">Pettit, D.</span></span> <i>“Fc Fusion Proteins”</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">558</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2F978-3-319-90603-4_24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=545-558&author=C.+Heath&author=D.+Pettit&title=%E2%80%9CFc+Fusion+Proteins%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-90603-4_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-90603-4_24%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DC.%26btitle%3D%25E2%2580%259CFc%2520Fusion%2520Proteins%25E2%2580%259D%26pub%3DSpringer%26date%3D2018%26spage%3D545%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielsky, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindappa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgate, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Laan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Challenges and approaches for the development of safer immunomodulatory biologics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nrd3974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnrd3974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=23535934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Gms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=306-324&author=J.+G.+Sathishauthor=S.+Sethuauthor=M.-C.+Bielskyauthor=L.+de+Haanauthor=N.+S.+Frenchauthor=K.+Govindappaauthor=J.+Greenauthor=C.+E.+M.+Griffithsauthor=S.+Holgateauthor=D.+Jonesauthor=I.+Kimberauthor=J.+Moggsauthor=D.+J.+Naisbittauthor=M.+Pirmohamedauthor=G.+Reichmannauthor=J.+Simsauthor=M.+Subramanyamauthor=M.+D.+Toddauthor=J.+W.+Van+Der%0ALaanauthor=R.+J.+Weaverauthor=B.+K.+Park&title=Challenges+and+approaches+for+the+development+of+safer+immunomodulatory+biologics&doi=10.1038%2Fnrd3974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and approaches for the development of safer immunomodulatory biologics</span></div><div class="casAuthors">Sathish, Jean G.; Sethu, Swaminathan; Bielsky, Marie-Christine; de Haan, Lolke; French, Neil S.; Govindappa, Karthik; Green, James; Griffiths, Christopher E. M.; Holgate, Stephen; Jones, David; Kimber, Ian; Moggs, Jonathan; Naisbitt, Dean J.; Pirmohamed, Munir; Reichmann, Gabriele; Sims, Jennifer; Subramanyam, Meena; Todd, Marque D.; Van Der Laan, Jan Willem; Weaver, Richard J.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">306-324</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases.  However, unwanted adverse reactions - including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity - pose a challenge to the development of new (and safer) immunomodulatory biologics.  In this article, we assess the safety issues assocd. with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions assocd. with their use.  We also outline how these approaches can inform the development of safer immunomodulatory biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz-XvsNkuJ2bVg90H21EOLACvtfcHk0ljaiVSQXKZ0fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Gms7o%253D&md5=7e7fbf6e02b97ca5b7316c0681211557</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd3974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3974%26sid%3Dliteratum%253Aachs%26aulast%3DSathish%26aufirst%3DJ.%2BG.%26aulast%3DSethu%26aufirst%3DS.%26aulast%3DBielsky%26aufirst%3DM.-C.%26aulast%3Dde%2BHaan%26aufirst%3DL.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DGovindappa%26aufirst%3DK.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DHolgate%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKimber%26aufirst%3DI.%26aulast%3DMoggs%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DReichmann%26aufirst%3DG.%26aulast%3DSims%26aufirst%3DJ.%26aulast%3DSubramanyam%26aufirst%3DM.%26aulast%3DTodd%26aufirst%3DM.%2BD.%26aulast%3DVan%2BDer%2BLaan%26aufirst%3DJ.%2BW.%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DChallenges%2520and%2520approaches%2520for%2520the%2520development%2520of%2520safer%2520immunomodulatory%2520biologics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D306%26epage%3D324%26doi%3D10.1038%2Fnrd3974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaro, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.-C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of recombinant bifunctional fusion proteins</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1517/17425255.2012.673585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1517%2F17425255.2012.673585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22428984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2qsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=581-595&author=X.+Chenauthor=J.+L.+Zaroauthor=W.-C.+Shen&title=Pharmacokinetics+of+recombinant+bifunctional+fusion+proteins&doi=10.1517%2F17425255.2012.673585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of recombinant bifunctional fusion proteins</span></div><div class="casAuthors">Chen, Xiaoying; Zaro, Jennica L.; Shen, Wei-Chiang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-595</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The development of biotechnol. has enabled the creation of various recombinant fusion proteins as a new class of biotherapeutics.  The uniqueness of fusion proteins lies in their ability to fuse two or more protein domains, providing vast opportunities to generate novel combinations of functions.  Pharmacokinetic (PK) studies, which are crit. components in preclin. and clin. drug development, have not been fully explored for fusion proteins.  The lack of general PK models and study guidelines has become a bottleneck for translation of fusion proteins from basic research to the clinic.  Areas covered: This article reviews the current status of PK studies for fusion proteins, covering the processes that affect PK.  According to their PK properties, a classification of fusion proteins is suggested along with examples from the clinic or under development.  Current limitations and future perspectives for PK of fusion proteins are also discussed.  Expert opinion: A PK model for bifunctional fusion proteins is presented to highlight the importance of mechanistic studies for a thorough understanding of the PK properties of fusion proteins.  The model suggests investigating the receptor binding and subsequent intracellular disposition of individual domains, which can have dramatic impact on the PK of fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXDDgiIURGWrVg90H21EOLACvtfcHk0ljaiVSQXKZ0fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2qsLg%253D&md5=3c2e586924eec40cdc1f58caf67ed33e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1517%2F17425255.2012.673585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2012.673585%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZaro%26aufirst%3DJ.%2BL.%26aulast%3DShen%26aufirst%3DW.-C.%26atitle%3DPharmacokinetics%2520of%2520recombinant%2520bifunctional%2520fusion%2520proteins%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2012%26volume%3D8%26spage%3D581%26epage%3D595%26doi%3D10.1517%2F17425255.2012.673585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, M. K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misuan, N.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1111/bcpt.13169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1111%2Fbcpt.13169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=30417596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVygsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=513-527&author=M.+K.+K.+Yapauthor=N.+Misuan&title=Exendin-4+from+Heloderma+suspectum+venom%3A+From+discovery+to+its+latest+application+as+type+II+diabetes+combatant&doi=10.1111%2Fbcpt.13169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant</span></div><div class="casAuthors">Yap, Michelle Khai Khun; Misuan, Nurhamimah</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-527</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Type II diabetes mellitus (T2DM) is a chronic non-communicable disease due to abnormal insulin actions causing uncontrolled hyperglycemia.  The treatment for T2DM, for instance, metformin and incretin mimetic, mainly focuses on the restoration of insulin sensitivity and secretion.  Exendin-4 is a short incretin-mimetic peptide consisting of 39 amino acids.  It is discovered in the venom of Heloderma suspectum as a full agonist for the glucagon-like peptide 1 (GLP-1) receptor and produces insulinotropic effects.  It is more resistant to enzymic degrdn. by dipeptidyl-peptidase-4 and has a longer half-life than the endogenous GLP-1; thus, it is further developed as an incretin hormone analog used to treat T2DM.  The helical region of the peptide first interacts with the extracellular N-terminal domain (NTD) of GLP-1 receptor while the C-terminal extension contg. the tryptophan cage further enhances its binding affinity.  After binding to the NTD of the receptor, it may cause the receptor to switch from its auto-inhibited state of the receptor to its auto-activated state.  Exendin-4 enhances the physiol. functions of β-cells and the up-regulation of GLP-1 receptors, thus reducing the plasma glucose levels.  Moreover, exendin-4 has also been found to ameliorate neuropathy, nephropathy and ventricular remodelling.  The therapeutic effects of exendin-4 have also been extrapolated into several clin. trials.  Although exendin-4 has a reasonable s.c. bioavailability, its half-life is rather short.  Therefore, several modifications have been undertaken to improve its pharmacokinetics and insulinotropic potency.  This review focuses on the pharmacol. of exendin-4 and the structure-function relationships of exendin-4 with GLP-1 receptor.  The review also highlights some challenges and future directions in the improvement of exendin-4 as an anti-diabetic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3mc8RLIIz7Vg90H21EOLACvtfcHk0lhDRNos8kzmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVygsrbM&md5=9d5098dc4ae141c675f2accff5fed821</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.13169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.13169%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DM.%2BK.%2BK.%26aulast%3DMisuan%26aufirst%3DN.%26atitle%3DExendin-4%2520from%2520Heloderma%2520suspectum%2520venom%253A%2520From%2520discovery%2520to%2520its%2520latest%2520application%2520as%2520type%2520II%2520diabetes%2520combatant%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2019%26volume%3D124%26spage%3D513%26epage%3D527%26doi%3D10.1111%2Fbcpt.13169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, B. L.</span></span> <span> </span><span class="NLM_article-title">The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent</span>. <i>Toxicon</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/j.toxicon.2010.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.toxicon.2010.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=21194543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=464-471&author=B.+L.+Furman&title=The+development+of+Byetta+%28exenatide%29+from+the+venom+of+the+Gila+monster+as+an+anti-diabetic+agent&doi=10.1016%2Fj.toxicon.2010.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent</span></div><div class="casAuthors">Furman, Brian L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicon</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-471</span>CODEN:
                <span class="NLM_cas:coden">TOXIA6</span>;
        ISSN:<span class="NLM_cas:issn">0041-0101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of Byetta (synthetic exendin-4; exenatide) as a treatment of diabetes arose from two, parallel lines of investigation.  The development of the incretin concept' which hypothesised that hormones from the gut contributed to the insulin secretion in response to meals, led to the identification of glucagon-like peptide 1 (GLP-1) as an important incretin' hormone.  GLP-1 not only increases insulin secretion but increases β-cell proliferation and survival, suppresses glucagon secretion, delays gastric emptying and suppresses appetite, all of these actions contributing to a potential anti-diabetic effect.  However, GLP-1 has a very short half due to its rapid breakdown by dipeptidyl peptidase IV and ectopeptidases.  A systematic investigation of the compn. and activity of venom from the Gila monster, Heloderma suspectum, led to the isolation of a 39-amino acid peptide, designated exendin-4, showing 53% structural homol. with GLP-1(7-36).  Exendin-4 mimicked GLP-1 through stimulating the GLP-1 receptor.  The much greater stability of exendin-4 led to its exptl. and clin. evaluation as an anti-diabetic agent and its introduction to the market in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6R1WgiHCCwrVg90H21EOLACvtfcHk0lhDRNos8kzmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGltbY%253D&md5=b2cf8ba0322b5eca9720c06a74b9e279</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.toxicon.2010.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxicon.2010.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DB.%2BL.%26atitle%3DThe%2520development%2520of%2520Byetta%2520%2528exenatide%2529%2520from%2520the%2520venom%2520of%2520the%2520Gila%2520monster%2520as%2520an%2520anti-diabetic%2520agent%26jtitle%3DToxicon%26date%3D2012%26volume%3D59%26spage%3D464%26epage%3D471%26doi%3D10.1016%2Fj.toxicon.2010.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muttenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alewood, P. F.</span></span> <span> </span><span class="NLM_article-title">Trends in peptide drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/s41573-020-00135-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41573-020-00135-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=33536635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjtF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2021&pages=309-325&author=M.+Muttenthalerauthor=G.+F.+Kingauthor=D.+J.+Adamsauthor=P.+F.+Alewood&title=Trends+in+peptide+drug+discovery&doi=10.1038%2Fs41573-020-00135-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in peptide drug discovery</span></div><div class="casAuthors">Muttenthaler, Markus; King, Glenn F.; Adams, David J.; Alewood, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Portfolio</span>)
        </div><div class="casAbstract">Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.  In this Perspective, we summarize key trends in peptide drug discovery and development, covering the early efforts focused on human hormones, elegant medicinal chem. and rational design strategies, peptide drugs derived from nature, and major breakthroughs in mol. biol. and peptide chem. that continue to advance the field.  We emphasize lessons from earlier approaches that are still relevant today as well as emerging strategies such as integrated venomics and peptide-display libraries that create new avenues for peptide drug discovery.  We also discuss the pharmaceutical landscape in which peptide drugs could be particularly valuable and analyze the challenges that need to be addressed for them to reach their full potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqatqpumo9qRLVg90H21EOLACvtfcHk0lhDRNos8kzmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjtF2qsro%253D&md5=6c2ca0a633489717737237749772881b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41573-020-00135-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-020-00135-8%26sid%3Dliteratum%253Aachs%26aulast%3DMuttenthaler%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DG.%2BF.%26aulast%3DAdams%26aufirst%3DD.%2BJ.%26aulast%3DAlewood%26aufirst%3DP.%2BF.%26atitle%3DTrends%2520in%2520peptide%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2021%26volume%3D20%26spage%3D309%26epage%3D325%26doi%3D10.1038%2Fs41573-020-00135-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palasek, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. M.</span></span> <span> </span><span class="NLM_article-title">Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1002/psc.804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fpsc.804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=17121420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVSgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=143-148&author=S.+A.+Palasekauthor=Z.+J.+Coxauthor=J.+M.+Collins&title=Limiting+racemization+and+aspartimide+formation+in+microwave-enhanced+Fmoc+solid+phase+peptide+synthesis&doi=10.1002%2Fpsc.804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis</span></div><div class="casAuthors">Palasek, Stacey A.; Cox, Zachary J.; Collins, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-148</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Microwave energy represents an efficient manner to accelerate both the deprotection and coupling reactions in 9-fluorenylmethyloxycarbonyl (Fmoc) solid phase-peptide synthesis (SPPS).  Typical SPPS side reactions including racemization and aspartimide formation can occur with microwave energy but can easily be controlled by routine use of optimized methods.  Cysteine, histidine, and aspartic acid were susceptible to racemization during microwave SPPS of a model 20mer peptide contg. all 20 natural amino acids.  Lowering the microwave coupling temp. from 80°C to 50°C limited racemization of histidine and cysteine.  Addnl., coupling of both histidine and cysteine can be performed conventionally while the rest of the peptide is synthesized using microwave without any deleterious effect, as racemization during the coupling reaction was limited to the activated ester state of the amino acids up to 80°C.  Use of the hindered amine, collidine, in the peptide coupling reaction also minimized formation of D-cysteine.  Aspartimide formation and subsequent racemization of aspartic acid was reduced by the addn. of HOBt to the deprotection soln. and/or use of piperazine in place of piperidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoucvuxZuEee7Vg90H21EOLACvtfcHk0lhDRNos8kzmhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVSgu7w%253D&md5=62d15696576d78b0b1f3d7af2024be5e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fpsc.804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.804%26sid%3Dliteratum%253Aachs%26aulast%3DPalasek%26aufirst%3DS.%2BA.%26aulast%3DCox%26aufirst%3DZ.%2BJ.%26aulast%3DCollins%26aufirst%3DJ.%2BM.%26atitle%3DLimiting%2520racemization%2520and%2520aspartimide%2520formation%2520in%2520microwave-enhanced%2520Fmoc%2520solid%2520phase%2520peptide%2520synthesis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2007%26volume%3D13%26spage%3D143%26epage%3D148%26doi%3D10.1002%2Fpsc.804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Sortase A-mediated on-resin peptide cleavage and in situ ligation: an efficient one-pot strategy for the synthesis of functional peptides and proteins</span>. <i>Org. Chem. Front.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1039/c7qo00481h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1039%2FC7QO00481H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFyit7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=2058-2062&author=X.+Chengauthor=T.+Zhuauthor=H.+Hongauthor=Z.+Zhouauthor=Z.+Wu&title=Sortase+A-mediated+on-resin+peptide+cleavage+and+in+situ+ligation%3A+an+efficient+one-pot+strategy+for+the+synthesis+of+functional+peptides+and+proteins&doi=10.1039%2Fc7qo00481h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase A-mediated on-resin peptide cleavage and in situ ligation: An efficient one-pot strategy for the synthesis of functional peptides and proteins</span></div><div class="casAuthors">Cheng, Xiaozhong; Zhu, Tao; Hong, Haofei; Zhou, Zhifang; Wu, Zhimeng</div><div class="citationInfo"><span class="NLM_cas:title">Organic Chemistry Frontiers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2058-2062</span>CODEN:
                <span class="NLM_cas:coden">OCFRA8</span>;
        ISSN:<span class="NLM_cas:issn">2052-4129</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Sortase A was firstly found to recognize a PEGA resin supported peptide donor contg. a LPXTG motif and to ligate with a suitable acceptor contg. oligo-glycine to afford conjugates in one-pot.  This approach combining enzymic on-resin cleavage, activation and in situ ligation, was employed to synthesize dual functional peptides, modify peptides with lipids, biotin and PEG, as well as protein N-terminal labeling in high efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPu8d09iH5wLVg90H21EOLACvtfcHk0li2y1_smd6T4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFyit7jL&md5=f152a43f9cf96cab0614bc3010aac8d9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1039%2FC7QO00481H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7QO00481H%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSortase%2520A-mediated%2520on-resin%2520peptide%2520cleavage%2520and%2520in%2520situ%2520ligation%253A%2520an%2520efficient%2520one-pot%2520strategy%2520for%2520the%2520synthesis%2520of%2520functional%2520peptides%2520and%2520proteins%26jtitle%3DOrg.%2520Chem.%2520Front.%26date%3D2017%26volume%3D4%26spage%3D2058%26epage%3D2062%26doi%3D10.1039%2Fc7qo00481h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luginbuhl, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaal, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umstead, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastria, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banskota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinglos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer</span>. <i>Nat. Biomed. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">0078</span>, <span class="refDoi"> DOI: 10.1038/s41551-017-0078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41551-017-0078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=29062587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ahtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=0078&author=K.+M.+Luginbuhlauthor=J.+L.+Schaalauthor=B.+Umsteadauthor=E.+M.+Mastriaauthor=X.+Liauthor=S.+Banskotaauthor=S.+Arnoldauthor=M.+Feinglosauthor=D.+D%E2%80%99Alessioauthor=A.+Chilkoti&title=One-week+glucose+control+via+zero-order+release+kinetics+from+an+injectable+depot+of+glucagon-like+peptide-1+fused+to+a+thermosensitive+biopolymer&doi=10.1038%2Fs41551-017-0078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer</span></div><div class="casAuthors">Luginbuhl, Kelli M.; Schaal, Jeffrey L.; Umstead, Bret; Mastria, Eric M.; Li, Xinghai; Banskota, Samagya; Arnold, Susan; Feinglos, Mark; D'Alessio, David; Chilkoti, Ashutosh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biomedical Engineering</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">0078</span>CODEN:
                <span class="NLM_cas:coden">NBEAB3</span>;
        ISSN:<span class="NLM_cas:issn">2157-846X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Stimulation of the glucagon-like peptide-1 (GLP1) receptor is a useful treatment strategy for type 2 diabetes due to pleiotropic effects, such as the regulation of islet hormones and the induction of satiety.  However, the native ligand for the GLP1 receptor has a short half-life owing to enzymic inactivation and rapid clearance.  Here, we show that a s.c. depot formed after a single injection of GLP1 recombinantly fused to a thermosensitive elastin-like polypeptide results in zero-order release kinetics and circulation times of up to 10 days in mice and 17 days in monkeys.  The optimized pharmacokinetics lead to 10 days of glycemic control in three different mouse models of diabetes, as well as the redn. of glycosylated Hb levels and wt. gain in ob/ob mice treated once weekly for 8 wk.  Our results suggest that the optimized GLP1 formulation could enhance therapeutic outcomes by eliminating peak-and-valley pharmacokinetics and improving overall safety and tolerability.  The design principles that we established should be broadly applicable for improving the pharmacol. performance of other peptide and protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9T72N1rjiu7Vg90H21EOLACvtfcHk0li2y1_smd6T4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ahtbzN&md5=ee183054285f94be1134d343b2383f75</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fs41551-017-0078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41551-017-0078%26sid%3Dliteratum%253Aachs%26aulast%3DLuginbuhl%26aufirst%3DK.%2BM.%26aulast%3DSchaal%26aufirst%3DJ.%2BL.%26aulast%3DUmstead%26aufirst%3DB.%26aulast%3DMastria%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBanskota%26aufirst%3DS.%26aulast%3DArnold%26aufirst%3DS.%26aulast%3DFeinglos%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DD.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DOne-week%2520glucose%2520control%2520via%2520zero-order%2520release%2520kinetics%2520from%2520an%2520injectable%2520depot%2520of%2520glucagon-like%2520peptide-1%2520fused%2520to%2520a%2520thermosensitive%2520biopolymer%26jtitle%3DNat.%2520Biomed.%2520Eng.%26date%3D2017%26volume%3D1%26spage%3D0078%26doi%3D10.1038%2Fs41551-017-0078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11403</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11500-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41598-017-11500-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=28900154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A280%3ADC%252BC1cbnsFaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=11403&author=Z.+Zhouauthor=S.+S.+Mandalauthor=G.+Liaoauthor=J.+Guoauthor=Z.+Guo&title=Synthesis+and+Evaluation+of+GM2-Monophosphoryl+Lipid+A+Conjugate+as+a+Fully+Synthetic+Self-Adjuvant+Cancer+Vaccine&doi=10.1038%2Fs41598-017-11500-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine</span></div><div class="casAuthors">Zhou Zhifang; Mandal Satadru S; Liao Guochao; Guo Jiatong; Guo Zhongwu; Liao Guochao; Guo Jiatong; Guo Zhongwu</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An efficient method was developed for the synthesis of a GM2 derivative suitable for the conjugation with various biomolecules.  This GM2 derivative was covalently linked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic cancer vaccines.  Immunological evaluations of the resultant conjugates in mice revealed that they elicited robust GM2-specific overall and IgG antibody responses.  Moreover, the GM2-MPLA conjugate was disclosed to elicit strong immune responses without the use of an adjuvant, proving its self-adjuvant property.  The antisera of both conjugates showed strong binding and mediated similarly effective complement-dependent cytotoxicity to GM2-expressing cancer cell line MCF-7.  Based on these results, it was concluded that both GM2-MPLA and GM2-KLH are promising candidates as therapeutic cancer vaccines, whereas fully synthetic GM2-MPLA, which has homogeneous and well-defined structure and self-adjuvant property, deserves more attention and studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpwNxFcBgHXQqdek-gHSrIfW6udTcc2eZZRQxlwzp4Kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbnsFaksA%253D%253D&md5=ba67ba06449353acfec00953166ca1be</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11500-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11500-w%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DMandal%26aufirst%3DS.%2BS.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520GM2-Monophosphoryl%2520Lipid%2520A%2520Conjugate%2520as%2520a%2520Fully%2520Synthetic%2520Self-Adjuvant%2520Cancer%2520Vaccine%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D11403%26doi%3D10.1038%2Fs41598-017-11500-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">779</span>, <span class="refDoi"> DOI: 10.3390/molecules24040779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.3390%2Fmolecules24040779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=779&author=X.+Zhongauthor=Z.+Chenauthor=Q.+Chenauthor=W.+Zhaoauthor=Z.+Chen&title=Novel+Site-Specific+Fatty+Chain-Modified+GLP-1+Receptor+Agonist+with+Potent+Antidiabetic+Effects&doi=10.3390%2Fmolecules24040779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel site-specific fatty chain-modified GLP-1 receptor agonist with potent antidiabetic effects</span></div><div class="casAuthors">Zhong, Xia; Chen, Zhu; Chen, Qiong; Zhao, Wei; Chen, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">779/1-779/11</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM).  Here, we designed a high-throughput GLP-1R extracellular domain (ECD)-based system that enabled the screening of high-potency receptor-biased GLP-1R agonists demonstrating new pharmacol. virtues.  Firstly, six 12-mer peptides (termed PEP01-06), screened from a large phage displayed peptide library were fused to the N-terminus of Exendin-4 (29-39) to generate PEP07-12.  By the use of four lysine-altered PEP07 (PEP13-16) as the starting point, a series of fatty chain conjugates (PEP17-20) were synthesized and evaluated by in vitro GLP-1R-based cell assays.  In addn., the acute and long-term in vivo effects on diet-induced obesity (DIO) mice were further evaluated.  All four conjugates showed good receptor activation efficacy, and PEP20 was selected to undergo further assessment.  Preclin. expts. in DIO mice demonstrated that PEP20 had significant insulinotropic activities and glucose-lowering abilities.  Moreover, a prolonged antidiabetic effect of PEP20 was also obsd. by the hypoglycemic test in DIO mice.  Furthermore, long-term treatment with PEP20 achieved beneficial effects on the food intake, wt. gain, Hb A1C (HbA1C) lowering activity, and glucose tolerance compared with the control and was similar to the Liraglutide.  In conclusion, PEP20, a GLP-1R ECD-biased agonist, may provide a novel therapeutic approach to T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Z3T88au4hbVg90H21EOLACvtfcHk0lgVpgQE8gl9Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7w%253D&md5=909487f6afc1b4195639dcfe8f3ec32d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040779%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DNovel%2520Site-Specific%2520Fatty%2520Chain-Modified%2520GLP-1%2520Receptor%2520Agonist%2520with%2520Potent%2520Antidiabetic%2520Effects%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D779%26doi%3D10.3390%2Fmolecules24040779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. HPLC profile of SrtA-mediated ligation and ESI-MS analysis of 6 (a), 7 (b), 8 (c), 9 (d), 10 (e), and 11 (f). HPLC conditions: 10–90% gradient of CH<sub>3</sub>CN/H<sub>2</sub>O over 20 min at a flow rate of 1 mL/min and monitored at 220 nm (# represents SrtA; (▲) represents the unreacted peptide or hydrolysis product; and (*) represents the unreacted peptide 2 or hydrolysis product).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemoenzymatic Synthesis of Ex4–DNP Conjugates 6–8 and FITC-Labeled Ex4–DNP Conjugates 9–11</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Activity was examined in vitro by measuring the cAMP response after receptor stimulation with native Ex4 and 1, and Ex4–DNP conjugates 6–8 in HEK293 cells that overexpressed human GLP-1R. (b) EC<sub>50</sub> (nM) values of each compound against GLP-1 R derived from the cAMP response curve fitting. The results were described as the mean ± SEM, <i>n</i> = 3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Glucose tolerance tests of PBS, native Ex4, and Ex4–DNP conjugates 6–8 (25 nmol/kg) in diabetic db/db mice. (a) Time response curves for the blood glucose level of each group. (b) Acute glucose-lowering effects are presented as calculated glucose AUC<sub>glucose 0–120min</sub> values. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) ELISA results of total antibody titers of pooled antisera collected on different days from C57BL/6 mice immunized with DNP–OVA conjugates (<i>n</i> = 20). (b) Assessment of the pharmacokinetic properties of FITC-labeled native Ex4 (peptide 2) and Ex4–DNP conjugates 9–11 in preimmunized C57BL/6 mice subcutaneously administered with 75 nmol/kg FITC-labeled native Ex4. Blood samples were collected at various time points for fluorescence quantification. For peptide 2, the clearance rate after 6 h was not plotted because the plasma concentrations promptly fell below the quantification limit. A noncompartmental fit was applied to the data to deduce the pharmacokinetic parameters shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Results are depicted as the mean ± SEM, <i>n</i> = 5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Glucose-lowering profile in the db/db mouse model without anti-DNP antibodies in blood after subcutaneous injection of PBS, native Ex4, and Ex4–DNP conjugates 6–8 (25 nmol/kg, <i>n</i> = 5). (b) Glucose-lowering profile in the db/db mouse model with anti-DNP antibodies in blood after subcutaneous injection of PBS, native Ex4, and Ex4–DNP conjugates 6–8 (25 nmol/kg, <i>n</i> = 5). (c) ELISA results of total antibody titers of pooled antisera collected on different days from db/db mice immunized with DNP–OVA conjugates (<i>n</i> = 25). (d) Hypoglycemic effect of PBS, native Ex4, and Ex4–DNP conjugates 6–8 was calculated by the glucose AUC value between 0 and 24 h (<i>n</i> = 5). The results are depicted as the means ± SEM, *<i>P</i> < 0.05 vs native Ex4 group, and <sup>&</sup><i>P</i> < 0.05 vs Ex4–DNP conjugate 6–8 groups before immunization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effects of PBS, twice-daily native Ex4, and once-daily conjugate 7 by subcutaneous injection on (a) body weight, (b) food intake, (c) water intake, and (d) FBG (fasted for 8 h) levels during chronic treatment in preimmunized db/db mice. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group, and <sup>#</sup><i>P</i> < 0.05 vs the native Ex4 group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Chronic treatment effects of PBS, native Ex4, and conjugate 7 on glucose tolerance, HbA1c, and lipid metabolism indicators in preimmunized db/db mice. (a) Blood glucose excursion during IPGTT performed at the end of the chronic treatment. (b) AUC of IPGTT for 0–120 min after the administration of glucose (dosage of 0.5 g/kg). (c) HbA1c levels before and after chronic treatment. (d) Plasma TG, (e) LDL-C, (f) HDL-C, and (g) TC levels measured after the sacrifice of animals. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group, and <sup>#</sup><i>P</i> < 0.05 vs the native Ex4 group. (▲) Note: Since the range of the glucometer is 1–33.3 mmol/L, when the reading of the glucometer is displayed as “HI”, maximal values of 33.3 mmol/L were substituted to enable statistical analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Toxicity effects of native Ex4 and conjugate 7 on the liver and kidney in preimmunized db/db mice after seven weeks of treatment. (a) AST, (b) ALT, (c) Crea, and (d) urea levels were measured by the corresponding assay kits on a BS-420 automatic biochemical analyzer after the sacrifice of animals. The results are depicted as the mean ± SEM (<i>n</i> = 5), *<i>P</i> < 0.05 vs the PBS group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/medium/jm1c00032_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Protective effect of native Ex4 and conjugate 7 on the kidney, liver, and pancreas of db/db mice. Histological examination of the liver (a), kidney (b), and pancreas (c) sections with H&E staining. (d) Immunohistochemistry examination of pancreas sections with insulin antibodies. A denser color reflects more insulin secretion (scale bars = 50 μm).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-8/acs.jmedchem.1c00032/20210415/images/large/jm1c00032_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00032&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">American
Diabetes Association</span> <span> </span><span class="NLM_article-title">2. Classification
and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">S14</span>– <span class="NLM_lpage">S31</span>, <span class="refDoi"> DOI: 10.2337/dc20-S002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.2337%2Fdc20-S002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=31862745" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2020&pages=S14-S31&author=American%0ADiabetes+Association&title=2.+Classification%0Aand+Diagnosis+of+Diabetes%3A+Standards+of+Medical+Care+in+Diabetes-2020&doi=10.2337%2Fdc20-S002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2337%2Fdc20-S002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc20-S002%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3D2.%2520Classification%250Aand%2520Diagnosis%2520of%2520Diabetes%253A%2520Standards%2520of%2520Medical%2520Care%2520in%2520Diabetes-2020%26jtitle%3DDiabetes%2520Care%26date%3D2020%26volume%3D43%26spage%3DS14%26epage%3DS31%26doi%3D10.2337%2Fdc20-S002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magliano, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, E. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavkov, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabesh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koye, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. E.</span></span> <span> </span><span class="NLM_article-title">Trends in incidence of total or type 2 diabetes: systematic review</span>. <i>BMJ</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">l5003</span>, <span class="refDoi"> DOI: 10.1136/bmj.l5003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1136%2Fbmj.l5003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=31511236" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=l5003&author=D.+J.+Maglianoauthor=R.+M.+Islamauthor=E.+L.+M.+Barrauthor=E.+W.+Greggauthor=M.+E.+Pavkovauthor=J.+L.+Hardingauthor=M.+Tabeshauthor=D.+N.+Koyeauthor=J.+E.+Shaw&title=Trends+in+incidence+of+total+or+type+2+diabetes%3A+systematic+review&doi=10.1136%2Fbmj.l5003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1136%2Fbmj.l5003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.l5003%26sid%3Dliteratum%253Aachs%26aulast%3DMagliano%26aufirst%3DD.%2BJ.%26aulast%3DIslam%26aufirst%3DR.%2BM.%26aulast%3DBarr%26aufirst%3DE.%2BL.%2BM.%26aulast%3DGregg%26aufirst%3DE.%2BW.%26aulast%3DPavkov%26aufirst%3DM.%2BE.%26aulast%3DHarding%26aufirst%3DJ.%2BL.%26aulast%3DTabesh%26aufirst%3DM.%26aulast%3DKoye%26aufirst%3DD.%2BN.%26aulast%3DShaw%26aufirst%3DJ.%2BE.%26atitle%3DTrends%2520in%2520incidence%2520of%2520total%2520or%2520type%25202%2520diabetes%253A%2520systematic%2520review%26jtitle%3DBMJ%26date%3D2019%26volume%3D366%26spage%3Dl5003%26doi%3D10.1136%2Fbmj.l5003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scully, C. C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span> <span> </span><span class="NLM_article-title">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00835</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00835" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=905-927&author=R.+Suzukiauthor=G.+A.+Brownauthor=J.+A.+Christopherauthor=C.+C.+G.+Scullyauthor=M.+Congreve&title=Recent+Developments+in+Therapeutic+Peptides+for+the+Glucagon-like+Peptide+1+and+2+Receptors&doi=10.1021%2Facs.jmedchem.9b00835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors</span></div><div class="casAuthors">Suzuki, Rie; Brown, Giles A.; Christopher, John A.; Scully, Conor C. G.; Congreve, Miles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are proglucagon derived peptides that are released from gut endocrine cells in response to nutrient intake.  These mols. are rapidly inactivated by the action of dipeptidyl peptidase IV (DPP-4) which limit their use as therapeutic agents.  The recent emergence of three-dimensional structures of G protein coupled receptors (GPCR) such as GLP-1R and glucagon receptor has helped to drive the rational design of innovative peptide mols. that hold promise as novel peptide therapeutics.  One emerging area is the discovery of multifunctional mols. that act at two or more pharmacol. systems to enhance therapeutic efficacy.  In addn., drug discovery efforts are also focusing on strategies to improve patient convenience through alternative routes of peptide delivery.  These novel strategies highlight the broad utility of peptide-based therapeutics in human disease settings where unmet needs still exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdugqq7LLcprVg90H21EOLACvtfcHk0lhQMZRH0P3Qwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFSisr3I&md5=98554f261b9fd88ed7a12e806869be6e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00835%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DG.%2BA.%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DScully%26aufirst%3DC.%2BC.%2BG.%26aulast%3DCongreve%26aufirst%3DM.%26atitle%3DRecent%2520Developments%2520in%2520Therapeutic%2520Peptides%2520for%2520the%2520Glucagon-like%2520Peptide%25201%2520and%25202%2520Receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D905%26epage%3D927%26doi%3D10.1021%2Facs.jmedchem.9b00835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koliaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doupis, J.</span></span> <span> </span><span class="NLM_article-title">Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus</span>. <i>Diabetes Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">121</span>, <span class="refDoi"> DOI: 10.1007/s13300-011-0002-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2Fs13300-011-0002-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22127804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVehsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=101-121&author=C.+Koliakiauthor=J.+Doupis&title=Incretin-based+therapy%3A+a+powerful+and+promising+weapon+in+the+treatment+of+type+2+diabetes+mellitus&doi=10.1007%2Fs13300-011-0002-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Koliaki, Chrysi; Doupis, John</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-121</span>CODEN:
                <span class="NLM_cas:coden">DTIHAP</span>;
        ISSN:<span class="NLM_cas:issn">1869-6961</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">A review.  Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease that increases significantly cardiovascular morbidity and mortality.  It is assocd. with obesity, insulin resistance, beta-cell dysfunction, and hyperglucagonemia, the combination of which typically leads to hyperglycemia.  Incretin-based treatment modalities, and in particular glucagon-like peptide 1 (GLP-1) receptor agonists, are able to successfully counteract several of the underlying pathophysiol. abnormalities of T2DM.  The pancreatic effects of GLP-1 receptor agonists include glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release in a strictly glucose-dependent manner, increased beta-cell proliferation, and decreased beta-cell apoptosis.  GLP-1 receptors are widely expressed throughout human body; thus, GLP-1-based therapies exert pleiotropic and multisystemic effects that extend far beyond pancreatic islets.  A large body of exptl. and clin. data have suggested a considerable protective role of GLP-1 analogs in the cardiovascular system (decreased blood pressure, improved endothelial and myocardial function, functional recovery of failing and ischemic heart, arterial vasodilatation), kidneys (increased diuresis and natriuresis), gastrointestinal tract (delayed gastric emptying, reduced gastric acid secretion), and central nervous system (appetite suppression, neuroprotective properties).  The pharmacol. use of GLP-1 receptor agonists has been shown to reduce bodyweight and systolic blood pressure, and significantly improve glycemic control and lipid profile.  Interestingly, wt. redn. induced by GLP-1 analogs reflects mainly loss of abdominal visceral fat.  The crit. issue of whether the emerging pos. cardiometabolic effects of GLP-1 analogs can be translated into better clin. outcomes for diabetic patients in terms of long-term hard endpoints, such as cardiovascular morbidity and mortality, remains to be elucidated with prospective, large-scale clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk98wVHFdMC7Vg90H21EOLACvtfcHk0lhQMZRH0P3Qwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVehsbzF&md5=8fcf51bba726a7d30d07d1e3d592abd3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs13300-011-0002-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13300-011-0002-3%26sid%3Dliteratum%253Aachs%26aulast%3DKoliaki%26aufirst%3DC.%26aulast%3DDoupis%26aufirst%3DJ.%26atitle%3DIncretin-based%2520therapy%253A%2520a%2520powerful%2520and%2520promising%2520weapon%2520in%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DDiabetes%2520Ther.%26date%3D2011%26volume%3D2%26spage%3D101%26epage%3D121%26doi%3D10.1007%2Fs13300-011-0002-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drucker, D. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1016/j.cmet.2018.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.cmet.2018.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=29617641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=740-756&author=D.+J.+Drucker&title=Mechanisms+of+Action+and+Therapeutic+Application+of+Glucagon-like+Peptide-1&doi=10.1016%2Fj.cmet.2018.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1</span></div><div class="casAuthors">Drucker, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-756</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion.  GLP-1 also inhibits gastric emptying and food intake, actions maximizing nutrient absorption while limiting wt. gain.  Here I review the circuits engaged by endogenous vs. pharmacol. GLP-1 action, highlighting key GLP-1 receptor (GLP-1R)-pos. cell types and pathways transducing metabolic and non-glycemic GLP-1 signals.  The role(s) of GLP-1 in the benefits and side effects assocd. with bariatric surgery are discussed and actions of GLP-1 controlling islet function, appetite, inflammation, and cardiovascular pathophysiol. are highlighted.  Refinement of the risk-vs.-benefit profile of GLP-1-based therapies for the treatment of diabetes and obesity has stimulated development of orally bioavailable agonists, allosteric modulators, and unimol. multi-agonists, all targeting the GLP-1R.  This review highlights established and emerging concepts, unanswered questions, and future challenges for development and optimization of GLP-1R agonists in the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-w0J5LcxUeLVg90H21EOLACvtfcHk0lh_CYglhuCE0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVKqs7k%253D&md5=1bdfca5836ed6bd1d2cf49de109f5e65</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DDrucker%26aufirst%3DD.%2BJ.%26atitle%3DMechanisms%2520of%2520Action%2520and%2520Therapeutic%2520Application%2520of%2520Glucagon-like%2520Peptide-1%26jtitle%3DCell%2520Metab.%26date%3D2018%26volume%3D27%26spage%3D740%26epage%3D756%26doi%3D10.1016%2Fj.cmet.2018.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meier, J. J.</span></span> <span> </span><span class="NLM_article-title">GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</span>. <i>Nat. Rev. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1038/nrendo.2012.140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnrendo.2012.140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22945360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=728-742&author=J.+J.+Meier&title=GLP-1+receptor+agonists+for+individualized+treatment+of+type+2+diabetes+mellitus&doi=10.1038%2Fnrendo.2012.140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Meier, Juris J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Endocrinology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">728-742</span>CODEN:
                <span class="NLM_cas:coden">NREABD</span>;
        ISSN:<span class="NLM_cas:issn">1759-5029</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and lowers glucose concns. by augmenting insulin secretion and suppressing glucagon release.  Addnl. effects of GLP-1 include retardation of gastric emptying, suppression of appetite and, potentially, inhibition of β-cell apoptosis.  Native GLP-1 is degraded within ∼2-3 min in the circulation; various GLP-1 receptor agonists have, therefore, been developed to provide prolonged in vivo actions.  These GLP-1 receptor agonists can be categorized as either short-acting compds., which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compds. (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose.  The pharmacokinetic differences between these drugs lead to important differences in their pharmacodynamic profiles.  The short-acting GLP-1 receptor agonists primarily lower postprandial blood glucose levels through inhibition of gastric emptying, whereas the long-acting compds. have a stronger effect on fasting glucose levels, which is mediated predominantly through their insulinotropic and glucagonostatic actions.  The adverse effect profiles of these compds. also differ.  The individual properties of the various GLP-1 receptor agonists might enable incretin-based treatment of type 2 diabetes mellitus to be tailored to the needs of each patient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8GZovdW_ldbVg90H21EOLACvtfcHk0lh_CYglhuCE0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslahsLnP&md5=5dc374bda9f06bb96494f8ed7a61018f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrendo.2012.140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrendo.2012.140%26sid%3Dliteratum%253Aachs%26aulast%3DMeier%26aufirst%3DJ.%2BJ.%26atitle%3DGLP-1%2520receptor%2520agonists%2520for%2520individualized%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DNat.%2520Rev.%2520Endocrinol.%26date%3D2012%26volume%3D8%26spage%3D728%26epage%3D742%26doi%3D10.1038%2Fnrendo.2012.140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miossec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knop, F.</span></span> <span> </span><span class="NLM_article-title">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1223</span>, <span class="refDoi"> DOI: 10.1517/17460441.2014.942638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1517%2F17460441.2014.942638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=25119443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1223&author=M.+Christensenauthor=P.+Miossecauthor=B.+Larsenauthor=U.+Wernerauthor=F.+Knop&title=The+design+and+discovery+of+lixisenatide+for+the+treatment+of+type+2+diabetes+mellitus&doi=10.1517%2F17460441.2014.942638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus</span></div><div class="casAuthors">Christensen, Mikkel; Miossec, Patrick; Larsen, Bjarne Due; Werner, Ulrich; Knop, Filip K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1223-1251</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Lixisenatide is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) used in the treatment of type 2 diabetes mellitus (T2DM).  It is used in combination with oral antidiabetics and/or basal insulin in patients inadequately controlled on these medications and who are undergoing diet and lifestyle modification.  GLP-1RAs glucose-dependently increase insulin secretion, decrease glucagon secretion, and slow gastric emptying, thereby improving glycemic control.  GLP-1RAs are assocd. with body wt. benefits and low rates of hypoglycemia which are welcome in patients with T2DM.  Areas covered: The authors describe the identification of GLP-1RAs as suitable targets for modification with structure-inducing probe technol. to improve stability and resistance to proteolytic degrdn.  Clin. studies have assessed lixisenatide across > 5000 patients as a monotherapy or add-on to a variety of commonly used antidiabetic medications.  These studies highlighted the effects of lixisenatide on gastric emptying, explaining its particular improvements in postprandial plasma glucose (PPG) excursions and underscoring its efficacy in combination with insulin glargine.  Lixisenatide was well tolerated, with nausea and vomiting being the most frequently reported adverse events.  Expert opinion: The once-daily administration of lixisenatide as well as its substantial sustained effect on gastric emptying and, hence, PPG excursions are all important features compared with the other GLP-1RAs.  The combination of two injectables, such as basal insulin to lower fasting plasma glucose and a GLP-1RA that curtails PPG excursions, is clin. valuable and could differentiate lixisenatide from other GLP-1RAs, esp. from those continuously acting GLP-1RAs with little effect on gastric emptying and PPG excursions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW0IfTdZVP3bVg90H21EOLACvtfcHk0lh_CYglhuCE0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtLzN&md5=aaf08b96c53617d3044e56447ca8e7f1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1517%2F17460441.2014.942638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2014.942638%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DM.%26aulast%3DMiossec%26aufirst%3DP.%26aulast%3DLarsen%26aufirst%3DB.%26aulast%3DWerner%26aufirst%3DU.%26aulast%3DKnop%26aufirst%3DF.%26atitle%3DThe%2520design%2520and%2520discovery%2520of%2520lixisenatide%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%2520mellitus%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2014%26volume%3D9%26spage%3D1223%26doi%3D10.1517%2F17460441.2014.942638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">578</span>, <span class="refDoi"> DOI: 10.3390/ijms18030578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.3390%2Fijms18030578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVSjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=578&author=W.+Saiauthor=H.+Tianauthor=K.+Yangauthor=D.+Tangauthor=J.+Baoauthor=Y.+Geauthor=X.+Songauthor=Y.+Zhangauthor=C.+Luoauthor=X.+Gaoauthor=W.+Yao&title=Systematic+Design+of+Trypsin+Cleavage+Site+Mutated+Exendin4-Cysteine+1%2C+an+Orally+Bioavailable+Glucagon-Like+Peptide-1+Receptor+Agonist&doi=10.3390%2Fijms18030578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic design of trypsin cleavage site mutated exendin4-cysteine 1, an orally bioavailable glucagon-like peptide-1 receptor agonist</span></div><div class="casAuthors">Sai, Wenbo; Tian, Hong; Yang, Kangmin; Tang, Daoqi; Bao, Jinxiao; Ge, Yang; Song, Xiaoda; Zhang, Yu; Luo, Cheng; Gao, Xiangdong; Yao, Wenbing</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">578/1-578/15</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Exendin-4 is a strong therapeutic candidate for the treatment of metabolic syndrome.  Related receptor agonist drugs have been on the market since 2005.  However, tech. limitations and the pain caused by s.c. injection have severely limited patient compliance.  The goal of the study is to investigate a biol. active exendin-4 analog could be administered orally.  Using i.p. glucose tolerance tests, we discovered that exendin4-cysteine administered by oral gavage had a distinct hypoglycemic effect in C57BL/6J mice.  Using Rosetta Design and Amber, we designed and screened a series of exendin4-cysteine analogs to identify those that retained biol. activity while resisting trypsin digestion.  Trypsin Cleavage Site Mutated Exendin4-cysteine 1 (TSME-1), an analog whose bioactivity was similar to exendin-4 and was almost completely resistant to trypsin, was screened out.  In addn., TSME-1 significantly normalized the blood glucose levels and the availability of TSME-1 was significantly higher than that of exendin-4 and exendin4-cysteine.  Collectively orally administered TSME-1, a trypsin-resistant exendin-4 analog obtained by the system, is a strong candidate for future treatments of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_hulc1rrukrVg90H21EOLACvtfcHk0lh_CYglhuCE0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVSjuro%253D&md5=eed720e67d6298f6e5434b145988cf7d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fijms18030578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18030578%26sid%3Dliteratum%253Aachs%26aulast%3DSai%26aufirst%3DW.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DD.%26aulast%3DBao%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DW.%26atitle%3DSystematic%2520Design%2520of%2520Trypsin%2520Cleavage%2520Site%2520Mutated%2520Exendin4-Cysteine%25201%252C%2520an%2520Orally%2520Bioavailable%2520Glucagon-Like%2520Peptide-1%2520Receptor%2520Agonist%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D578%26doi%3D10.3390%2Fijms18030578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.ejmech.2018.07.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=30096651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=177-187&author=J.+Hanauthor=Y.+Huangauthor=X.+Chenauthor=F.+Zhouauthor=Y.+Feiauthor=J.+Fu&title=Rational+design+of+dimeric+lipidated+Xenopus+glucagon-like+peptide+1+analogues+as+long-acting+antihyperglycaemic+agents&doi=10.1016%2Fj.ejmech.2018.07.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycemic agents</span></div><div class="casAuthors">Han, Jing; Huang, Yue; Chen, Xinyu; Zhou, Feng; Fei, Yingying; Fu, Junjie</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">177-187</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Dimerization is viewed as an effective means to enhance the binding affinity and therapeutic potency of peptides.  Both dimerization and lipidation effectively prolong the half-life of peptides in vivo by increasing hydrodynamic size and facilitating phys. interactions with serum albumin.  Here, we report a novel method to discover long-acting glucagon-like peptide 1 (GLP-1) analogs by rational design based on Xenopus GLP-1 through a combined dimerization and lipidization strategy.  On the basis of our previous structure anal. of Xenopus GLP-1, palmitic acid and a C-terminal Cys were firstly introduced into two Xenopus GLP-1 analogs (1 and 2), and the afforded 3 and 4 were further reacted with bis-maleimide amine to afford two dimeric lipidated Xenopus GLP-1 analogs (5 and 6).  The in vitro and in vivo biol. activities of 5 and 6 were significantly improved as compared with their monomers.  Moreover, the selected compd. 6 showed greater hypoglycemic and insulinotropic activities than liraglutide even when the dose of 6 was reduced to half in db/db mice.  Pharmacokinetic test revealed that 6 had a ∼ 3-fold longer half-life than liraglutide in Kunming mice and SD rats, and the longer half-life of 6 led to excellent long-acting hypoglycemic effects as confirmed by two different pharmacol. methods conducted on db/db mice.  Finally, a 7 wk chronic study conducted on db/db mice demonstrated the better therapeutic efficacies of 6 on glucose tolerance normalization, HbA1c redn. and pancreas islets protection than liraglutide.  The present research showed that combined dimerization and lipidization is effective when applied to Xenopus GLP-1 analog to develop novel GLP-1 analog for the treatment of type 2 diabetes.  In addn., the promising preclin. data of 6 suggested the therapeutic potential of 6 as a novel anti-diabetic agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu69hLGs6cPLVg90H21EOLACvtfcHk0lio1vH1eG0KEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVygurnO&md5=ae25a20f5222a840602f9bece420e690</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.072%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DFei%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DRational%2520design%2520of%2520dimeric%2520lipidated%2520Xenopus%2520glucagon-like%2520peptide%25201%2520analogues%2520as%2520long-acting%2520antihyperglycaemic%2520agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D177%26epage%3D187%26doi%3D10.1016%2Fj.ejmech.2018.07.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäffer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spetzler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kofoed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steensgaard, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strauss, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gram, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thygesen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reedtz-Runge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7370</span>– <span class="NLM_lpage">7380</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00726</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7370-7380&author=J.+Lauauthor=P.+Blochauthor=L.+Sch%C3%A4fferauthor=I.+Petterssonauthor=J.+Spetzlerauthor=J.+Kofoedauthor=K.+Madsenauthor=L.+B.+Knudsenauthor=J.+McGuireauthor=D.+B.+Steensgaardauthor=H.+M.+Straussauthor=D.+X.+Gramauthor=S.+M.+Knudsenauthor=F.+S.+Nielsenauthor=P.+Thygesenauthor=S.+Reedtz-Rungeauthor=T.+Kruse&title=Discovery+of+the+Once-Weekly+Glucagon-Like+Peptide-1+%28GLP-1%29+Analogue+Semaglutide&doi=10.1021%2Facs.jmedchem.5b00726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide</span></div><div class="casAuthors">Lau, Jesper; Bloch, Paw; Schaffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Moeller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7370-7380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity.  The aim of the present studies was to design a once weekly GLP-1 analog by increasing albumin affinity and secure full stability against metabolic degrdn.  The fatty acid moiety and the linking chem. to GLP-1 were the key features to secure high albumin affinity and GLP-1 receptor (GLP-1R) potency and in obtaining a prolonged exposure and action of the GLP-1 analog.  Semaglutide was selected as the optimal once weekly candidate.  Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26.  The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) was three-fold decreased compared to liraglutide, whereas the albumin affinity was increased.  The plasma half-life was 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.  Semaglutide is currently in phase 3 clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8tFc0FzEro7Vg90H21EOLACvtfcHk0lio1vH1eG0KEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtl2qu7%252FM&md5=0478fe17f9f4dcc0cb58919b1c55869a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00726%26sid%3Dliteratum%253Aachs%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DBloch%26aufirst%3DP.%26aulast%3DSch%25C3%25A4ffer%26aufirst%3DL.%26aulast%3DPettersson%26aufirst%3DI.%26aulast%3DSpetzler%26aufirst%3DJ.%26aulast%3DKofoed%26aufirst%3DJ.%26aulast%3DMadsen%26aufirst%3DK.%26aulast%3DKnudsen%26aufirst%3DL.%2BB.%26aulast%3DMcGuire%26aufirst%3DJ.%26aulast%3DSteensgaard%26aufirst%3DD.%2BB.%26aulast%3DStrauss%26aufirst%3DH.%2BM.%26aulast%3DGram%26aufirst%3DD.%2BX.%26aulast%3DKnudsen%26aufirst%3DS.%2BM.%26aulast%3DNielsen%26aufirst%3DF.%2BS.%26aulast%3DThygesen%26aufirst%3DP.%26aulast%3DReedtz-Runge%26aufirst%3DS.%26aulast%3DKruse%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520Once-Weekly%2520Glucagon-Like%2520Peptide-1%2520%2528GLP-1%2529%2520Analogue%2520Semaglutide%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7370%26epage%3D7380%26doi%3D10.1021%2Facs.jmedchem.5b00726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9955</span>– <span class="NLM_lpage">9968</span>, <span class="refDoi"> DOI: 10.1021/jm4017448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4017448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9955-9968&author=J.+Hanauthor=L.+Sunauthor=Y.+Chuauthor=Z.+Liauthor=D.+Huangauthor=X.+Zhuauthor=H.+Qianauthor=W.+Huang&title=Design%2C+synthesis%2C+and+biological+activity+of+novel+dicoumarol+glucagon-like+peptide+1+conjugates&doi=10.1021%2Fjm4017448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates</span></div><div class="casAuthors">Han, Jing; Sun, Lidan; Chu, Yingying; Li, Zheng; Huang, Dandan; Zhu, Xiaoyun; Qian, Hai; Huang, Wenlong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9955-9968</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Twelve novel dicoumarol glucagon-like peptide 1 (GLP-1) conjugates were designed, synthesized, and tested for biol. activity.  All derivs. retained receptor activation efficacy, and exhibited improved albumin affinity and in vitro stability in rat plasma.  The in vivo elimination half-lives of 13c and 13l (22.07 and 18.78 h, resp.) were much longer than those of the GLP-1 receptor agonists exendin-4 (2.82 h) and liraglutide (12.53 h).  The prolonged in vivo antidiabetic effects of 13c and 13l on db/db mice were confirmed by the hypoglycemic efficacy test and the multiple i.p. glucose tolerance test.  Importantly, a once daily administration of 13c to db/db mice for 7 wk provided long-term beneficial effects by lowering glycated Hb (HbA1c) levels to 5.05%, which was lower than with liraglutide treatment (5.41%).  These results suggest that 13c is a promising long-lasting GLP-1 mimetic that may be suitable for clin. use following further research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTz1d3aaqq0LVg90H21EOLACvtfcHk0lgZo7VgnuJ6ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnJ&md5=cc6a253589304c9b29db4871474dbedf</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm4017448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4017448%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DChu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DQian%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activity%2520of%2520novel%2520dicoumarol%2520glucagon-like%2520peptide%25201%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9955%26epage%3D9968%26doi%3D10.1021%2Fjm4017448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simakova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luginbuhl, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershfield, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matyjaszewski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity</span>. <i>Nat. Biomed. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">0002</span>, <span class="refDoi"> DOI: 10.1038/s41551-016-0002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41551-016-0002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ahur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=0002&author=Y.+Qiauthor=A.+Simakovaauthor=N.+J.+Gansonauthor=X.+Liauthor=K.+M.+Luginbuhlauthor=I.+Ozerauthor=W.+Liuauthor=M.+S.+Hershfieldauthor=K.+Matyjaszewskiauthor=A.+Chilkoti&title=A+brush-polymer+conjugate+of+exendin-4+reduces+blood+glucose+for+up+to+five+days+and+eliminates+poly%28ethylene+glycol%29+antigenicity&doi=10.1038%2Fs41551-016-0002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity</span></div><div class="casAuthors">Qi, Yizhi; Simakova, Antonina; Ganson, Nancy J.; Li, Xinghai; Luginbuhl, Kelli M.; Ozer, Imran; Liu, Wenge; Hershfield, Michael S.; Matyjaszewski, Krzysztof; Chilkoti, Ashutosh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biomedical Engineering</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">0002</span>CODEN:
                <span class="NLM_cas:coden">NBEAB3</span>;
        ISSN:<span class="NLM_cas:issn">2157-846X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The delivery of therapeutic peptides and proteins is often challenged by short half-lives and the consequent need for frequent injections that limit efficacy, reduce patient compliance and increase treatment cost.  Here, we demonstrate that a single s.c. injection of site-specific (C-terminal) conjugates of exendin-4 (exendin)-a therapeutic peptide that is clin. used to treat type 2 diabetes mellitus-and poly[oligo(ethylene glycol) Me ether methacrylate] (POEGMA) with precisely controlled mol. wts. lowered blood glucose for up to 120 h in fed mice.  Most notably, we show that an exendin-C-POEGMA conjugate with an av. of nine side-chain ethylene glycol (EG) repeats exhibits significantly lower reactivity towards patient-derived anti-poly(ethylene glycol) (anti-PEG) antibodies than two US FDA-approved PEGylated drugs, and that reducing the side-chain length to three EG repeats completely eliminates PEG antigenicity without compromising in vivo efficacy.  Our findings establish the site-specific conjugation of POEGMA as a next-generation PEGylation technol. for improving the pharmacol. performance of traditional PEGylated drugs, whose safety and efficacy are hindered by pre-existing anti-PEG antibodies in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5EnxB3iRfBLVg90H21EOLACvtfcHk0lgZo7VgnuJ6ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ahur3J&md5=6b947841a437e5c765b0d7d6f053e94e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41551-016-0002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41551-016-0002%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DY.%26aulast%3DSimakova%26aufirst%3DA.%26aulast%3DGanson%26aufirst%3DN.%2BJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLuginbuhl%26aufirst%3DK.%2BM.%26aulast%3DOzer%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DHershfield%26aufirst%3DM.%2BS.%26aulast%3DMatyjaszewski%26aufirst%3DK.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DA%2520brush-polymer%2520conjugate%2520of%2520exendin-4%2520reduces%2520blood%2520glucose%2520for%2520up%2520to%2520five%2520days%2520and%2520eliminates%2520poly%2528ethylene%2520glycol%2529%2520antigenicity%26jtitle%3DNat.%2520Biomed.%2520Eng.%26date%3D2017%26volume%3D1%26spage%3D0002%26doi%3D10.1038%2Fs41551-016-0002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S. K.</span></span> <span> </span><span class="NLM_article-title">Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">4121</span>– <span class="NLM_lpage">4128</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2010.01.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.biomaterials.2010.01.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=20149450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtFKis78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=4121-4128&author=J.-H.+Kongauthor=E.+J.+Ohauthor=S.+Y.+Chaeauthor=K.+C.+Leeauthor=S.+K.+Hahn&title=Long+acting+hyaluronate%2D%2Dexendin+4+conjugate+for+the+treatment+of+type+2+diabetes&doi=10.1016%2Fj.biomaterials.2010.01.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Long acting hyaluronate - exendin 4 conjugate for the treatment of type 2 diabetes</span></div><div class="casAuthors">Kong, Ji-Hyun; Oh, Eun Ju; Chae, Su Young; Lee, Kang Choon; Hahn, Sei Kwang</div><div class="citationInfo"><span class="NLM_cas:title">Biomaterials</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4121-4128</span>CODEN:
                <span class="NLM_cas:coden">BIMADU</span>;
        ISSN:<span class="NLM_cas:issn">0142-9612</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Despite clin. exploitation of exendin 4 for the treatment of type 2 diabetes, the significantly short half-life requiring twice a day injection has limited the wide applications.  In this work, a protocol for the synthesis of long acting hyaluronate (HA) - exendin 4 conjugate was successfully developed using Michael addn. chem. between vinyl sulfone modified HA (HA-VS) and thiolated exendin 4.  The exendin 4 content could be controlled in the range of 5-30 mols. per single HA chain with a bioconjugation efficiency higher than 90%.  The conjugation of exendin 4 with HA resulted in about 20 times improved in vitro serum stability maintaining the hypoglycemic and gluco-regulatory bioactivities of exendin 4.  HA - exendin 4 conjugates showed excellent glucose-lowering capabilities in type 2 db/db mice demonstrating protracted hypoglycemic effect up to 3 days after a single s.c. injection.  Furthermore, insulin immunohistochem. anal. of islets in db/db mice confirmed the improved insulinotropic activity of HA - exendin 4 conjugates.  The HA - exendin 4 conjugates will be investigated further as a twice a week injection dosage form for clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUN06zMLTLlLVg90H21EOLACvtfcHk0lgZo7VgnuJ6ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtFKis78%253D&md5=9eed2b7dd0a6228bcb0595104960d3db</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2010.01.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2010.01.091%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DJ.-H.%26aulast%3DOh%26aufirst%3DE.%2BJ.%26aulast%3DChae%26aufirst%3DS.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DHahn%26aufirst%3DS.%2BK.%26atitle%3DLong%2520acting%2520hyaluronate--exendin%25204%2520conjugate%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DBiomaterials%26date%3D2010%26volume%3D31%26spage%3D4121%26epage%3D4128%26doi%3D10.1016%2Fj.biomaterials.2010.01.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment</span>. <i>Carbohydr. Polym.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>249</i></span>,  <span class="NLM_fpage">116864</span>– <span class="NLM_lpage">116872</span>, <span class="refDoi"> DOI: 10.1016/j.carbpol.2020.116864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.carbpol.2020.116864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=32933691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKnt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=249&publication_year=2020&pages=116864-116872&author=S.+Daiauthor=S.+Liuauthor=C.+Liauthor=Z.+Zhouauthor=Z.+Wu&title=Site-selective+modification+of+exendin+4+with+variable+molecular+weight+dextrans+by+oxime-ligation+chemistry+for+improving+type+2+diabetic+treatment&doi=10.1016%2Fj.carbpol.2020.116864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment</span></div><div class="casAuthors">Dai, Shijie; Liu, Shaozhong; Li, Chen; Zhou, Zhifang; Wu, Zhimeng</div><div class="citationInfo"><span class="NLM_cas:title">Carbohydrate Polymers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">249</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116864</span>CODEN:
                <span class="NLM_cas:coden">CAPOD8</span>;
        ISSN:<span class="NLM_cas:issn">0144-8617</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dextrans, as natural and biocompatible polysaccharides, are a promising candidate as PEG alternatives to improve the therapeutic profiles of biotherapeuticals.  In this work, we chem. mutated the lysine residue in native Ex4 to aminooxyl contg. lysine (K*) and three Ex4 analogs (Ex4-12K*, Ex4-27K*, Ex4-12K*-27K*) were synthesized and site-selectively modified with variable Mw of dextrans by facile oxime-ligation chem.  The biol. activities of six dextran-Ex4 conjugates were studied by in vitro and in vivo expt.  It was demonstrated that dextranylation at the 12-site of Ex4 detd. the in vitro potency as GLP-1R agonist and the in vivo acute glucose-lowering activity.  Furthermore, the in vivo long-acting antidiabetic expt. demonstrated that hypoglycemic effect was strongly dependent on the dextranylation site of Ex4 as well as the size of dextran.  And Dextran-Ex4-12K*(20,000) exhibited the best long acting hypoglycemic activity in STZ/HFD-induced T2D mice and is a promising once daily reagent for T2D treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6pk86P6OKaLVg90H21EOLACvtfcHk0ljYznAL_1XpGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKnt7%252FL&md5=1cf12aa03e1570169b9d834c00963e82</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.carbpol.2020.116864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.carbpol.2020.116864%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSite-selective%2520modification%2520of%2520exendin%25204%2520with%2520variable%2520molecular%2520weight%2520dextrans%2520by%2520oxime-ligation%2520chemistry%2520for%2520improving%2520type%25202%2520diabetic%2520treatment%26jtitle%3DCarbohydr.%2520Polym.%26date%3D2020%26volume%3D249%26spage%3D116864%26epage%3D116872%26doi%3D10.1016%2Fj.carbpol.2020.116864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">Molecular Design of Peptide-Fc Fusion Drugs</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.2174/1389200219666180821095355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.2174%2F1389200219666180821095355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=30129406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFejsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=203-208&author=L.+Ningauthor=B.+Heauthor=P.+Zhouauthor=R.+Derdaauthor=J.+Huang&title=Molecular+Design+of+Peptide-Fc+Fusion+Drugs&doi=10.2174%2F1389200219666180821095355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Design of Peptide-Fc Fusion Drugs</span></div><div class="casAuthors">Ning, Lin; He, Bifang; Zhou, Peng; Derda, Ratmir; Huang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-208</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Peptide-Fc fusion drugs, also known as peptibodies, are a category of biol. therapeutics in which the Fc region of an antibody is genetically fused to a peptide of interest.  However, to develop such kind of drugs is laborious and expensive.  Rational design is urgently needed.  We summarized the key steps in peptide-Fc fusion technol. and stressed the main computational resources, tools, and methods that had been used in the rational design of peptide-Fc fusion drugs.  We also raised open questions about the computer-aided mol. design of peptide-Fc.  The design of peptibody consists of four steps.  First, identify peptide leads from native ligands, biopanning, and computational design or prediction.  Second, select the proper Fc region from different classes or subclasses of Ig.  Third, fuse the peptide leads and Fc together properly.  At last, evaluate the immunogenicity of the constructs.  At each step, there are quite a few useful resources and computational tools.  Reviewing the mol. design of peptibody will certainly help make the transition from peptide leads to drugs on the market quicker and cheaper.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo78dJRpa4-97Vg90H21EOLACvtfcHk0ljYznAL_1XpGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFejsbzF&md5=ee8643ca6b72120311586f14b590d527</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.2174%2F1389200219666180821095355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200219666180821095355%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DP.%26aulast%3DDerda%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DMolecular%2520Design%2520of%2520Peptide-Fc%2520Fusion%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2019%26volume%3D20%26spage%3D203%26epage%3D208%26doi%3D10.2174%2F1389200219666180821095355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roopenian, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akilesh, S.</span></span> <span> </span><span class="NLM_article-title">FcRn: the neonatal Fc receptor comes of age</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1038/nri2155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnri2155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=17703228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsV2qtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=715-725&author=D.+C.+Roopenianauthor=S.+Akilesh&title=FcRn%3A+the+neonatal+Fc+receptor+comes+of+age&doi=10.1038%2Fnri2155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">FcRn: the neonatal Fc receptor comes of age</span></div><div class="casAuthors">Roopenian, Derry C.; Akilesh, Shreeram</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">715-725</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from a mother to her fetus.  In addn., throughout life, FcRn protects IgG from degrdn., thereby explaining the long half-life of this class of antibody in the serum.  In recent years, it has become clear that FcRn is expressed in various sites in adults, where its potential function is now beginning to emerge.  In addn., recent studies have examd. the interaction between FcRn and the Fc portion of IgG with the aim of either improving the serum half-life of therapeutic monoclonal antibodies or reducing the half-life of pathogenic antibodies.  This review summarizes these two areas of FcRn biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5skHElvYC7rVg90H21EOLACvtfcHk0ljYznAL_1XpGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsV2qtbw%253D&md5=2a8ac184952c13877635d8ebc0e53956</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnri2155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2155%26sid%3Dliteratum%253Aachs%26aulast%3DRoopenian%26aufirst%3DD.%2BC.%26aulast%3DAkilesh%26aufirst%3DS.%26atitle%3DFcRn%253A%2520the%2520neonatal%2520Fc%2520receptor%2520comes%2520of%2520age%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D715%26epage%3D725%26doi%3D10.1038%2Fnri2155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heath, C.</span>; <span class="NLM_string-name">Pettit, D.</span></span> <span> </span><span class="NLM_article-title">“Fc Fusion Proteins”</span>.  <i>Challenges in Protein Product Development</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">558</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2F978-3-319-90603-4_24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=545-558&author=C.+Heath&author=D.+Pettit&title=Challenges+in+Protein+Product+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-90603-4_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-90603-4_24%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DC.%26atitle%3D%25E2%2580%259CFc%2520Fusion%2520Proteins%25E2%2580%259D%26btitle%3DChallenges%2520in%2520Protein%2520Product%2520Development%26pub%3DSpringer%26date%3D2018%26spage%3D545%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span> <i>Fusion Protein Technologies for Biopharmaceuticals. Applications and Challenges</i>; <span class="NLM_publisher-name">Wiley</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2F9781118354599" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=S.+Schmidt&title=Fusion+Protein+Technologies+for+Biopharmaceuticals.+Applications+and+Challenges"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2F9781118354599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9781118354599%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DS.%26btitle%3DFusion%2520Protein%2520Technologies%2520for%2520Biopharmaceuticals.%2520Applications%2520and%2520Challenges%26pub%3DWiley%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, A.</span></span> <span> </span><span class="NLM_article-title">Comparing antibody and small-molecule therapies for cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/nrc1913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnrc1913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=16929325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=714-727&author=K.+Imaiauthor=A.+Takaoka&title=Comparing+antibody+and+small-molecule+therapies+for+cancer&doi=10.1038%2Fnrc1913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing antibody and small-molecule therapies for cancer</span></div><div class="casAuthors">Imai, Kohzoh; Takaoka, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">714-727</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The 'magic bullet' concept of specifically targeting cancer cells at the same time as sparing normal tissues is now proven, as several monoclonal antibodies and targeted small-mol. compds. have been approved for cancer treatment.  Both antibodies and small-mol. compds. are therefore promising tools for target-protein-based cancer therapy.  We discuss and compare the distinctive properties of these two therapeutic strategies to provide a better view for the development of new drugs and the future direction of cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDfUrcKvj1GLVg90H21EOLACvtfcHk0ljZEmWxebslig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XosVOmsLo%253D&md5=31cfa17a5e3ddba75b2e32632aaa0deb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc1913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1913%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DK.%26aulast%3DTakaoka%26aufirst%3DA.%26atitle%3DComparing%2520antibody%2520and%2520small-molecule%2520therapies%2520for%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D714%26epage%3D727%26doi%3D10.1038%2Fnrc1913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golding, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strome, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauna, Z. E.</span></span> <span> </span><span class="NLM_article-title">Fc fusion as a platform technology: potential for modulating immunogenicity</span>. <i>Trends Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.tibtech.2014.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.tibtech.2014.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=25488117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=27-34&author=D.+Levinauthor=B.+Goldingauthor=S.+E.+Stromeauthor=Z.+E.+Sauna&title=Fc+fusion+as+a+platform+technology%3A+potential+for+modulating+immunogenicity&doi=10.1016%2Fj.tibtech.2014.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Fc fusion as a platform technology: potential for modulating immunogenicity</span></div><div class="casAuthors">Levin, Ditza; Golding, Basil; Strome, Scott E.; Sauna, Zuben E.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-34</span>CODEN:
                <span class="NLM_cas:coden">TRBIDM</span>;
        ISSN:<span class="NLM_cas:issn">0167-7799</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The platform technol. of fragment crystallizable (Fc) fusion, in which the Fc region of an antibody is genetically linked to an active protein drug, is among the most successful of a new generation of bioengineering strategies.  Immunogenicity is a crit. safety concern in the development of any protein therapeutic.  While the therapeutic goal of generating Fc-fusion proteins has been to extend half-life, there is a crit. mass of literature from immunol. indicating that appropriate design of the Fc component has the potential to engage the immune system for product-specific outcomes.  In the context of Fc-fusion therapeutics, a review of progress in understanding Fc biol. suggests the prospect of engineering products that have an extended half-life and are able to modulate the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqycjBdv1yE5bVg90H21EOLACvtfcHk0ljZEmWxebslig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFCrtrrN&md5=fe4cba49e6eb8c303b0cf7726bc1bf66</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tibtech.2014.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibtech.2014.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DD.%26aulast%3DGolding%26aufirst%3DB.%26aulast%3DStrome%26aufirst%3DS.%2BE.%26aulast%3DSauna%26aufirst%3DZ.%2BE.%26atitle%3DFc%2520fusion%2520as%2520a%2520platform%2520technology%253A%2520potential%2520for%2520modulating%2520immunogenicity%26jtitle%3DTrends%2520Biotechnol.%26date%3D2015%26volume%3D33%26spage%3D27%26epage%3D34%26doi%3D10.1016%2Fj.tibtech.2014.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1007/s13238-017-0408-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2Fs13238-017-0408-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=28421387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFCru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=15-32&author=L.+Liu&title=Pharmacokinetics+of+monoclonal+antibodies+and+Fc-fusion+proteins&doi=10.1007%2Fs13238-017-0408-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins</span></div><div class="casAuthors">Liu, Liming</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-32</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">A review.  There are many factors that can influence the pharmacokinetics (PK) of a mAb or Fc-fusion mol. with the primary determinant being FcRn-mediated recycling.  Through Fab or Fc engineering, IgG-FcRn interaction can be used to generate a variety of therapeutic antibodies with significantly enhanced half-life or ability to remove unwanted antigen from circulation.  Glycosylation of a mAb or Fc-fusion protein can have a significant impact on the PK of these mols.  MAb charge can be important and variants with pI values of 1-2 unit difference are likely to impact PK with lower pI values being favorable for a longer half-life.  Most mAbs display target mediated drug disposition (TMDD), which can have significant consequences on the study designs of preclin. and clin. studies.  The PK of mAb can also be influenced by anti-drug antibody (ADA) response and off-target binding, which require careful consideration during the discovery stage. mAbs are primarily absorbed through the lymphatics via convection and can be conveniently administered by the s.c. (s.c.) route in large doses/vols. with co-formulation of hyaluronidase.  The human PK of a mAb can be reasonably estd. using cynomolgus monkey data and allometric scaling methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxt43BRiGzHLVg90H21EOLACvtfcHk0ljZEmWxebslig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFCru70%253D&md5=29227aae984bad9b7d2124aaf2f8c6ff</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs13238-017-0408-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-017-0408-4%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26atitle%3DPharmacokinetics%2520of%2520monoclonal%2520antibodies%2520and%2520Fc-fusion%2520proteins%26jtitle%3DProtein%2520Cell%26date%3D2018%26volume%3D9%26spage%3D15%26epage%3D32%26doi%3D10.1007%2Fs13238-017-0408-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Umpierrez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofé Povedano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez Manghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shurzinske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pechtner, V.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2168</span>– <span class="NLM_lpage">2176</span>, <span class="refDoi"> DOI: 10.2337/dc13-2759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.2337%2Fdc13-2759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=24842985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFertrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=2168-2176&author=G.+Umpierrezauthor=S.+Tof%C3%A9+Povedanoauthor=F.+P%C3%A9rez+Manghiauthor=L.+Shurzinskeauthor=V.+Pechtner&title=Efficacy+and+Safety+of+Dulaglutide+Monotherapy+Versus+Metformin+in+Type+2+Diabetes+in+a+Randomized+Controlled+Trial+%28AWARD-3%29&doi=10.2337%2Fdc13-2759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)</span></div><div class="casAuthors">Umpierrez, Guillermo; Povedano, Santiago Tofe; Manghi, Federico Perez; Shurzinske, Linda; Pechtner, Valeria</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2168-2176</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">The objective of the study was to compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes.  The primary objective compared dulaglutide 1.5 mg and metformin on change from baseline glycosylated Hb A1c (HbA1c) at 26 wk.  This 52-wk double-blind study randomized patients to s.c. dulaglutide 1.5 mg, dulaglutide 0.75 mg, or metformin.  Patients (N = 807) had HbA1c ≥6.5% (≥48 mmol/mol) and ≤9.5% (≤80 mmol/mol) with diet and exercise alone or low-dose oral antihyperglycemic medication (OAM) monotherapy; OAMs were discontinued at beginning of lead-in period.  At 26 wk, changes from baseline HbA1c (least squares [LS] mean ± SE) were: dulaglutide 1.5 mg, -0.78 ± 0.06% (-8.5 ± 0.70 mmol/mol); dulaglutide 0.75 mg, -0.71 ± 0.06% (-7.8 ± 0.70 mmol/mol); and metformin, -0.56 ± 0.06% (-6.1 ± 0.70 mmol/mol).  Dulaglutide 1.5 and 0.75 mg were superior to metformin (LS mean difference): -0.22% (-2.4 mmol/mol) and -0.15% (-1.6 mmol/mol) (one-sided P < 0.025, both comparisons), resp.  Greater percentages reached HbA1c targets <7.0% (<53 mmol/mol) and ≤6.5% (≤48 mmol/mol) with dulaglutide 1.5 and 0.75 mg compared with metformin (P < 0.05, all comparisons).  No severe hypoglycemia was reported.  Compared with metformin, decrease in wt. was similar with dulaglutide 1.5 mg and smaller with dulaglutide 0.75 mg.  Over 52 wk, nausea, diarrhea, and vomiting were the most common adverse events; incidences were similar between dulaglutide and metformin.  Dulaglutide improves glycemic control and is well tolerated as monotherapy in patients with early stage type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPn3-np1l5YLVg90H21EOLACvtfcHk0ljZEmWxebslig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFertrfN&md5=7addb4e532a46045d81054967ade6437</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2337%2Fdc13-2759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc13-2759%26sid%3Dliteratum%253Aachs%26aulast%3DUmpierrez%26aufirst%3DG.%26aulast%3DTof%25C3%25A9%2BPovedano%26aufirst%3DS.%26aulast%3DP%25C3%25A9rez%2BManghi%26aufirst%3DF.%26aulast%3DShurzinske%26aufirst%3DL.%26aulast%3DPechtner%26aufirst%3DV.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Dulaglutide%2520Monotherapy%2520Versus%2520Metformin%2520in%2520Type%25202%2520Diabetes%2520in%2520a%2520Randomized%2520Controlled%2520Trial%2520%2528AWARD-3%2529%26jtitle%3DDiabetes%2520Care%26date%3D2014%26volume%3D37%26spage%3D2168%26epage%3D2176%26doi%3D10.2337%2Fdc13-2759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perdomo, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sällberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahlne, A.</span></span> <span> </span><span class="NLM_article-title">Neutralization of HIV-1 by redirection of natural antibodies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">12515</span>– <span class="NLM_lpage">12520</span>, <span class="refDoi"> DOI: 10.1073/pnas.0805777105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1073%2Fpnas.0805777105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=18719129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKqtL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=12515-12520&author=M.+F.+Perdomoauthor=M.+Leviauthor=M.+S%C3%A4llbergauthor=A.+Vahlne&title=Neutralization+of+HIV-1+by+redirection+of+natural+antibodies&doi=10.1073%2Fpnas.0805777105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Neutralization of HIV-1 by redirection of natural antibodies</span></div><div class="casAuthors">Perdomo, Maria F.; Levi, Michael; Saellberg, Matti; Vahlne, Anders</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">12515-12520</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The great variability and high glycosylation of gp120 poses a great challenge for the design of a functional immune therapy.  The binding region of the CD4 receptor to gp120, however, is well conserved and may constitute a target to limit viral entry and infectivity.  Our strategy consists in using a preexisting pool of natural antibodies directed toward the gal(α1,3)gal disaccharide and to redirect it to HIV.  We here show that using CD4-derived, gp120-binding, synthetic peptides chem. linked to gal(α1,3)gal can redirect these natural antibodies and improve the HIV-1 neutralizing activity of the CD4-derived peptides in vitro.  Importantly, the binding of the CD4-gal(α1,3)gal peptides to HIV-1-infected cells conferred antibody-dependent cellular cytotoxicity after the addn. of human sera.  Thus, the temporary redirection of naturally occurring antibodies and their biol. activities to a new antigen represents a completely new way of targeting a human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7dCLnN9mcX7Vg90H21EOLACvtfcHk0liDk5akr-9Nlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKqtL7F&md5=5f7633d4dd71b82511704cb0c0feb66b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805777105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805777105%26sid%3Dliteratum%253Aachs%26aulast%3DPerdomo%26aufirst%3DM.%2BF.%26aulast%3DLevi%26aufirst%3DM.%26aulast%3DS%25C3%25A4llberg%26aufirst%3DM.%26aulast%3DVahlne%26aufirst%3DA.%26atitle%3DNeutralization%2520of%2520HIV-1%2520by%2520redirection%2520of%2520natural%2520antibodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D12515%26epage%3D12520%26doi%3D10.1073%2Fpnas.0805777105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, R. T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hank, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sondel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiessling, L. L.</span></span> <span> </span><span class="NLM_article-title">Rhamnose glycoconjugates for the recruitment of endogenous anti-carbohydrate antibodies to tumor cells</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1393</span>– <span class="NLM_lpage">1398</span>, <span class="refDoi"> DOI: 10.1002/cbic.201402019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fcbic.201402019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=24909955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptlOhtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1393-1398&author=R.+T.+C.+Sheridanauthor=J.+Hudonauthor=J.+A.+Hankauthor=P.+M.+Sondelauthor=L.+L.+Kiessling&title=Rhamnose+glycoconjugates+for+the+recruitment+of+endogenous+anti-carbohydrate+antibodies+to+tumor+cells&doi=10.1002%2Fcbic.201402019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Rhamnose Glycoconjugates for the Recruitment of Endogenous Anti-Carbohydrate Antibodies to Tumor Cells</span></div><div class="casAuthors">Sheridan, Rachael T. C.; Hudon, Jonathan; Hank, Jacquelyn A.; Sondel, Paul M.; Kiessling, Laura L.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1393-1398</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Immunotherapy is a promising strategy for targeting tumors.  One emerging approach is to harness the immune effector functions of natural antibodies to destroy tumor cells.  Dinitrophenyl (DNP) and the galactose-α-1,3-galactose (αGal) epitope are two haptens that bind endogenous antibodies.  One potential alternative is the deoxysugar L-rhamnose.  We compared these candidates by using a biosensor assay to evaluate human sera for endogenous antibody concn., antibody isotype distribution, and longevity of antibody-hapten interactions.  Antibodies recognizing α-rhamnose are of equal or greater abundance and affinity as those recognizing αGal.  Moreover, both rhamnose and αGal epitopes are more effective than DNP at recruiting the IgG antibody subtype.  Exposure of tumor cells to rhamnose-bearing glycolipids and human serum promotes complement-mediated cytotoxicity.  These data highlight the utility of α-rhamnose-contg. glycoconjugates to direct the immune system to target cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfhJfAmJ583LVg90H21EOLACvtfcHk0liDk5akr-9Nlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptlOhtr8%253D&md5=a4107919152fad35bac947a40ec11573</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201402019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201402019%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DR.%2BT.%2BC.%26aulast%3DHudon%26aufirst%3DJ.%26aulast%3DHank%26aufirst%3DJ.%2BA.%26aulast%3DSondel%26aufirst%3DP.%2BM.%26aulast%3DKiessling%26aufirst%3DL.%2BL.%26atitle%3DRhamnose%2520glycoconjugates%2520for%2520the%2520recruitment%2520of%2520endogenous%2520anti-carbohydrate%2520antibodies%2520to%2520tumor%2520cells%26jtitle%3DChembiochem%26date%3D2014%26volume%3D15%26spage%3D1393%26epage%3D1398%26doi%3D10.1002%2Fcbic.201402019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rullo, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthusamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, D. A.</span></span> <span> </span><span class="NLM_article-title">Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3642</span>– <span class="NLM_lpage">3646</span>, <span class="refDoi"> DOI: 10.1002/anie.201510866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fanie.201510866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC28XisV2hu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=3642-3646&author=A.+F.+Rulloauthor=K.+J.+Fitzgeraldauthor=V.+Muthusamyauthor=M.+Liuauthor=C.+Yuanauthor=M.+Huangauthor=M.+Kimauthor=A.+E.+Choauthor=D.+A.+Spiegel&title=Re-engineering+the+Immune+Response+to+Metastatic+Cancer%3A+Antibody-Recruiting+Small+Molecules+Targeting+the+Urokinase+Receptor&doi=10.1002%2Fanie.201510866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor</span></div><div class="casAuthors">Rullo, Anthony F.; Fitzgerald, Kelly J.; Muthusamy, Viswanathan; Liu, Min; Yuan, Cai; Huang, Mingdong; Kim, Minsup; Cho, Art E.; Spiegel, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3642-3646</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Developing selective strategies to treat metastatic cancers remains a significant challenge.  Herein, the authors report the first antibody-recruiting small mol. (ARM) that is capable of recognizing the urokinase-type plasminogen activator receptor (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediated destruction of cancer cells.  A co-crystal structure of the ARM-U2/uPAR complex was obtained, representing the first crystal structure of uPAR complexed with a non-peptide ligand.  Finally, the authors demonstrated that ARM-U2 substantially suppresses tumor growth in vivo with no evidence of wt. loss, unlike the std.-of-care agent doxorubicin.  This work underscores the promise of antibody-recruiting mols. as immunotherapeutics for treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9N4WFnZZaibVg90H21EOLACvtfcHk0liDk5akr-9Nlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisV2hu7k%253D&md5=448db82700404ed8f3cff8b0aea75b81</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510866%26sid%3Dliteratum%253Aachs%26aulast%3DRullo%26aufirst%3DA.%2BF.%26aulast%3DFitzgerald%26aufirst%3DK.%2BJ.%26aulast%3DMuthusamy%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DA.%2BE.%26aulast%3DSpiegel%26aufirst%3DD.%2BA.%26atitle%3DRe-engineering%2520the%2520Immune%2520Response%2520to%2520Metastatic%2520Cancer%253A%2520Antibody-Recruiting%2520Small%2520Molecules%2520Targeting%2520the%2520Urokinase%2520Receptor%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D3642%26epage%3D3646%26doi%3D10.1002%2Fanie.201510866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEnaney, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegel, D. A.</span></span> <span> </span><span class="NLM_article-title">Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1021/cb300119g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb300119g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpsl2isr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1139-1151&author=P.+J.+McEnaneyauthor=C.+G.+Parkerauthor=A.+X.+Zhangauthor=D.+A.+Spiegel&title=Antibody-recruiting+molecules%3A+an+emerging+paradigm+for+engaging+immune+function+in+treating+human+disease&doi=10.1021%2Fcb300119g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Recruiting Molecules: An Emerging Paradigm for Engaging Immune Function in Treating Human Disease</span></div><div class="casAuthors">McEnaney, Patrick J.; Parker, Christopher G.; Zhang, Andrew X.; Spiegel, David A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-1151</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Synthetic immunol., the development of synthetic systems capable of modulating and/or manipulating immunol. functions, represents an emerging field of research with manifold possibilities.  One focus of this area has been to create low mol. wt. synthetic species, called antibody-recruiting mols. (ARMs), which are capable of enhancing antibody binding to disease-relevant cells or viruses, thus leading to their immune-mediated clearance.  This article provides a thorough discussion of contributions in this area, beginning with the history of small-mol.-based technologies for modulating antibody recognition, followed by a systematic review of the various applications of ARM-based strategies.  Thus, we describe ARMs capable of targeting cancer, bacteria, and viral pathogens, along with some of the scientific discoveries that have resulted from their development.  Research in this area underscores the many exciting possibilities at the interface of org. chem. and immunobiol. and is positioned to advance both basic and clin. science in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDb9zR6YedEbVg90H21EOLACvtfcHk0liTl2cE8ibQ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpsl2isr0%253D&md5=17dcc667dae735c02b1f35a4cd6139c9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb300119g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300119g%26sid%3Dliteratum%253Aachs%26aulast%3DMcEnaney%26aufirst%3DP.%2BJ.%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DZhang%26aufirst%3DA.%2BX.%26aulast%3DSpiegel%26aufirst%3DD.%2BA.%26atitle%3DAntibody-recruiting%2520molecules%253A%2520an%2520emerging%2520paradigm%2520for%2520engaging%2520immune%2520function%2520in%2520treating%2520human%2520disease%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1139%26epage%3D1151%26doi%3D10.1021%2Fcb300119g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feigman, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pires, M. M.</span></span> <span> </span><span class="NLM_article-title">Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">664</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.7b00261</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.7b00261" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFalt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=664-672&author=M.+J.+S.+Feigmanauthor=M.+M.+Pires&title=Synthetic+Immunobiotics%3A+A+Future+Success+Story+in+Small+Molecule-Based+Immunotherapy%3F&doi=10.1021%2Facsinfecdis.7b00261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?</span></div><div class="casAuthors">Feigman, Mary J. Sabulski; Pires, Marcos M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">664-672</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug resistance to our current stock of antibiotics is projected to increase to levels that threaten our ability to reduce and eliminate bacterial infections, which is now considered one of the primary health care crises of the 21st century.  Traditional antibiotic agents (e.g., penicillin) paved the way for massive advances in human health, but we need novel strategies to maintain the upper hand in the battle against pathogenic bacteria.  Nontraditional strategies, such as targeted immunotherapies, could prove fruitful in complementing our antibiotic arsenal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFM6Jj0ZTk77Vg90H21EOLACvtfcHk0liTl2cE8ibQ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFalt78%253D&md5=ce0f95dab09fcfeb97ecf6c23e4491ab</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.7b00261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.7b00261%26sid%3Dliteratum%253Aachs%26aulast%3DFeigman%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DPires%26aufirst%3DM.%2BM.%26atitle%3DSynthetic%2520Immunobiotics%253A%2520A%2520Future%2520Success%2520Story%2520in%2520Small%2520Molecule-Based%2520Immunotherapy%253F%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2018%26volume%3D4%26spage%3D664%26epage%3D672%26doi%3D10.1021%2Facsinfecdis.7b00261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uvyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Geest, B. G.</span></span> <span> </span><span class="NLM_article-title">Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3036</span>– <span class="NLM_lpage">3043</span>, <span class="refDoi"> DOI: 10.1002/cbic.202000261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fcbic.202000261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=32497371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlGjsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=3036-3043&author=A.+Uvynauthor=B.+G.+De+Geest&title=Multivalent+Antibody-Recruiting+Macromolecules%3A+Linking+Increased+Binding+Affinity+with+Enhanced+Innate+Immune+Killing&doi=10.1002%2Fcbic.202000261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing</span></div><div class="casAuthors">Uvyn, Annemiek; De Geest, Bruno G.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3036-3043</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Antibody-recruiting mols. (ARMs) are a novel class of immunotherapeutics.  They are capable of introducing antibodies onto disease-relevant targets such as cancer cells, bacterial cells or viruses.  This can induce antibody-mediated immune responses such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent phagocytosis (ADCP), which can kill the pathogen.  In contrast to the classic ARMs, multivalent ARMs could offer the advantage of increasing the efficiency of antibody recruitment and subsequent innate immune killing.  Such compds. consist of multiple target-binding termini (TBT) and/or antibody-binding termini (ABT).  Those multivalent interactions are able to convert low binding affinities into increased binding avidities.  This minireview summarizes the current status of multivalent ARMs and gives insight into possible benefits, hurdles still to be overcome and future perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKeC3-HYj2UrVg90H21EOLACvtfcHk0liTl2cE8ibQ9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlGjsrrL&md5=04afa78e2d7d33e05446f6ffa56ae08b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fcbic.202000261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.202000261%26sid%3Dliteratum%253Aachs%26aulast%3DUvyn%26aufirst%3DA.%26aulast%3DDe%2BGeest%26aufirst%3DB.%2BG.%26atitle%3DMultivalent%2520Antibody-Recruiting%2520Macromolecules%253A%2520Linking%2520Increased%2520Binding%2520Affinity%2520with%2520Enhanced%2520Innate%2520Immune%2520Killing%26jtitle%3DChembiochem%26date%3D2020%26volume%3D21%26spage%3D3036%26epage%3D3043%26doi%3D10.1002%2Fcbic.202000261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">9331</span>– <span class="NLM_lpage">9338</span>, <span class="refDoi"> DOI: 10.1039/c9sc03840j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1039%2FC9SC03840J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=32110296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GisLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=9331-9338&author=H.+Hongauthor=Z.+Zhouauthor=K.+Zhouauthor=S.+Liuauthor=Z.+Guoauthor=Z.+Wu&title=Site-specific+C-terminal+dinitrophenylation+to+reconstitute+the+antibody+Fc+functions+for+nanobodies&doi=10.1039%2Fc9sc03840j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies</span></div><div class="casAuthors">Hong, Haofei; Zhou, Zhifang; Zhou, Kun; Liu, Shaozhong; Guo, Zhongwu; Wu, Zhimeng</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">9331-9338</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Nanobodies are a class of camelid-derived single-domain antibodies that have many potential advantages over conventional antibodies and have been utilized to develop new therapeutic strategies for cancer and other diseases.  However, nanobodies lack the Fc region of a conventional antibody, which possesses many functions, e.g., eliciting antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), essential for effective immunotherapy.  The small mol. size of nanobodies also leads to poor pharmacokinetics, such as short in vivo half-life.  To address these deficiencies, an endogenous antibody-based strategy to reconstitute the Fc functions for nanobodies was developed.  As a proof-of-principle, an anti-human EGFR nanobody, 7D12, was selected to conduct C-terminal modification with the dinitrophenyl (DNP) hapten through Sortase A-mediated site-specific ligation.  It was expected that the DNP motif would recruit endogenous human anti-DNP antibodies to indirectly reinstate the Fc functions.  The resultant nanobody-DNP conjugates were shown to exhibit specific and high affinity binding to human EGFR expressed on target cancer cells.  It was further proved that in the presence of anti-DNP antibody, these conjugates could mediate potent ADCC and CDC in vitro and exhibit significantly elongated half-life in vivo.  Ultimately, it was proven in severe combined immunodeficiency (SCID) mice that treatment with the nanobody 7D12-DNP conjugate and anti-DNP mouse serum could inhibit xenograft tumor growth efficiently.  In view of the abundance of anti-DNP and other endogenous antibodies in the human blood system, this could be a generally applicable approach employed to reconstitute the Fc functions for nanobodies and develop nanobody-based cancer immunotherapy and other therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0EAw15epMgbVg90H21EOLACvtfcHk0lhMU4WzjOF5Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GisLnL&md5=0be311dbfea15059b4f0574127ca2810</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1039%2FC9SC03840J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC03840J%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSite-specific%2520C-terminal%2520dinitrophenylation%2520to%2520reconstitute%2520the%2520antibody%2520Fc%2520functions%2520for%2520nanobodies%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D9331%26epage%3D9338%26doi%3D10.1039%2Fc9sc03840j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1686</span>– <span class="NLM_lpage">1694</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00350</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00350" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVWlt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1686-1694&author=S.+Liauthor=B.+Yuauthor=J.+Wangauthor=Y.+Zhengauthor=H.+Zhangauthor=M.+J.+Walkerauthor=Z.+Yuanauthor=H.+Zhuauthor=J.+Zhangauthor=P.+G.+Wangauthor=B.+Wang&title=Biomarker-Based+Metabolic+Labeling+for+Redirected+and+Enhanced+Immune+Response&doi=10.1021%2Facschembio.8b00350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response</span></div><div class="casAuthors">Li, Shanshan; Yu, Bingchen; Wang, Jiajia; Zheng, Yueqin; Zhang, Huajie; Walker, Margaret J.; Yuan, Zhengnan; Zhu, He; Zhang, Jun; Wang, Peng George; Wang, Binghe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1686-1694</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Installation of an antibody-recruiting moiety on the surface of disease-relevant cells can lead to the selective destruction of targets by the immune system.  Such an approach can be an alternative strategy to traditional chemotherapeutics in cancer therapy and possibly other diseases.  Herein we describe the development of a new strategy to selectively label targets with an antibody-recruiting moiety through its covalent and stable installation, complementing existing methods of employing reversible binding.  This is achieved through selective delivery of 1,3,4-O-acetyl-N-azidoacetylmannosamine (Ac3ManNAz) to folate receptor-overexpressing cells using an Ac3ManNAz-folate conjugate via a cleavable linker.  As such, Ac3ManNAz is converted to cell surface glycan bearing an azido group, which serves as an anchor to introduce L-rhamnose (Rha), a hapten, via a click reaction with aza-dibenzocyclooctyne (DBCO)-Rha.  We tested this method in several cell lines including KB, HEK-293, and MCF7 and were able to demonstrate the following: (1) Rha can be selectively installed to the folate receptor overexpressing cell surface and (2) the Rha installed on the target surface can recruit anti-rhamnose (anti-Rha) antibodies, leading to the destruction of target cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMhIC7Ddio4rVg90H21EOLACvtfcHk0lhMU4WzjOF5Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVWlt7rM&md5=df3989eba48e1390d954543cc1266130</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00350%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DM.%2BJ.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%2BG.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DBiomarker-Based%2520Metabolic%2520Labeling%2520for%2520Redirected%2520and%2520Enhanced%2520Immune%2520Response%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D1686%26epage%3D1694%26doi%3D10.1021%2Facschembio.8b00350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrillo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsubo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hakamata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashiruddin, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbas, C. F.,  3rd</span></span> <span> </span><span class="NLM_article-title">In vivo programming of endogenous antibodies via oral administration of adaptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5952</span>– <span class="NLM_lpage">5961</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.bmc.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=28988625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1SqtrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=5952-5961&author=M.+Naganoauthor=N.+Carrilloauthor=N.+Otsuboauthor=W.+Hakamataauthor=H.+Banauthor=R.+P.+Fullerauthor=N.+K.+Bashiruddinauthor=C.+F.+Barbas&title=In+vivo+programming+of+endogenous+antibodies+via+oral+administration+of+adaptor+ligands&doi=10.1016%2Fj.bmc.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo programming of endogenous antibodies via oral administration of adaptor ligands</span></div><div class="casAuthors">Nagano, Masanobu; Carrillo, Nancy; Otsubo, Nobumasa; Hakamata, Wataru; Ban, Hitoshi; Fuller, Roberta P.; Bashiruddin, Nasir K.; Barbas, Carlos F., III</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5952-5961</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Vaccination is a reliable method of prophylaxis and a crucial measure for public health.  However, the majority of vaccines cannot be administered orally due to their degrdn. in the harsh gut environment or inability to cross the GI tract.  In this study, we report the first proof-of-concept study of orally producible chem. programmed antibodies via specific conjugation of adaptor ligands to endogenous antibodies, in vivo.  Pre-immunization with 2,4-dinitrophenyl (DNP), or the reactive hapten, 1,3-diketone (DK), or a novel reactive hapten, vinyl sulfone (VS) in mice, followed by oral administration of adaptor ligands composed of the hapten and biotin to the pre-immunized mice resulted in successful in vivo formation of the biotin-hapten-antibody complexes within 2 h.  Pharmacokinetic evaluations revealed that apparent serum concns. of programmed antibodies were up to 144 nM and that the serum half-lives reached up to 34.4 h.  These findings show promise for the future development of orally bioavailable drug-hapten-antibody complexes as a strategy to quickly and easily modulate immune targets for aggressive pathogens as well as cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkD-jzH7jQJ7Vg90H21EOLACvtfcHk0lhMU4WzjOF5Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1SqtrbF&md5=b216ca9d24b6a6915da82058dfb296e7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DNagano%26aufirst%3DM.%26aulast%3DCarrillo%26aufirst%3DN.%26aulast%3DOtsubo%26aufirst%3DN.%26aulast%3DHakamata%26aufirst%3DW.%26aulast%3DBan%26aufirst%3DH.%26aulast%3DFuller%26aufirst%3DR.%2BP.%26aulast%3DBashiruddin%26aufirst%3DN.%2BK.%26aulast%3DBarbas%26aufirst%3DC.%2BF.%26atitle%3DIn%2520vivo%2520programming%2520of%2520endogenous%2520antibodies%2520via%2520oral%2520administration%2520of%2520adaptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D5952%26epage%3D5961%26doi%3D10.1016%2Fj.bmc.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keum, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jon, S.</span></span> <span> </span><span class="NLM_article-title">A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2010</span>, <span class="refDoi"> DOI: 10.1002/anie.201811509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fanie.201811509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFShurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=2005-2010&author=B.+Yuauthor=D.+Hwangauthor=H.+Jeonauthor=H.+Kimauthor=Y.+Leeauthor=H.+Keumauthor=J.+Kimauthor=D.+Y.+Leeauthor=Y.+Kimauthor=J.+Chungauthor=S.+Jon&title=A+Hybrid+Platform+Based+on+a+Bispecific+Peptide-Antibody+Complex+for+Targeted+Cancer+Therapy&doi=10.1002%2Fanie.201811509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Hybrid Platform Based on a Bispecific Peptide-Antibody Complex for Targeted Cancer Therapy</span></div><div class="casAuthors">Yu, Byeongjun; Hwang, Dobeen; Jeon, Hyungsu; Kim, Hyungjun; Lee, Yonghyun; Keum, Hyeongseop; Kim, Jinjoo; Lee, Dong Yun; Kim, Yujin; Chung, Junho; Jon, Sangyong</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2010</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Peptide-based therapeutics have suffered from a short plasma half-life.  On the other hand, antibodies suffer from poor penetration into solid tumors owing to their large size.  Herein, we present a new mol. form, namely a hybrid complex between a hapten-labeled bispecific peptide and an anti-hapten antibody ("HyPEP-body"), that may be able to overcome the aforementioned limitation.  The bispecific peptide contg. a cotinine tag was synthesized by linking a peptide specific to fibronectin extra domain B (EDB) and a peptide able to bind and inhibit vascular endothelial growth factor (VEGF), yielding cot-biPEPEDB-VEGF.  Simple mixing of cot-biPEPEDB-VEGF and anti-cotinine antibody (Abcot) yielded the hybrid complex, HyPEPEDB-VEGF.  HyPEPEDB-VEGF retained the characteristics of the included peptides, and showed improved pharmacokinetic behavior.  Moreover, HyPEPEDB-VEGF showed tumor growth inhibition with excellent tumor accumulation and penetration.  These findings suggest that the hybrid platform described here offers a soln. for most peptide therapeutics that suffer from a short circulation half-life in blood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7E2TogCy_E7Vg90H21EOLACvtfcHk0lgT4JdWqAQ1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFShurw%253D&md5=4723c7b7385a8044dbed20bf34534db0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201811509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201811509%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DHwang%26aufirst%3DD.%26aulast%3DJeon%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DKeum%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DJon%26aufirst%3DS.%26atitle%3DA%2520Hybrid%2520Platform%2520Based%2520on%2520a%2520Bispecific%2520Peptide-Antibody%2520Complex%2520for%2520Targeted%2520Cancer%2520Therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D2005%26epage%3D2010%26doi%3D10.1002%2Fanie.201811509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, V. P.</span></span> <span> </span><span class="NLM_article-title">Persistence of hapten antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1084/jem.139.2.278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1084%2Fjem.139.2.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=4129823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADyaE2cXksVyns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=1974&pages=278-294&author=D.+H.+Schmidtauthor=B.+M.+Kaufmanauthor=V.+P.+Butler&title=Persistence+of+hapten+antibody+complexes+in+the+circulation+of+immunized+animals+after+a+single+intravenous+injection+of+hapten&doi=10.1084%2Fjem.139.2.278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten</span></div><div class="casAuthors">Schmidt, Donald H.; Kaufman, Bette M.; Butler, Vincent P., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-94</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    </div><div class="casAbstract">When injected into immunized animals, a specific hapten, namely digoxin, formed complexes with its corresponding antibodies, and these complexes persisted in the circulation for longer than 1 year after a single i.v. injection of that hapten.  Thus, the biol. half-life of a hapten may be markedly prolonged when the hapten is bound to specific antibody.  The persistence of antibody-hapten complexes in the circulation suggests that these complexes may not be deposited in tissues and raises the possibility that low mol. wt. determinants may be capable of preventing or reversing the deposition of immune complexes contg. macromol. antigens in the tissues of exptl. animals and man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJoHq3SVmE7Vg90H21EOLACvtfcHk0lgT4JdWqAQ1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXksVyns78%253D&md5=4148c7a56c15ee8ddfb9f24e5dfdb345</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1084%2Fjem.139.2.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.139.2.278%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DD.%2BH.%26aulast%3DKaufman%26aufirst%3DB.%2BM.%26aulast%3DButler%26aufirst%3DV.%2BP.%26atitle%3DPersistence%2520of%2520hapten%2520antibody%2520complexes%2520in%2520the%2520circulation%2520of%2520immunized%2520animals%2520after%2520a%2520single%2520intravenous%2520injection%2520of%2520hapten%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D1974%26volume%3D139%26spage%3D278%26epage%3D294%26doi%3D10.1084%2Fjem.139.2.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostovetzky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larralde, C.</span></span> <span> </span><span class="NLM_article-title">Natural DNP-binding immunoglobulins and antibody multispecificity</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1016/0161-5890(84)90143-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2F0161-5890%2884%2990143-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=6504050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADyaL2MXksVSmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1984&pages=883-888&author=E.+Ortegaauthor=M.+Kostovetzkyauthor=C.+Larralde&title=Natural+DNP-binding+immunoglobulins+and+antibody+multispecificity&doi=10.1016%2F0161-5890%2884%2990143-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Natural DNP-binding immunoglobulins and antibody multispecificity</span></div><div class="casAuthors">Ortega, Enrique; Kostovetzky, Myriam; Larralde, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">883-8</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    </div><div class="casAbstract">Anti-dinitrophenyl activity was found in normal human Igs with av. affinities (104-106 L/mol) and frequencies (2-15%) that correlate well with those expected from multispecific binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNE8BZo_MM1LVg90H21EOLACvtfcHk0lgT4JdWqAQ1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXksVSmtQ%253D%253D&md5=3b43fbdf0c9d83ca297948e825381788</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0161-5890%2884%2990143-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0161-5890%252884%252990143-3%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DE.%26aulast%3DKostovetzky%26aufirst%3DM.%26aulast%3DLarralde%26aufirst%3DC.%26atitle%3DNatural%2520DNP-binding%2520immunoglobulins%2520and%2520antibody%2520multispecificity%26jtitle%3DMol.%2520Immunol.%26date%3D1984%26volume%3D21%26spage%3D883%26epage%3D888%26doi%3D10.1016%2F0161-5890%2884%2990143-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farah, F. S.</span></span> <span> </span><span class="NLM_article-title">Natural antibodies specific to the 2, 4 dinitrophenyl group</span>. <i>Immunology</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">226</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=4733801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADyaE3sXkvFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1973&pages=217-226&author=F.+S.+Farah&title=Natural+antibodies+specific+to+the+2%2C+4+dinitrophenyl+group"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Natural antibodies specific to the 2,4-dinitrophenyl group</span></div><div class="casAuthors">Farah, F. S.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">217-26</span>CODEN:
                <span class="NLM_cas:coden">IMMUAM</span>;
        ISSN:<span class="NLM_cas:issn">0019-2805</span>.
    </div><div class="casAbstract">An immunoadsorbent, 2,4-dinitrophenyl (DNP)-aminoethyl cellulose, specifically retained a protein fraction from pooled or individual normal human γ-globulins.  The fraction behaved like DNP-antigen-induced antibody in tests of specific activity including fluorescence quenching, spectral shift anal., and equil. dialysis.  The "natural" antibodies to DNP were present in max. concn. of 0.8% of the IgG fraction, and usually less.  A similar fraction was found in normal rabbit serum but not in purified rabbit antibodies of another specificity.  The anti-DNP activity was found in the Fab fragment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryC09QMBDbS7Vg90H21EOLACvtfcHk0lgtMIOASP97Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXkvFSgu70%253D&md5=30b51e3f284448fa0f6b5cbd66a3b313</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFarah%26aufirst%3DF.%2BS.%26atitle%3DNatural%2520antibodies%2520specific%2520to%2520the%25202%252C%25204%2520dinitrophenyl%2520group%26jtitle%3DImmunology%26date%3D1973%26volume%3D25%26spage%3D217%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Sortase-Mediated Transpeptidation for Site-Specific Modification of Peptides, Glycopeptides, and Proteins</span>. <i>J. Carbohydr. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1080/07328303.2011.635251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1080%2F07328303.2011.635251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22468018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=48-66&author=Z.+Wuauthor=Z.+Guo&title=Sortase-Mediated+Transpeptidation+for+Site-Specific+Modification+of+Peptides%2C+Glycopeptides%2C+and+Proteins&doi=10.1080%2F07328303.2011.635251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase-Mediated Transpeptidation for Site-Specific Modification of Peptides, Glycopeptides, and Proteins</span></div><div class="casAuthors">Wu, Zhimeng; Guo, Zhongwu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Carbohydrate Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-66</span>CODEN:
                <span class="NLM_cas:coden">JCACDM</span>;
        ISSN:<span class="NLM_cas:issn">0732-8303</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  Sortases are a family of transpeptidases found in gram-pos. bacteria responsible for covalent anchoring of cell surface proteins to bacterial cell walls.  It has been discovered that sortase A (SrtA) of Staphylococcus aureus origin is rather promiscuous and can accept various mols. as substrates.  As a result, SrtA has been widely used to ligate peptides and proteins with a variety of nucleophiles, and the ligation products are useful for research in chem. biol., proteomics, biomedicine, etc.  This review summarizes the recent applications of SrtA with special emphasis on SrtA-catalyzed ligation of carbohydrates with peptides and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBd9DBA3SnprVg90H21EOLACvtfcHk0lgtMIOASP97Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWktrY%253D&md5=9d914e9a6f148e53954c75fb56a53630</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1080%2F07328303.2011.635251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07328303.2011.635251%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DSortase-Mediated%2520Transpeptidation%2520for%2520Site-Specific%2520Modification%2520of%2520Peptides%252C%2520Glycopeptides%252C%2520and%2520Proteins%26jtitle%3DJ.%2520Carbohydr.%2520Chem.%26date%3D2012%26volume%3D31%26spage%3D48%26epage%3D66%26doi%3D10.1080%2F07328303.2011.635251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsukiji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamune, T.</span></span> <span> </span><span class="NLM_article-title">Sortase-mediated ligation: a gift from Gram-positive bacteria to protein engineering</span>. <i>Chembiochem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1002/cbic.200800724</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fcbic.200800724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=19199328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktVajt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=787-798&author=S.+Tsukijiauthor=T.+Nagamune&title=Sortase-mediated+ligation%3A+a+gift+from+Gram-positive+bacteria+to+protein+engineering&doi=10.1002%2Fcbic.200800724"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase-mediated ligation: a gift from gram-positive bacteria to protein engineering</span></div><div class="casAuthors">Tsukiji, Shinya; Nagamune, Teruyuki</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">787-798</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review on sortase-mediated ligation and current state of its applications.  Topics discussed include: recombinant sol. sortase; transpeptidation mechanism; substrate specificity; introduction of new functionalities into proteins; covalent immobilization of proteins onto solid supports; protein-protein bioconjugation; protein circularization; and self-cleavable tag for one-step purifn. of recombinant proteins.  It also tackles the prepn. of oligopeptide-nucleic acid hybrids; chemoenzymic synthesis of neoglycoconjugates; and cell-surface protein labeling/engineering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhN3wUx_gQ97Vg90H21EOLACvtfcHk0lg4G-rIWcOhvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktVajt7o%253D&md5=121bdaba8de4db865d821683b7d968ff</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200800724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200800724%26sid%3Dliteratum%253Aachs%26aulast%3DTsukiji%26aufirst%3DS.%26aulast%3DNagamune%26aufirst%3DT.%26atitle%3DSortase-mediated%2520ligation%253A%2520a%2520gift%2520from%2520Gram-positive%2520bacteria%2520to%2520protein%2520engineering%26jtitle%3DChembiochem%26date%3D2009%26volume%3D10%26spage%3D787%26epage%3D798%26doi%3D10.1002%2Fcbic.200800724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Göke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehmann, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göke, B.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>268</i></span>,  <span class="NLM_fpage">19650</span>– <span class="NLM_lpage">19655</span>, <span class="refDoi"> DOI: 10.1016/s0021-9258(19)36565-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2FS0021-9258%2819%2936565-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=8396143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A280%3ADyaK3sznsV2lsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=19650-19655&author=R.+G%C3%B6keauthor=H.+C.+Fehmannauthor=T.+Linnauthor=H.+Schmidtauthor=M.+Krauseauthor=J.+Engauthor=B.+G%C3%B6ke&title=Exendin-4+is+a+high+potency+agonist+and+truncated+exendin-%289-39%29-amide+an+antagonist+at+the+glucagon-like+peptide+1-%287-36%29-amide+receptor+of+insulin-secreting+beta-cells&doi=10.1016%2Fs0021-9258%2819%2936565-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells</span></div><div class="casAuthors">Goke R; Fehmann H C; Linn T; Schmidt H; Krause M; Eng J; Goke B</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of biological chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">19650-5</span>
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Exendin-4 purified from Heloderma suspectum venom shows structural relationship to the important incretin hormone glucagon-like peptide 1-(7-36)-amide (GLP-1).  We demonstrate that exendin-4 and truncated exendin-(9-39)-amide specifically interact with the GLP-1 receptor on insulinoma-derived cells and on lung membranes.  Exendin-4 displaced 125I-GLP-1, and unlabeled GLP-1 displaced 125I-exendin-4 from the binding site at rat insulinoma-derived RINm5F cells.  Exendin-4 had, like GLP-1, a pronounced effect on intracellular cAMP generation, which was reduced by exendin-(9-39)-amide.  When combined, GLP-1 and exendin-4 showed additive action on cAMP.  They each competed with the radio-labeled version of the other peptide in cross-linking experiments.  The apparent molecular mass of the respective ligand-binding protein complex was 63,000 Da.  Exendin-(9-39)-amide abolished the cross-linking of both peptides.  Exendin-4, like GLP-1, stimulated dose dependently the glucose-induced insulin secretion in isolated rat islets, and, in mouse insulinoma beta TC-1 cells, both peptides stimulated the proinsulin gene expression at the level of transcription.  Exendin-(9-39)-amide reduced these effects.  In conclusion, exendin-4 is an agonist and exendin-(9-39)-amide is a specific GLP-1 receptor antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEDSP0hDZIaM-crCu0nI_sfW6udTcc2eaEych6XxSos7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3sznsV2lsw%253D%253D&md5=653efa77c17fd5c860ed9a03f2040f94</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2936565-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252936565-2%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B6ke%26aufirst%3DR.%26aulast%3DFehmann%26aufirst%3DH.%2BC.%26aulast%3DLinn%26aufirst%3DT.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKrause%26aufirst%3DM.%26aulast%3DEng%26aufirst%3DJ.%26aulast%3DG%25C3%25B6ke%26aufirst%3DB.%26atitle%3DExendin-4%2520is%2520a%2520high%2520potency%2520agonist%2520and%2520truncated%2520exendin-%25289-39%2529-amide%2520an%2520antagonist%2520at%2520the%2520glucagon-like%2520peptide%25201-%25287-36%2529-amide%2520receptor%2520of%2520insulin-secreting%2520beta-cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D19650%26epage%3D19655%26doi%3D10.1016%2Fs0021-9258%2819%2936565-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heath, C.</span>; <span class="NLM_string-name">Pettit, D.</span></span> <i>“Fc Fusion Proteins”</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">558</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1007%2F978-3-319-90603-4_24" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=545-558&author=C.+Heath&author=D.+Pettit&title=%E2%80%9CFc+Fusion+Proteins%E2%80%9D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-90603-4_24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-319-90603-4_24%26sid%3Dliteratum%253Aachs%26aulast%3DHeath%26aufirst%3DC.%26btitle%3D%25E2%2580%259CFc%2520Fusion%2520Proteins%25E2%2580%259D%26pub%3DSpringer%26date%3D2018%26spage%3D545%26epage%3D558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielsky, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Haan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govindappa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, C. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holgate, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimber, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moggs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naisbitt, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der
Laan, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span> <span> </span><span class="NLM_article-title">Challenges and approaches for the development of safer immunomodulatory biologics</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1038/nrd3974</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fnrd3974" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=23535934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Gms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=306-324&author=J.+G.+Sathishauthor=S.+Sethuauthor=M.-C.+Bielskyauthor=L.+de+Haanauthor=N.+S.+Frenchauthor=K.+Govindappaauthor=J.+Greenauthor=C.+E.+M.+Griffithsauthor=S.+Holgateauthor=D.+Jonesauthor=I.+Kimberauthor=J.+Moggsauthor=D.+J.+Naisbittauthor=M.+Pirmohamedauthor=G.+Reichmannauthor=J.+Simsauthor=M.+Subramanyamauthor=M.+D.+Toddauthor=J.+W.+Van+Der%0ALaanauthor=R.+J.+Weaverauthor=B.+K.+Park&title=Challenges+and+approaches+for+the+development+of+safer+immunomodulatory+biologics&doi=10.1038%2Fnrd3974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and approaches for the development of safer immunomodulatory biologics</span></div><div class="casAuthors">Sathish, Jean G.; Sethu, Swaminathan; Bielsky, Marie-Christine; de Haan, Lolke; French, Neil S.; Govindappa, Karthik; Green, James; Griffiths, Christopher E. M.; Holgate, Stephen; Jones, David; Kimber, Ian; Moggs, Jonathan; Naisbitt, Dean J.; Pirmohamed, Munir; Reichmann, Gabriele; Sims, Jennifer; Subramanyam, Meena; Todd, Marque D.; Van Der Laan, Jan Willem; Weaver, Richard J.; Park, B. Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">306-324</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immunomodulatory biologics, which render their therapeutic effects by modulating or harnessing immune responses, have proven their therapeutic utility in several complex conditions including cancer and autoimmune diseases.  However, unwanted adverse reactions - including serious infections, malignancy, cytokine release syndrome, anaphylaxis and hypersensitivity as well as immunogenicity - pose a challenge to the development of new (and safer) immunomodulatory biologics.  In this article, we assess the safety issues assocd. with immunomodulatory biologics and discuss the current approaches for predicting and mitigating adverse reactions assocd. with their use.  We also outline how these approaches can inform the development of safer immunomodulatory biologics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz-XvsNkuJ2bVg90H21EOLACvtfcHk0lhzoZwJXSnmdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Gms7o%253D&md5=7e7fbf6e02b97ca5b7316c0681211557</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd3974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3974%26sid%3Dliteratum%253Aachs%26aulast%3DSathish%26aufirst%3DJ.%2BG.%26aulast%3DSethu%26aufirst%3DS.%26aulast%3DBielsky%26aufirst%3DM.-C.%26aulast%3Dde%2BHaan%26aufirst%3DL.%26aulast%3DFrench%26aufirst%3DN.%2BS.%26aulast%3DGovindappa%26aufirst%3DK.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DGriffiths%26aufirst%3DC.%2BE.%2BM.%26aulast%3DHolgate%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DKimber%26aufirst%3DI.%26aulast%3DMoggs%26aufirst%3DJ.%26aulast%3DNaisbitt%26aufirst%3DD.%2BJ.%26aulast%3DPirmohamed%26aufirst%3DM.%26aulast%3DReichmann%26aufirst%3DG.%26aulast%3DSims%26aufirst%3DJ.%26aulast%3DSubramanyam%26aufirst%3DM.%26aulast%3DTodd%26aufirst%3DM.%2BD.%26aulast%3DVan%2BDer%2BLaan%26aufirst%3DJ.%2BW.%26aulast%3DWeaver%26aufirst%3DR.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BK.%26atitle%3DChallenges%2520and%2520approaches%2520for%2520the%2520development%2520of%2520safer%2520immunomodulatory%2520biologics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D306%26epage%3D324%26doi%3D10.1038%2Fnrd3974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaro, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.-C.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of recombinant bifunctional fusion proteins</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1517/17425255.2012.673585</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1517%2F17425255.2012.673585" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=22428984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvV2qsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=581-595&author=X.+Chenauthor=J.+L.+Zaroauthor=W.-C.+Shen&title=Pharmacokinetics+of+recombinant+bifunctional+fusion+proteins&doi=10.1517%2F17425255.2012.673585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of recombinant bifunctional fusion proteins</span></div><div class="casAuthors">Chen, Xiaoying; Zaro, Jennica L.; Shen, Wei-Chiang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-595</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The development of biotechnol. has enabled the creation of various recombinant fusion proteins as a new class of biotherapeutics.  The uniqueness of fusion proteins lies in their ability to fuse two or more protein domains, providing vast opportunities to generate novel combinations of functions.  Pharmacokinetic (PK) studies, which are crit. components in preclin. and clin. drug development, have not been fully explored for fusion proteins.  The lack of general PK models and study guidelines has become a bottleneck for translation of fusion proteins from basic research to the clinic.  Areas covered: This article reviews the current status of PK studies for fusion proteins, covering the processes that affect PK.  According to their PK properties, a classification of fusion proteins is suggested along with examples from the clinic or under development.  Current limitations and future perspectives for PK of fusion proteins are also discussed.  Expert opinion: A PK model for bifunctional fusion proteins is presented to highlight the importance of mechanistic studies for a thorough understanding of the PK properties of fusion proteins.  The model suggests investigating the receptor binding and subsequent intracellular disposition of individual domains, which can have dramatic impact on the PK of fusion proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXDDgiIURGWrVg90H21EOLACvtfcHk0lhzoZwJXSnmdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvV2qsLg%253D&md5=3c2e586924eec40cdc1f58caf67ed33e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1517%2F17425255.2012.673585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425255.2012.673585%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZaro%26aufirst%3DJ.%2BL.%26aulast%3DShen%26aufirst%3DW.-C.%26atitle%3DPharmacokinetics%2520of%2520recombinant%2520bifunctional%2520fusion%2520proteins%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2012%26volume%3D8%26spage%3D581%26epage%3D595%26doi%3D10.1517%2F17425255.2012.673585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, M. K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misuan, N.</span></span> <span> </span><span class="NLM_article-title">Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1111/bcpt.13169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1111%2Fbcpt.13169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=30417596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVygsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=513-527&author=M.+K.+K.+Yapauthor=N.+Misuan&title=Exendin-4+from+Heloderma+suspectum+venom%3A+From+discovery+to+its+latest+application+as+type+II+diabetes+combatant&doi=10.1111%2Fbcpt.13169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant</span></div><div class="casAuthors">Yap, Michelle Khai Khun; Misuan, Nurhamimah</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-527</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Type II diabetes mellitus (T2DM) is a chronic non-communicable disease due to abnormal insulin actions causing uncontrolled hyperglycemia.  The treatment for T2DM, for instance, metformin and incretin mimetic, mainly focuses on the restoration of insulin sensitivity and secretion.  Exendin-4 is a short incretin-mimetic peptide consisting of 39 amino acids.  It is discovered in the venom of Heloderma suspectum as a full agonist for the glucagon-like peptide 1 (GLP-1) receptor and produces insulinotropic effects.  It is more resistant to enzymic degrdn. by dipeptidyl-peptidase-4 and has a longer half-life than the endogenous GLP-1; thus, it is further developed as an incretin hormone analog used to treat T2DM.  The helical region of the peptide first interacts with the extracellular N-terminal domain (NTD) of GLP-1 receptor while the C-terminal extension contg. the tryptophan cage further enhances its binding affinity.  After binding to the NTD of the receptor, it may cause the receptor to switch from its auto-inhibited state of the receptor to its auto-activated state.  Exendin-4 enhances the physiol. functions of β-cells and the up-regulation of GLP-1 receptors, thus reducing the plasma glucose levels.  Moreover, exendin-4 has also been found to ameliorate neuropathy, nephropathy and ventricular remodelling.  The therapeutic effects of exendin-4 have also been extrapolated into several clin. trials.  Although exendin-4 has a reasonable s.c. bioavailability, its half-life is rather short.  Therefore, several modifications have been undertaken to improve its pharmacokinetics and insulinotropic potency.  This review focuses on the pharmacol. of exendin-4 and the structure-function relationships of exendin-4 with GLP-1 receptor.  The review also highlights some challenges and future directions in the improvement of exendin-4 as an anti-diabetic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC3mc8RLIIz7Vg90H21EOLACvtfcHk0lhzoZwJXSnmdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVygsrbM&md5=9d5098dc4ae141c675f2accff5fed821</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.13169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.13169%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DM.%2BK.%2BK.%26aulast%3DMisuan%26aufirst%3DN.%26atitle%3DExendin-4%2520from%2520Heloderma%2520suspectum%2520venom%253A%2520From%2520discovery%2520to%2520its%2520latest%2520application%2520as%2520type%2520II%2520diabetes%2520combatant%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2019%26volume%3D124%26spage%3D513%26epage%3D527%26doi%3D10.1111%2Fbcpt.13169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, B. L.</span></span> <span> </span><span class="NLM_article-title">The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent</span>. <i>Toxicon</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/j.toxicon.2010.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1016%2Fj.toxicon.2010.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=21194543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2012&pages=464-471&author=B.+L.+Furman&title=The+development+of+Byetta+%28exenatide%29+from+the+venom+of+the+Gila+monster+as+an+anti-diabetic+agent&doi=10.1016%2Fj.toxicon.2010.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent</span></div><div class="casAuthors">Furman, Brian L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicon</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">464-471</span>CODEN:
                <span class="NLM_cas:coden">TOXIA6</span>;
        ISSN:<span class="NLM_cas:issn">0041-0101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of Byetta (synthetic exendin-4; exenatide) as a treatment of diabetes arose from two, parallel lines of investigation.  The development of the incretin concept' which hypothesised that hormones from the gut contributed to the insulin secretion in response to meals, led to the identification of glucagon-like peptide 1 (GLP-1) as an important incretin' hormone.  GLP-1 not only increases insulin secretion but increases β-cell proliferation and survival, suppresses glucagon secretion, delays gastric emptying and suppresses appetite, all of these actions contributing to a potential anti-diabetic effect.  However, GLP-1 has a very short half due to its rapid breakdown by dipeptidyl peptidase IV and ectopeptidases.  A systematic investigation of the compn. and activity of venom from the Gila monster, Heloderma suspectum, led to the isolation of a 39-amino acid peptide, designated exendin-4, showing 53% structural homol. with GLP-1(7-36).  Exendin-4 mimicked GLP-1 through stimulating the GLP-1 receptor.  The much greater stability of exendin-4 led to its exptl. and clin. evaluation as an anti-diabetic agent and its introduction to the market in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6R1WgiHCCwrVg90H21EOLACvtfcHk0lhzoZwJXSnmdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGltbY%253D&md5=b2cf8ba0322b5eca9720c06a74b9e279</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.toxicon.2010.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxicon.2010.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DB.%2BL.%26atitle%3DThe%2520development%2520of%2520Byetta%2520%2528exenatide%2529%2520from%2520the%2520venom%2520of%2520the%2520Gila%2520monster%2520as%2520an%2520anti-diabetic%2520agent%26jtitle%3DToxicon%26date%3D2012%26volume%3D59%26spage%3D464%26epage%3D471%26doi%3D10.1016%2Fj.toxicon.2010.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muttenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alewood, P. F.</span></span> <span> </span><span class="NLM_article-title">Trends in peptide drug discovery</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/s41573-020-00135-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41573-020-00135-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=33536635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjtF2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2021&pages=309-325&author=M.+Muttenthalerauthor=G.+F.+Kingauthor=D.+J.+Adamsauthor=P.+F.+Alewood&title=Trends+in+peptide+drug+discovery&doi=10.1038%2Fs41573-020-00135-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Trends in peptide drug discovery</span></div><div class="casAuthors">Muttenthaler, Markus; King, Glenn F.; Adams, David J.; Alewood, Paul F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-325</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Portfolio</span>)
        </div><div class="casAbstract">Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain.  In this Perspective, we summarize key trends in peptide drug discovery and development, covering the early efforts focused on human hormones, elegant medicinal chem. and rational design strategies, peptide drugs derived from nature, and major breakthroughs in mol. biol. and peptide chem. that continue to advance the field.  We emphasize lessons from earlier approaches that are still relevant today as well as emerging strategies such as integrated venomics and peptide-display libraries that create new avenues for peptide drug discovery.  We also discuss the pharmaceutical landscape in which peptide drugs could be particularly valuable and analyze the challenges that need to be addressed for them to reach their full potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqatqpumo9qRLVg90H21EOLACvtfcHk0ljD9KfW1d53sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjtF2qsro%253D&md5=6c2ca0a633489717737237749772881b</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fs41573-020-00135-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41573-020-00135-8%26sid%3Dliteratum%253Aachs%26aulast%3DMuttenthaler%26aufirst%3DM.%26aulast%3DKing%26aufirst%3DG.%2BF.%26aulast%3DAdams%26aufirst%3DD.%2BJ.%26aulast%3DAlewood%26aufirst%3DP.%2BF.%26atitle%3DTrends%2520in%2520peptide%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2021%26volume%3D20%26spage%3D309%26epage%3D325%26doi%3D10.1038%2Fs41573-020-00135-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palasek, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, J. M.</span></span> <span> </span><span class="NLM_article-title">Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis</span>. <i>J. Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.1002/psc.804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1002%2Fpsc.804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=17121420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVSgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=143-148&author=S.+A.+Palasekauthor=Z.+J.+Coxauthor=J.+M.+Collins&title=Limiting+racemization+and+aspartimide+formation+in+microwave-enhanced+Fmoc+solid+phase+peptide+synthesis&doi=10.1002%2Fpsc.804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis</span></div><div class="casAuthors">Palasek, Stacey A.; Cox, Zachary J.; Collins, Jonathan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Peptide Science</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-148</span>CODEN:
                <span class="NLM_cas:coden">JPSIEI</span>;
        ISSN:<span class="NLM_cas:issn">1075-2617</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Microwave energy represents an efficient manner to accelerate both the deprotection and coupling reactions in 9-fluorenylmethyloxycarbonyl (Fmoc) solid phase-peptide synthesis (SPPS).  Typical SPPS side reactions including racemization and aspartimide formation can occur with microwave energy but can easily be controlled by routine use of optimized methods.  Cysteine, histidine, and aspartic acid were susceptible to racemization during microwave SPPS of a model 20mer peptide contg. all 20 natural amino acids.  Lowering the microwave coupling temp. from 80°C to 50°C limited racemization of histidine and cysteine.  Addnl., coupling of both histidine and cysteine can be performed conventionally while the rest of the peptide is synthesized using microwave without any deleterious effect, as racemization during the coupling reaction was limited to the activated ester state of the amino acids up to 80°C.  Use of the hindered amine, collidine, in the peptide coupling reaction also minimized formation of D-cysteine.  Aspartimide formation and subsequent racemization of aspartic acid was reduced by the addn. of HOBt to the deprotection soln. and/or use of piperazine in place of piperidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoucvuxZuEee7Vg90H21EOLACvtfcHk0ljD9KfW1d53sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVSgu7w%253D&md5=62d15696576d78b0b1f3d7af2024be5e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fpsc.804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsc.804%26sid%3Dliteratum%253Aachs%26aulast%3DPalasek%26aufirst%3DS.%2BA.%26aulast%3DCox%26aufirst%3DZ.%2BJ.%26aulast%3DCollins%26aufirst%3DJ.%2BM.%26atitle%3DLimiting%2520racemization%2520and%2520aspartimide%2520formation%2520in%2520microwave-enhanced%2520Fmoc%2520solid%2520phase%2520peptide%2520synthesis%26jtitle%3DJ.%2520Pept.%2520Sci.%26date%3D2007%26volume%3D13%26spage%3D143%26epage%3D148%26doi%3D10.1002%2Fpsc.804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Sortase A-mediated on-resin peptide cleavage and in situ ligation: an efficient one-pot strategy for the synthesis of functional peptides and proteins</span>. <i>Org. Chem. Front.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1039/c7qo00481h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1039%2FC7QO00481H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFyit7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=2058-2062&author=X.+Chengauthor=T.+Zhuauthor=H.+Hongauthor=Z.+Zhouauthor=Z.+Wu&title=Sortase+A-mediated+on-resin+peptide+cleavage+and+in+situ+ligation%3A+an+efficient+one-pot+strategy+for+the+synthesis+of+functional+peptides+and+proteins&doi=10.1039%2Fc7qo00481h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Sortase A-mediated on-resin peptide cleavage and in situ ligation: An efficient one-pot strategy for the synthesis of functional peptides and proteins</span></div><div class="casAuthors">Cheng, Xiaozhong; Zhu, Tao; Hong, Haofei; Zhou, Zhifang; Wu, Zhimeng</div><div class="citationInfo"><span class="NLM_cas:title">Organic Chemistry Frontiers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2058-2062</span>CODEN:
                <span class="NLM_cas:coden">OCFRA8</span>;
        ISSN:<span class="NLM_cas:issn">2052-4129</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Sortase A was firstly found to recognize a PEGA resin supported peptide donor contg. a LPXTG motif and to ligate with a suitable acceptor contg. oligo-glycine to afford conjugates in one-pot.  This approach combining enzymic on-resin cleavage, activation and in situ ligation, was employed to synthesize dual functional peptides, modify peptides with lipids, biotin and PEG, as well as protein N-terminal labeling in high efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPu8d09iH5wLVg90H21EOLACvtfcHk0ljD9KfW1d53sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFyit7jL&md5=f152a43f9cf96cab0614bc3010aac8d9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1039%2FC7QO00481H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7QO00481H%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSortase%2520A-mediated%2520on-resin%2520peptide%2520cleavage%2520and%2520in%2520situ%2520ligation%253A%2520an%2520efficient%2520one-pot%2520strategy%2520for%2520the%2520synthesis%2520of%2520functional%2520peptides%2520and%2520proteins%26jtitle%3DOrg.%2520Chem.%2520Front.%26date%3D2017%26volume%3D4%26spage%3D2058%26epage%3D2062%26doi%3D10.1039%2Fc7qo00481h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luginbuhl, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaal, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umstead, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mastria, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banskota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feinglos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alessio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilkoti, A.</span></span> <span> </span><span class="NLM_article-title">One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer</span>. <i>Nat. Biomed. Eng.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">0078</span>, <span class="refDoi"> DOI: 10.1038/s41551-017-0078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41551-017-0078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=29062587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1ahtbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=0078&author=K.+M.+Luginbuhlauthor=J.+L.+Schaalauthor=B.+Umsteadauthor=E.+M.+Mastriaauthor=X.+Liauthor=S.+Banskotaauthor=S.+Arnoldauthor=M.+Feinglosauthor=D.+D%E2%80%99Alessioauthor=A.+Chilkoti&title=One-week+glucose+control+via+zero-order+release+kinetics+from+an+injectable+depot+of+glucagon-like+peptide-1+fused+to+a+thermosensitive+biopolymer&doi=10.1038%2Fs41551-017-0078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer</span></div><div class="casAuthors">Luginbuhl, Kelli M.; Schaal, Jeffrey L.; Umstead, Bret; Mastria, Eric M.; Li, Xinghai; Banskota, Samagya; Arnold, Susan; Feinglos, Mark; D'Alessio, David; Chilkoti, Ashutosh</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biomedical Engineering</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">0078</span>CODEN:
                <span class="NLM_cas:coden">NBEAB3</span>;
        ISSN:<span class="NLM_cas:issn">2157-846X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Stimulation of the glucagon-like peptide-1 (GLP1) receptor is a useful treatment strategy for type 2 diabetes due to pleiotropic effects, such as the regulation of islet hormones and the induction of satiety.  However, the native ligand for the GLP1 receptor has a short half-life owing to enzymic inactivation and rapid clearance.  Here, we show that a s.c. depot formed after a single injection of GLP1 recombinantly fused to a thermosensitive elastin-like polypeptide results in zero-order release kinetics and circulation times of up to 10 days in mice and 17 days in monkeys.  The optimized pharmacokinetics lead to 10 days of glycemic control in three different mouse models of diabetes, as well as the redn. of glycosylated Hb levels and wt. gain in ob/ob mice treated once weekly for 8 wk.  Our results suggest that the optimized GLP1 formulation could enhance therapeutic outcomes by eliminating peak-and-valley pharmacokinetics and improving overall safety and tolerability.  The design principles that we established should be broadly applicable for improving the pharmacol. performance of other peptide and protein therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9T72N1rjiu7Vg90H21EOLACvtfcHk0ljz4ijlTPf7sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1ahtbzN&md5=ee183054285f94be1134d343b2383f75</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fs41551-017-0078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41551-017-0078%26sid%3Dliteratum%253Aachs%26aulast%3DLuginbuhl%26aufirst%3DK.%2BM.%26aulast%3DSchaal%26aufirst%3DJ.%2BL.%26aulast%3DUmstead%26aufirst%3DB.%26aulast%3DMastria%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DBanskota%26aufirst%3DS.%26aulast%3DArnold%26aufirst%3DS.%26aulast%3DFeinglos%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Alessio%26aufirst%3DD.%26aulast%3DChilkoti%26aufirst%3DA.%26atitle%3DOne-week%2520glucose%2520control%2520via%2520zero-order%2520release%2520kinetics%2520from%2520an%2520injectable%2520depot%2520of%2520glucagon-like%2520peptide-1%2520fused%2520to%2520a%2520thermosensitive%2520biopolymer%26jtitle%3DNat.%2520Biomed.%2520Eng.%26date%3D2017%26volume%3D1%26spage%3D0078%26doi%3D10.1038%2Fs41551-017-0078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11403</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11500-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.1038%2Fs41598-017-11500-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=28900154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A280%3ADC%252BC1cbnsFaksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=11403&author=Z.+Zhouauthor=S.+S.+Mandalauthor=G.+Liaoauthor=J.+Guoauthor=Z.+Guo&title=Synthesis+and+Evaluation+of+GM2-Monophosphoryl+Lipid+A+Conjugate+as+a+Fully+Synthetic+Self-Adjuvant+Cancer+Vaccine&doi=10.1038%2Fs41598-017-11500-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine</span></div><div class="casAuthors">Zhou Zhifang; Mandal Satadru S; Liao Guochao; Guo Jiatong; Guo Zhongwu; Liao Guochao; Guo Jiatong; Guo Zhongwu</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">An efficient method was developed for the synthesis of a GM2 derivative suitable for the conjugation with various biomolecules.  This GM2 derivative was covalently linked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic cancer vaccines.  Immunological evaluations of the resultant conjugates in mice revealed that they elicited robust GM2-specific overall and IgG antibody responses.  Moreover, the GM2-MPLA conjugate was disclosed to elicit strong immune responses without the use of an adjuvant, proving its self-adjuvant property.  The antisera of both conjugates showed strong binding and mediated similarly effective complement-dependent cytotoxicity to GM2-expressing cancer cell line MCF-7.  Based on these results, it was concluded that both GM2-MPLA and GM2-KLH are promising candidates as therapeutic cancer vaccines, whereas fully synthetic GM2-MPLA, which has homogeneous and well-defined structure and self-adjuvant property, deserves more attention and studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRpwNxFcBgHXQqdek-gHSrIfW6udTcc2ea0yTfTaVg997ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbnsFaksA%253D%253D&md5=ba67ba06449353acfec00953166ca1be</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11500-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11500-w%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DMandal%26aufirst%3DS.%2BS.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DZ.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520GM2-Monophosphoryl%2520Lipid%2520A%2520Conjugate%2520as%2520a%2520Fully%2520Synthetic%2520Self-Adjuvant%2520Cancer%2520Vaccine%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D11403%26doi%3D10.1038%2Fs41598-017-11500-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span> <span> </span><span class="NLM_article-title">Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">779</span>, <span class="refDoi"> DOI: 10.3390/molecules24040779</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=10.3390%2Fmolecules24040779" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=779&author=X.+Zhongauthor=Z.+Chenauthor=Q.+Chenauthor=W.+Zhaoauthor=Z.+Chen&title=Novel+Site-Specific+Fatty+Chain-Modified+GLP-1+Receptor+Agonist+with+Potent+Antidiabetic+Effects&doi=10.3390%2Fmolecules24040779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Novel site-specific fatty chain-modified GLP-1 receptor agonist with potent antidiabetic effects</span></div><div class="casAuthors">Zhong, Xia; Chen, Zhu; Chen, Qiong; Zhao, Wei; Chen, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">779/1-779/11</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM).  Here, we designed a high-throughput GLP-1R extracellular domain (ECD)-based system that enabled the screening of high-potency receptor-biased GLP-1R agonists demonstrating new pharmacol. virtues.  Firstly, six 12-mer peptides (termed PEP01-06), screened from a large phage displayed peptide library were fused to the N-terminus of Exendin-4 (29-39) to generate PEP07-12.  By the use of four lysine-altered PEP07 (PEP13-16) as the starting point, a series of fatty chain conjugates (PEP17-20) were synthesized and evaluated by in vitro GLP-1R-based cell assays.  In addn., the acute and long-term in vivo effects on diet-induced obesity (DIO) mice were further evaluated.  All four conjugates showed good receptor activation efficacy, and PEP20 was selected to undergo further assessment.  Preclin. expts. in DIO mice demonstrated that PEP20 had significant insulinotropic activities and glucose-lowering abilities.  Moreover, a prolonged antidiabetic effect of PEP20 was also obsd. by the hypoglycemic test in DIO mice.  Furthermore, long-term treatment with PEP20 achieved beneficial effects on the food intake, wt. gain, Hb A1C (HbA1C) lowering activity, and glucose tolerance compared with the control and was similar to the Liraglutide.  In conclusion, PEP20, a GLP-1R ECD-biased agonist, may provide a novel therapeutic approach to T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Z3T88au4hbVg90H21EOLACvtfcHk0ljz4ijlTPf7sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotlCrs7w%253D&md5=909487f6afc1b4195639dcfe8f3ec32d</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24040779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24040779%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DZ.%26atitle%3DNovel%2520Site-Specific%2520Fatty%2520Chain-Modified%2520GLP-1%2520Receptor%2520Agonist%2520with%2520Potent%2520Antidiabetic%2520Effects%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D779%26doi%3D10.3390%2Fmolecules24040779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00032">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_60647"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00032?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00032</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data and characterizations of native Ex4, Ex4-LPETGGS (peptide 1), FITC-labeled Ex4-LPETGGS (peptide 2), and conjugate 6–11; standard curve of the cAMP concentration using competitive cAMP ELISA, peptide 2 and conjugate 9–11 generated by fluorescence reading, and DNP moiety concentration as a function of optical density; ELISA results of the binding activity between Ex4–DNP conjugates and anti-DNP antibodies; quantitative analysis of immunostaining for insulin; flow cytometry evaluation of the HEK293-GLP1-R-AcGFP cell construction; procedure and protocol for the expression and purification of SrtA in <i>Escherichia coli</i> BL21 (DE3); preparation of DNP-carrier protein conjugates; ELISA protocol for DNP-antibody titer determination; ELISA protocol for determination of the binding activity between Ex4–DNP conjugates and anti-DNP antibodies or preimmunized mouse serum; and HEK293-GLP1-R-AcGFP construction (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00032/suppl_file/jm1c00032_si_001.pdf">jm1c00032_si_001.pdf (1.03 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00032&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-8%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00032" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00032" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997873e8b73c5e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
